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Pancreatic ductal adenocarcinoma is a highly desmoplastic tumour, and non-malignant 
stromal cells contribute to progression and treatment resistance. Inflammatory cells in 
particular are known drivers of carcinogenesis, and macrophages are one of the most 
abundant inflammatory leucocytes. Therefore, exploring how macrophages drive 
tumour progression in pancreatic cancer would not only aid in understanding disease 
biology but could also offer insight to novel treatment strategies. 
Results presented in this thesis show macrophages secrete factors that drive 
epithelial-to-mesenchymal transition, promote invasion and lead to expression of 
checkpoint inhibitors.  
To determine what factors were driving this phenotype, the serine protease 
inhibitor SerpinB3 was initially explored, as it was highly upregulated in cancer cells 
cultured with conditioned media from macrophages. However, SerpinB3 gene 
overexpression and knockdown did not confirm a direct role for this gene in mediating 
migration and invasion.  
Further investigation revealed macrophages were secreting the cytokine 
oncostatin M, which was driving a metastatic phenotype through activation of the 
STAT3 pathway. Expression of oncostatin M receptor was upregulated in cancer cells 
following culture with macrophage conditioned media and conferred a worse 
prognosis in patient samples. STAT3 pathway activation by oncostatin M led to 
increased invasion in vitro, particularly of the highly tumourigenic cancer stem cell 
population, and increased metastasis in vivo. Moreover, oncostatin M mediated 
expression of the immune ‘checkpoint’ inhibitors on the surface of pancreatic cancer 
cells. Using antibody and small molecule inhibitors, reversion of these signalling 
pathway effects were seen and preliminary data from in vivo assays showed decreased 
metastasis formation with cytokine receptor antibody inhibition. 
Overall, the findings in this thesis contribute to emerging knowledge of how 
tumour associated macrophages drive tumour progression in pancreatic 
adenocarcinoma. Not only do they promote invasion and metastatic potential through 
oncostatin M secretion, but also potentiate inherent biological properties of cancer 
stem cells and assist in immune tolerance. In addition, results provide preliminary data 
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1.1 Pancreatic Cancer 
Pancreatic cancer has a median overall survival (OS) of less than six months and 5-
year survival of less than 5% (Vincent et al. 2011). Although surgery offers the 
prospect of long-term survival, only 20% of pancreatic cancer patients have resectable 
disease at diagnosis, and even these patients have a 5-year survival rate of 15-20% 
(Oettle et al. 2013).  
Several factors influence poor outcomes in pancreatic cancer, including the tendency 
for late stage at diagnosis, lack of validated screening tests and biomarkers, tumour 
genetic heterogeneity, dense stroma contributing to rapid tumour progression and 
ineffective treatment strategies (Kleeff et al. 2016).  
Pancreatic cancer is set to surpass breast, prostate and colorectal cancer to become the 
third common cause of cancer death by 2030 (Rahib et al. 2014). Accordingly, there is 
an urgent unmet need to overcome the significant challenges at both a biological and 
clinical level to improve our understanding and outcomes of this devastating disease. 
 
1.1.1 Anatomy and Physiology of Normal Pancreas  
 
The pancreas is a retroperitoneal organ and has major functions in both digestion and 
glucose metabolism. 80% of the pancreas is composed of exocrine tissue and the 
remaining 20% is endocrine in origin. 
The exocrine functions of the pancreas rely on two types of cells: acinar and ductal. 
Acinar cells constitute the bulk of the organ and are organised into grape-like clusters 
that produce digestive enzymes (Figure 1.1). The ducts add mucus and bicarbonate to 
this enzyme mixture, and empty into the duodenum.  
The endocrine pancreas consists of four cells types; α-, β-, PP (pancreatic polypeptide) 
and δ- cells. These cells are organised into compact islets within acinar tissue and 
secrete hormone into the blood stream that are then dispersed throughout the body. α- 
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and β- cells produce glucagon and insulin to regulate glucose levels. PP and δ- cells 
secrete PP and somatostatin to regulate the secretory properties of the other cell types 
















Figure 1.1 Anatomy of the pancreas  
A) Anatomic location of the pancreas B) The exocrine pancreas composed of dutcal and acinar cells C) 
The endocrine pancreas composed of α-, β-, PP and δ- cells (taken from Bardeesy and DePinho, 2002). 
 
 
1.1.2 Epidemiology and Risk Factors 
Most recent figure estimates 8,319 new cases per year of pancreatic cancer in the UK 
(CRUK). Worldwide, the estimated 5-year prevalence of people living with pancreatic 
cancer is 4.1 per 100,000 (Ferlay et al. 2014). Incidence increases with age, and the 





The vast majority of pancreatic tumours are sporadic (>80%), with only a minority 
associated with inherited germline mutations, BRCA2 being the most common 
(Ducreux et al. 2015). Several studies have established risk factors for pancreatic 
cancer, with smoking being the main acquired factor (overall relative risk 1.74), 
followed by obesity (Yeo 2015).  Other risk factors associated include chronic 
pancreatitis and diabetes mellitus (Zavoral et al. 2011).  
 
1.1.3 Histological Subtypes  
Types of pancreatic cancers can be subdivided into the cell of origin, broadly exocrine 
vs. endocrine. The most common type is exocrine, and of these the overwhelming 
majority (90%) are adenocarcinomas. These cells originate from the epithelial cell 
lining of pancreatic duct and therefore form gland like structures. Mucinous tumours 
are the other exocrine subtype, accounting for <10% of all tumours. Endocrine 
pancreatic tumours are relatively uncommon, accounting for <5% of all pancreatic 
cancers (Fesinmeyer et al. 2005). Adenocarcinoma of the pancreas has the worst 
overall survival (Figure 1.2). As it is also the most common type of pancreatic tumour, 
focussing on pancreatic ductal adenocarcinoma (PDAC) is of great clinical importance 





Figure 1.2 Survival by histological subtype 
Kaplan Meier curves comparing 5-year survival in pancreatic histological subtypes; adenocarcinoma 
(n=31,357), mucinous (n=2,865) and endocrine (n=1,054) (taken from Feisimeyer et al.). 
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1.1.4 Molecular and Genomic Subtypes  
There are commonly precursor lesions that develop prior to PDAC, which build an 
accumulation of mutations in both tumour suppressor and oncogenes that spur 
malignant progression. The most frequent precursors are microscopic pancreatic 
intraepithelial neoplasia (PanIN), which consist of microscopic (<5mm) mucinous-
papillary lesions. These lesions eventually form invasive carcinoma through an 
adenoma-carcinoma sequence that leads to clonal expansion and subsequent 
acquisition of further mutations (Figure 1.3). The earliest activating mutation and most 
commonly mutated gene in PDAC is the KRAS oncogene (Li et al. 2004) (Table 1.1). 
Point mutations at codon 12 (from GGT to GAT or GTT, or more rarely CGT) occur 
in 75-97% of human PDAC (Almoguera et al. 1988). 
 
 
Figure 1.3 Genetic progression model of PDAC 






Table 1.1 Common mutated genes in PDAC 
The most common genetic mutations in PDAC and frequency of mutation (modified from Li et al., 
2004 and Bardeesy and DePinho, 2002). 
Gene Type Frequency 
KRAS  
(v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) 
Oncogene 75-100% 
HER2/ERBB2  
(neuro/gliobastoma derived oncogene homolog) 
Oncogene 65-70% 
TP53  
(Tumour protein p53) 
Tumour suppressor 40-75% 
SMAD4  
(SMAD family member 4) 
Tumour suppressor 30% 
CDKN2A 
(cyclin-dependent kinase inhibitor 2A) 
Tumour suppressor 27-98% 
CDKN2B  
(cyclin-dependent kinase inhibitor 2B) 
Tumour suppressor 27-48% 
BRCA  
(breast cancer early onset) 
Tumour suppressor 7-10% 
FHIT 
(fragile histidine triad) 
Tumour suppressor 66-70% 
 
With rapid advancement in Next-Generation Sequencing technologies, it is now 
possible to compile whole-genome sequencing of established solid tumours to better 
analyse their mutational landscape. Several groups have undertaken whole genome 
sequencing in PDAC, revealing various molecular / genetic subtypes (Bailey et al. 
2016; Collisson et al. 2011; Moffitt et al. 2015; Waddell et al. 2015). By identifying 
these new genetic subclasses, one can begin to understand patterns and biological 
behaviours in tumour subtypes, which may eventually lead to better prognostication 
and development of predictive therapies. 
Two studies in particular have revealed important findings in relation to the tumour 
microenvironment (TME) and immune infiltrate in PDAC. Bailey et al. defined 4 
PDAC subtypes: squamous, pancreatic progenitor, immunogenic and aberrantly 
differentiated endocrine exocrine (ADEX) (Bailey et al. 2016). Importantly, the 
immunogenic class of tumours was associated with a significant immune infiltrate, 
including macrophage gene signatures, which related to a worse OS (Figure 1.4). The 
immunogenic subclass of tumours demonstrated upregulation of immune related 
markers, such as programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated 
protein 4 (CTLA4), which relate to acquired tumour immune suppression pathways, 
inferring potential therapeutic targeting opportunities.  
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Figure 1.4 Survival and macrophage gene signature in PDAC  
Kaplan Meier analysis comparing patients with high or low macrophage cell signature scores following 
integrated genomic analysis of 93 PDAC patients using combination of while-genome and deep-exome 








Moffit et al. performed microdissection of stromal vs. tumour tissue in individual 
patients to capture the precise involvement of each compartment relative to patient 
outcome. An ‘activated’ stromal subtype was found, which displayed diverse genes 
including those associated with macrophages, chemokine ligands, fibroblast activation 
genes and matrix metalloproteinases (MMPs). Importantly, when comparing patients 
with ‘normal’ or ‘activated’ stroma, the activated had a worse median survival 
compared to normal.  
Both of these studies therefore imply that the non-cancer compartments of PDAC 
tumours, such as immune cells and stromal tissue, play an important role in clinical 





1.1.5 Diagnosis and Staging 
Early symptoms of pancreatic cancer commonly arise from mass effect. Primary 
tumours are situated either in the head, body or tail of the organ (Table 1.2), with head 
tumours likely to be diagnosed at an earlier stage due to bile duct / pancreatic duct 
obstruction causing jaundice (Ducreux et al. 2015). Other symptoms include 
abdominal pain, weight loss, steatorrhoea and new-onset diabetes.  
Table 1.2 Pancreatic tumour locations 
 
Anatomic location Frequency 
Head 60-70% 
Body / Tail 20-25% 
Diffuse 10-20% 
 
Various imaging modalities can be used to diagnose pancreatic cancer. Currently, the 
standard of care for investigation of a suspected pancreatic malignancy is computer 
tomography (CT) scan. Endoscopic ultrasound (EUS) can also be used for staging and 
biopsy. No clear benefit has been found for magnetic resonance imaging (MRI) over 
CT (Ducreux et al. 2015).  
Blood tests are routinely carried out in a suspected diagnosis of pancreatic cancer. 
Serum carbohydrate antigen 19-9 (CA19-9) is increased in almost 80% of patients 
with advanced disease, and although prognostic (preoperative levels ≥500 IU/ml 
indicate worse prognosis after surgery), it is not reliable for diagnosis and is therefore 
not recommended as a marker for disease (Ducreux et al. 2015).  As yet, there are no 
further biomarkers that aid diagnosis or prognostic outcomes. 
Following confirmation of disease on cytology / histology, staging of pancreatic 
cancer is undertaken (Table 1.3). Staging is based on the size and extent of the primary 
tumour in relation to adjacent structures such as blood vessels, nodal involvement and 
distant metastasis. By staging disease, an assessment of whether it is resectable, 
borderline resectable or unresectable can be determined in a multidisciplinary setting. 
There are various definitions of what constitutes resectable disease, but broadly it is 
based on the absence of metastasis and the extent of blood vessel involvement; 
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tumours must have no contact with local arteries (coeliac axis, superior mesenteric 
artery or common hepatic) and have no or <180° contact with local veins (superior 
mesenteric vein or portal vein) (NCCN guidelines 2015).  
Table 1.3 American Joint Committee on Cancer (AJCC) staging of Pancreatic Cancer 
 
Primary Tumour  
(T) 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour limited to the pancreas, ≤2 cm in greatest dimension 
T2 Tumour limited to the pancreas, >2 cm in greatest dimension 
T3 Tumour extends beyond the pancreas but without involvement 
of the coeliac axis or the superior mesenteric artery 





NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
Distant Metastases 
(M) 
M0 No distant metastasis 
M1 Distant metastasis 
 
 
1.1.6 Treatment of Pancreatic Cancer 
Once a pancreatic tumour has been deemed resectable, borderline resectable or 
unresectable, a treatment strategy can be formulated. Treatment is broadly divided into 
‘curative’, in the case of resectable and borderline resectable disease, and ‘palliative’ 
























Figure 1.5 Treatment strategy for pancreatic cancer 
Treatment of pancreatic cancer (based on ESMO guidelines - Ducreux et al. 2015). RT, radiotherapy; 5-FU, 5-fluorouracil; LV, leucovorin. 
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1.1.6.1 Treatment of Resectable Disease 
The only curative treatment of PDAC is surgical resection. Patients who have been 
assessed as having a high probability of R0 resection (i.e. resection margin negative) 
will proceed to surgery. Theoretically, neoadjuvant therapy could improve the 
prospect of an R0 resection by downstaging the primary tumour. However the benefits 
of neoadjuvant therapy in resectable disease remains unclear, especially as PDAC is a 
rapidly progressing cancer. One study has shown that 19% of patients classed as 
‘resectable’ and given neoadjuvant therapy developed radiological metastatic disease 
by the end of treatment (White et al. 2001). Definitive answers to the questions 
surrounding neoadjuvant therapy for initially resectable disease will hopefully be 
answered by the Phase III NEOPA-study (NCT01900327), which is currently 
recruiting. This study aims to demonstrate an OS increase following neoadjuvant 
treatment (gemcitabine and radiation) vs. primary surgery alone in resectable non-
metastatic patients.  
The current standard practice for patients with resectable disease remains upfront 
surgery. Those with head of pancreas tumours undergo pancreatoduodenectomy 
(Whipple procedure). Patients with body or tail of pancreas tumours will undergo a 
distal pancreatectomy.  
Several trials have investigated adjuvant treatment following surgery; The European 
Study Group for Pancreatic Cancer (ESPAC)-1 trial randomised patients following 
intended curative resection. Patients were assigned to one of four arms: exclusive 
adjuvant chemotherapy (bolus 5-fluorouracil (5-FU) and folinic acid), chemoradiation 
(split course 40Gy and 5-FU), chemoradiation followed by chemotherapy or 
surveillance alone (Neoptolemos et al. 2001). No significant differences were seen 
with adjuvant chemoradiation in patients who had undergone either R0 or R1 (i.e. 
positive resection margins following surgery) resections. However, a clear benefit of 
adjuvant chemotherapy was seen when taking R0 and R1 patients collectively, with a 
median survival of 19.7 months in the chemotherapy group compared to 14 months 
with no chemotherapy (p=0.0005). Following this study, CONKO-001 confirmed a 
benefit in disease free survival (DFS) with adjuvant chemotherapy. Patients receiving 
6 months gemcitabine had a 13.4 month DFS compared to 6.7 months (p<0.001) 
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(Oettle et al. 2007). Subsequent follow up analysis of this study in 2013 proved a 
benefit in OS with adjuvant treatment, observing a 5-year OS of 20.7% in the 
treatment group compared to 10.4% in the control arm (p=0.01) (Oettle et al. 2013). 
Findings from these studies collectively support the use of adjuvant chemotherapy 
following surgical resection of localised disease. 
When examining whether the type of adjuvant chemotherapy is important, ESPAC-3 
compared gemcitabine or 5-FU and found no statistical differences between the two 
groups (Neoptolemos et al. 2010). However, the most recent data from ESPAC-4 has 
now determined a new standard of care of gemcitabine and capecitabine within 12 
weeks of R0 and R1 surgery, as this regimen gave an improved OS compared to 
gemcitabine alone (Neoptolemos et al. 2017). Specifically in Japanese patients, the use 
of a novel chemotherapeutic agent, S-1, was shown to be superior to gemcitabine in 
the adjuvant setting (5-year OS of 24.5% with gemcitabine compared to 44.1% with S-
1; p<0.0001). However, this agent has yet to be assessed in non-Asian patients. 
Results from adjuvant use of gemcitabine alone vs. gemcitabine with nab-paclitaxel 
are pending (NCT01964430). 
Despite curative intent and benefits of adjuvant treatment, the outcome of patients 
with resectable disease remains extremely poor. There is a high chance of disease 
recurrence and the 5-year survival rate is 15-20% (Oettle et al. 2013). In addition, 
results from ESPAC-4 show at best a median survival of only 28 months with adjuvant 
treatment (Neoptolemos et al. 2017). 
 
1.1.6.2 Treatment of Borderline Resectable & Locally Advanced     
Disease  
Limited data exists on the benefits of neoadjuvant treatment in patients with borderline 
resectable disease. The aim of this treatment is to limit residual disease after resection, 
reduce lymph node positive disease and treat micrometastasis. Two meta-analyses 
have explored outcome of pre-operative treatment in the form of chemotherapy, 
radiotherapy or chemoradiation (Assifi et al., 2011; Gillen et al. 2010). These analyses 
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could be criticised for including a heterogeneous mix of studies with both borderline 
resectable and resectable lesions included. However, despite this, improved R0 
resections rates and promising survival rates were seen with neoadjuvant treatment in 
both studies. Therefore, although no clear consensus exists, patients with borderline 
resectable disease should be considered for chemotherapy followed by chemoradiation 
to downstage disease if they are unable to enrol in prospective clinical trials assessing 
neoadjuvant treatment. 
Locally advanced tumours are those deemed unresectable in the absence of metastasis, 
and not potentially resectable with neoadjuvant treatments. The median OS for this 
group remains low (<1 year) and there is a lack of robust data to identify how best to 
treat this cohort of patients as no randomised prospective data exists. General 
consensus extrapolated from randomised trials in the metastatic setting is treatment 
with chemotherapy, either FOLFIRINOX or combination of gemcitabine+/-nab-
paclitaxel (Conroy et al. 2011; Faris et al. 2013; Von Hoff et al. 2013). After response 
or stabilisation to chemotherapy is achieved, consolidation treatment with 
chemoradiation could be considered as a maintenance treatment in selected patients, 
especially following a capecitabine-based induction regimen (Mukherjee et al. 2013). 
In patients with good performance status and local progression only, locoregional 
treatment with chemoradiation or radiotherapy alone could be given if further 
chemotherapy (i.e. due to toxicity) is contraindicated (Salgado et al. 2017). 
 
1.1.6.3 Treatment of Metastatic Disease 
The current therapeutic options for patients with Stage IV (i.e. metastatic) PDAC 
include single agent gemcitabine, gemcitabine in conjunction with nab-paclitaxel 
(abraxane) or combination FOLFIRINOX therapy.  
Gemcitabine is a nucleoside analogue that competes with the naturally present 
deoxycytidine, a pyrimidine deoxynucleoside, to integrate into an elongating DNA 
chain. In advanced PDAC, gemcitabine improved OS compared to fluorouracil (5.6 
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vs. 4.4 months; p=0.002) and was thus used as standard of care for many years 
(Burris et al. 1997).  
In 2010, the FOLFIRINOX schedule showed best-ever survival data in metastatic 
disease, with 11.1 months OS in the combination arm compared to 6.8 months with 
gemcitabine alone (hazard ratio (HR) 0.47; p<0.0001) (Conroy et al. 2011). However, 
despite an improved OS, progression free survival (PFS) and response rate (RR) 
compared to gemcitabine alone, this trial showed a less favourable toxicity profile, 
with significantly higher incidences of grade 3 or 4 toxicities. Consequently, although 
it showed the first real improvement in OS and PFS, this regimen is limited to younger 
patients with good performance state (0-1) only (Figure 1.5), and therefore only the 
minority of PDAC patients realistically receive it. 
After many failed randomised trials with drugs in combination with gemcitabine 
alone, positive results were reported in 2013 when combining gemcitabine with nab-
paclitaxel in metastatic patients (Von Hoff et al. 2013). Nab-paclitaxel in combination 
with gemcitabine compared to gemcitabine alone gave a better median OS (8.5 vs. 6.7 
months HR 0.72; p<0.001), improved median PFS (5.5 vs. 3.7 months p<0.001) and a 
higher RR (23% vs. 7% p<0.001). Although neuropathy of grade 3 was greater in the 
combination group, this improved to grade 1 or lower in a median of 29 days. 
Therefore, this regime is also offered in the metastatic setting in place of single agent 
gemcitabine.  
With regards to second-line treatment in the metastatic setting, the NAPOLI-1 study 
compared nanoliposomal irinotecan (nal-I), leucovorin, and infusional 5FU with 
leucovorin and infusional 5-FU alone and with nal-I alone following failure of 
gemcitabine-based chemotherapy. Combination treatment was better than single agent 
5FU alone, with an improvement in OS from 4.2 to 6.1 months (HR, 0.67; P = 0.012) 
(Wang-Gillam et al. 2016). Therefore this treatment could be offered to fit patients 
following failure of first line therapy in the metastatic setting. This regime has gained 
approval from the European Medicine Agency (EMA) but has yet to receive NICE 
approval within the UK.  
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Despite advances in our understanding of chemotherapy, the median survival for 
patients with metastatic disease remains poor and at best 11.1 months (Conroy et al. 
2011). Thus, the need for more effective therapies to prevent recurrence and treat 
















Figure 1.6 Percentage and 5-year relative survival by stage at diagnosis  
Localised: confined to primary site; Regional: spread to regional lymph nodes; Distant: metastatic 
disease (adapted from SEER 18 2006-2012). 
1.2 Cancer Metastasis 
A metastasis is defined as colonisation of tumour cells from the primary site of cancer 
to a distant organ. For all tumour types, metastasis is arguably the greatest contributor 
to patient death (Steeg 2016). In PDAC, the vast majority of patients present with 
distant spread (SEER online data) defined as Stage IV disease (Figure 1.6). Median 
survival is 2-6 months and the 5-year survival rate is only 1-2% (CRUK).  Even in the 
5-25% of patients who present with resectable disease, there is a high chance of 
metastatic recurrence, with one study showing 46% of patients undergoing curative 
resection eventually presenting with distant metastasis (Fischer et al. 2012). These 
findings therefore suggest that even at the time of resection in localised disease, 
dissemination of cells from the primary site has occurred below the detection ability of 
imaging techniques, resulting in relapse and mortality. Adjuvant chemotherapy is 
given to reduce this occurrence, however the median survival in patients who undergo 
surgical resection remains only 12-20 months (Fischer et al. 2012), suggesting current 
therapies are inadequate.  
Understanding the processes by which metastatic disease forms in PDAC is therefore 
vital. By doing so, new treatment strategies could be developed, particularly in the 










1.2.1 Invasion and Epithelial-to-Mesenchymal Transition 
An important step in tumour progression to form metastasis is the acquisition of 
tumour invasion. Tumour cells initially invade the basement membrane to begin the 
process of metastasis. Invasion is therefore defined as proteolytic destruction of the 
ECM and increased motility. Once this initial step has taken place, tumour cells 
entering the bloodstream (either directly or via the lymphatic system) then extravasate 
the bloodstream to colonise distant sites. The original ‘soil and seed’ hypothesis was 
proposed by Paget 100 years ago (Paget 1889) and described how metastasis formed 
on the basis of ‘seeds’ (tumour cells) colonising ‘congenial soil’ (the metastatic 
microenvironment) to allow the progressive outgrowth of tumour cells at the distant 
site.  
Many mechanistic pathways have been proposed for the initial ‘seeding’ and invasion 
of tumour cells from the primary site of disease. One of the most studied is epithelial-
to-mesenchymal transition (EMT), a plastic biological process describing the loss of 
adherence and cell-cell junction in an epithelial cell towards a more mesenchymal cell 
phenotype, allowing motility. Within the field, this process has been described as 
critical for acquisition of malignant phenotype in epithelial cancer cells (Thiery 2002). 
EMT was first termed in the context of embryology, and subsequently three types are 
thought to exist; type 1 in embryogenesis, gastrulation and neural crest formation; type 
2 is in tissue regeneration and wound healing; and type 3 in malignancy, invasion and 
metastasis (Kalluri and Weinberg 2009).  
In type 3 EMT, there are extensive in vitro and in vivo data explaining the initiation of 
EMT by changes in regulatory pathways that lead to a loss of cellular adhesions, loss 
of apico-basal polarity, gain of front-rear polarity and detachment to allow the cells to 
locally invade. EMT is regulated by several ‘master’ regulator pathways, including 
signalling through transforming growth factor (TGF)-β, Notch and Wnt. Common to 
these pathways is the loss of E-cadherin and gain of transcription factors such as 
Twist1, Snail 1, Slug, Zeb1, Zeb2 and proteins such as Vimentin and Loxl2 (Craene 
and Berx 2013). Once activated, these transcription factors act pleiotropically to 
choreograph the EMT process and trigger a series of intracellular signalling networks 
involving, amongst others, ERK, MAPK, PI3K, Akt, Smads, RhoB, β-catenin, 
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lymphoid enhancer binding factor, Ras, and c-Fos as well as cell surface proteins such 
as β4 integrins, α5β1 integrin, and αVβ6 integrin (Tse and Kalluri 2007). Upregulation 
of enzymes that degrade the extracellular matrix (ECM) are induced, and cells undergo 
a robust reorganisation of the actin-cytoskeleton resulting in a change of shape. 
Despite a complex networking signalling, the key feature of EMT is the mesenchymal 
property of increased invasion and migration.  
Some have argued that EMT is dispensable for metastasis in PDAC, given that genetic 





Cre recombinase+ (KPC) mouse model (Zheng et al. 2015). 
However, most recent data suggest that Zeb1 instead is the driving EMT transcription 
factor for this PDAC mouse model, as deletion of this gene led to less distant 
metastasis formation as well as reduced tumour grade and invasion (Krebs et al. 2017). 
EMT cells are typically growth arrested, with several studies showing EMT-inducing 
transcription factors directly inhibiting proliferation (Brabletz et al. 2001; Thiery et al. 
2009; Tsai et al. 2012). This EMT phenotype however is ‘plastic’, as cells need to 
resume their epithelial properties (such as proliferation) in order to colonise distant 
metastatic sites. This reversion has been demonstrated through findings that EMT-
derived migratory cancer cells established as secondary colonies at distant sites 
histologically resemble the primary tumour from which they derived (Kalluri and 
Weinberg 2009). Thus, metastasised cells must shed their mesenchymal phenotype to 
form secondary tumours through mesenchymal-to-epithelial transition (MET). This 
step in metastasis formation in cancer is less well understood, and still requires direct 
experimental validation. 
 
1.2.2 Cancer Stem Cells and Metastasis 
Evidence supports the existence of a highly tumourigenic population of cancer cells 
that bear stem cell properties and represent an integral part of the development and 
maintenance of various human cancers, referred to as cancer stem cells (CSCs) (Clarke 
et al. 2006). Similar to normal stem cells, a hierarchical model of tumour development 
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lies in the ability of this subset of cells to undergo self-renewal and produce a 
heterogeneous lineage of cancer cells that form a tumour (Figure 1.7). Therefore based 
on this hypothesis, CSCs represent a population with tumour-initiating potential, not 
only forming the primary tumour but also capable of generating tumour metastases. 
This theory is one that is being explored in current literature, but difficult to prove in 
part due to the difficultly in identifying optimal markers that distinguish CSCs from 
non-CSCs and also due to variations in these markers between tumour types. Despite 
this, expression of certain cancer stem-like markers correlates with the occurrence of 
metastasis and reduced survival in patients (Kreso and Dick 2014), supporting their 
involvement in distant dissemination of disease. In PDAC, Hermann et al. have shown 
that the invasive front of pancreatic tumours contains a distinct subpopulation of CSCs 
defined by CD133
+
 / C-X-C chemokine receptor (CXCR) -4
+
, and depleting this 







The cancer stem cell model descriding tumours as heterogeneous in which only the cancer stem cell 
subset (CSC in red) has the anility to proliferate to form new tumours. 
 
 
A link between stemness and EMT is debatable. Although not all cells undergoing 
EMT are stem cells, there is some evidence in breast cancer that EMT drives stem-like 
properties (i.e. de-differentiation); Mani et al. show that induction of EMT in human 
mammary epithelial cells by overexpression of transcription factors Snail and Twist 
Figure 1.7 The Cancer Stem Cell Model 
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), and these cells give rise to metastasis 
(Mani et al. 2008). Similar results in breast cancer were found by Morel et al. (Morel 
et al. 2008),  Dyck et al (Dyck et al. 1996) and Gupta et al. (Gupta et al. 2009). There 
is little data supporting this phenotype in PDAC, although Rhim et al. show 





 expression and exhibit stem cell properties, but no mechanistic link 
between the transcription factor and the stem phenotype is derived (Rhim et al. 2012).   
As with normal stem cells, to some extent CSCs also require external signals for 
optimal balance between self-renewal, activation and differentiation. There is evidence 
that these could be derived from the TME, and has been termed the ‘CSC niche’ 
(Medema JP 2011). Thus, non-cancer cells are vital in influencing the cancer cell 













1.3 The Tumour Microenvironment  
Cancer stroma is a highly complex environment containing malignant and host cells as 
well as non-cellular elements, including metabolites, ECM, fibres, ions, secreted 
proteins and free acids. In PDAC, the majority of tissue is stromal, which can form up 
to 70% of the tumour bulk (Bardeesy and DePinho 2002). PDAC is commonly 
resistant to treatment and it is postulated that one of the contributing factors to 
resistance is the intense stromal reaction serving not only as a barrier to chemotherapy 
but also to provide pro-tumourigenic signals (Rishi et al. 2015).  Certainly, the once 
held cancer-cell-centric view in treating malignancy is now shifting to encompass the 
TME, with interest on targeting stromal components that play an active role in 
sustaining cancer growth, progression, invasion and metastasis to treat disease. 
 
1.3.1 Cancer-associated Inflammation 
Inflammatory cells are key components of the TME and are recognised as integral 
factors in contributing to carcinogenesis. Colotta et al. were the first to describe the 
link between inflammation and malignancy (Colotta et al. 2009), and it is now an 
established hallmark of cancer (Hanahan and Weinberg 2011).  Epidemiological and 
experimental data indicate that a highly inflammatory TME within PDAC contributes 
to the development and progression of tumourigenesis (Rhim et al. 2012), for example 
chronic pancreatitis is known to increase the risk of developing pancreatic cancer 
(Guerra et al. 2007; Malka et al. 2002). 
The relationship between immune cells and cancer within the TME is complex. 
Inflammatory cells and mediators, including cytokines, chemokines and 
prostaglandins, co-ordinate a milieu of pro-inflammatory responses which act in both 
an autocrine and paracrine manner on malignant and non-malignant cells (Mantovani 
et al. 2008). A chronic inflammatory state within the TME can drive tumour 
progression, for example by sustaining the immunosuppressive cell populations 
including regulatory T cells (Treg), which suppress the anti-tumour immune response 









 mice models of PDAC, a prominent leucocyte infiltration was 
associated with low grade preinvasive lesions. A more immunosuppressive infiltrate, 
including immature myeloid cells (also known as myeloid-derived suppressor cells), 
tumour-associated macrophages (TAMs) and Treg cells then dominated the initial 
response and remained in invasive lesions (Clark et al. 2007). Thus, immune cell 
infiltrate may dictate the ability of PDAC cells to disseminate from the primary 
tumour site and consequently targeting inflammation in PDAC may lead to less 
metastasis. In vivo, this was demonstrated by Rhim et al. using the immunosupressive 
agent dexamethasone, which abolished circulating pancreatic cancer cells (Rhim et al. 
2012). In conclusion, inflammation plays a role in driving PDAC tumourigenesis and 
pre-clinical data supports the concept of targeting this hallmark of cancer to inhibit 















Macrophages are one of the most abundant immune cells within the TME and are 
known to drive inflammation (Allavena et al. 2008). Therefore understanding the role 
of these immune cells in driving cancer may aid in developing a viable anti-
inflammatory treatment strategy.  
Macrophages are dominant immune cells that modulate tissue homeostasis and play a 
vital role in host inflammation and infection in response to pathogens and disease 
(Gordon and Taylor 2005). Their functions in normal states are to engulf invading 
bacteria and cell debris at inflamed and injured sites, secrete immunomodulatory 
cytokines, present antigen to T cells and act as accessory cells in lymphocytes 
activation. It is thought that two distinct populations of macrophages exist in 
homeostatic states; ‘elicited’ macrophages, recruited mainly from the bone marrow in 
response to inflammatory stimuli, and ‘resident’ macrophages, derived from 
embryonic (yolk sac) progenitors (Gordon and Taylor 2005). Elicited macrophages are 
derived from blood monocytes. Monocytes themselves originate in the bone marrow 
from haematopoetic stem cells (HSCs) and arise from a series of sequential 
differentiation stages (Figure 1.8). 
 
Figure 1.8 Macrophage ontogeny 
Continuous generation of monocytes takes place within bone marrow from hematopoietic stem cells. 
Myeloid progenitors eventually give rise to monocytes, which function in tissue as macrophages or 
dendritic cells. Commitment to differentiation into a monocyte, macrophage or dendritic cell occurs as a 




Monocytes are released into the circulation and within a few days they seed tissues by 
the process of extravastion through the endothelium. They eventually differentiate into 
either dendritic cells (DCs) or macrophages (Figure 1.8). Dependent on the tissue 
location and the inflammatory insult, there is evidence that both recruitment of 
monocytes / macrophages and local proliferation takes place to replenish and maintain 
the tissue-specific population of macrophages under normal pathological conditions 
(Gordon and Taylor 2005). ‘Resident’ embryonic macrophages on the other hand take 
residence in tissues prior to birth and maintain themselves within local tissue 
throughout adulthood independently of bone marrow derived precursors. Recently 
developed fate mapping techniques have enabled the identification and tracking of 
different embryonic macrophage populations into adulthood, and have revealed this 
population of macrophages to complex and heterogeneous (Epelman, Lavine, and 
Randolph 2014). In pancreatic cancer, heterogeneity in the ontogeny of TAMs has 
been demonstrated. Both monocytes and tissue-resident macrophages of embryonic 
origin are sources of TAMs in PDAC tissue. These populations display different 
phenotypes, with monocyte-derived TAMs being more potent at sampling tumour 
antigen and embryonic TAMs having higher expression of pro-fibrotic factors (Zhu et 
al. 2017). This appreciation of macrophage origin and heterogeneity is vital when 
exploring the effects of targeting the macrophage population within PDAC, for 
example the loss on the monocyte-derived macrophages had limited effects on tumour 
progression compared to loss of the tissue-resident population, which significantly 
reduced tumour progression.   
 
1.4.1 Macrophage Phenotype and Activation 
Macrophages are one of the most plastic cells of the haematopoietic system, showing 
great phenotypic and functional diversity. One way to classify tissue macrophages is 
according to their anatomical location, which then dictates functional phenotype. 
Well-described specialised resident macrophages include osteoclasts (bone), alveolar 
macrophages (lung), histiocytes (interstitial connective tissue) and Kuppfer cells 
(liver) (Murray and Wynn 2011).  
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Diversity of macrophage function is greatly influenced by the surrounding 
microenvironment. They respond not only to inflammatory stimuli but also to signals 
from antigen-specific immune cells and even macrophage-derived factors. Previously, 
the most commonly used classification of their activation state was the ‘classically 
activated’ M1 phenotype, and ‘alternatively activated’ M2 phenotype. This 
classification arose in the 1990s, when differential effects on macrophage gene 
expression were noted in response to external stimuli akin to the Th1/Th2 paradigm 
(Stein et al. 1992); M1 macrophages polarised in response to bacterial moieties such as 
lipolysaccharide (LPS) and the Th1 cytokine interferon (IFN)-γ, whilst M2 
macrophages polarised in response to the Th2 cytokine interleukin (IL)-4. These 
findings have been since validated both in vitro with peripheral blood monocyte-
derived macrophages, and in vivo (Biswas and Mantovani 2010) (Figure 1.9). Based 
on these two activation states, consistent differences in function, metabolism and 
subsequent cytokine production have been observed. M1 macrophages produce large 
quantities of pro-inflammatory cytokines (e.g. IL1β, IL12, and tumour necrosis factor 
(TNF)-α) that promote cell-mediated Th1 responses, have increased major 
histocompatibility complex class (MHC) class II expression, and are implicated in 
killing of pathogens and tumour cells (Gordon and Taylor 2005). In contrast, M2 
macrophages secrete IL10 and other cytokines that mediate Th2 responses, moderate 
inflammatory responses and promote tissue re-modelling and repair (Gordon and 




Figure 1.9 The ‘old’ paradigm: differentiation pathways of ‘classical’ M1 & ‘alternate’ M2 
macrophages 
FR, folate receptor; GR, galactose receptor; IFNγR, IFNγ receptor; IL1decoyR, IL1 decoy receptor; 
MHCII, major histocompatibility complex class II; MR, mannose receptor; SR, scavenging receptor; 
RNI, reactive nitrogen intermediate; ROI, reactive oxygen intermediate. 
 
The concept of M1/M2 however has now been updated, with the old binary definition 
viewed as out-dated and oversimplified. Although this nomenclature is useful to 
describe the two extremes of population, expert consensus recognises the complexities 
in macrophage activation, phenotype and plasticity. The current view is that 
macrophages are most likely to exist in a spectrum of activation states depending on 
the exact composition of the activating signals present in the microenvironment rather 
than one or the other (Murray et al. 2014). Therefore instead of fitting within the 
constant and dualistic definition of M1/M2 as described in Figure 1.9, it is likely that 
the plasticity of macrophages within the tumour microenvironment leads to constant 
and complex changes in phenotype driven by gene and surface marker expression 
leading to a heterogeneous population at any given time.  
Leading experts from the field of macrophage biology have therefore suggested the 
use of stimulators and activators to describe TAM polarisation, for example M(IL-4), 
M(LPS) and so forth (Martinez and Gordon 2014; Murray et al. 2014; Noy and Pollard 
2014). Unfortunately, this nomenclature has yet to be fully taken up throughout the 
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field, and thus the M1/M2 classification is not only used in older publications, but still 
remains in use for some current publications referenced in this thesis. Therefore, in 
view of current consensus guidelines, where ‘M1’ or ‘M2’ is used in a publication to 
define a macrophage population, the polarisation method has also been stated.  
 
1.4.2 Tumour Associated Macrophages 
Macrophages are a major component in leucocyte infiltration of the TME, and their 
role in tumourigenesis is complex. Early studies into the role of TAMs initially 
reported that activation by bacterial moieties and cytokines enable tumour cell kill 
(Evans and Alexander 1970). However, it soon became apparent that they could also 
promote tumour growth and metastasis (Mantovani et al. 1979). Thus, early on in the 
investigation of TAMs, a dual function was demonstrated. 
TAMs in tumour tissue are derived from tissue-resident macrophages, as demonstrated 
with microglial cells in glioma (Feng et al. 2015), and cytokine recruited blood 
monocytes and monocyte-related myeloid-derived suppressor cells (M-MDSCs) 



















The dual supportive and inhibitory role of macrophages within tumours is largely 
driven by the TME (Beatty et al. 2011). Granulocyte macrophage colony stimulating 
factor (GMCSF) driven macrophages mediate an antitumour / cytotoxic effect, whilst 
IL4, IL13 and macrophage colony stimulating factor (MCSF) driven macrophages are 
typically pro-tumourigenic, supporting several hallmarks of cancer, including 
angiogenesis, cell invasion and migration, and suppression of anti-tumour immune 
responses (Ruffell and Coussens 2015) (Figure 1.9). The phenotype of TAMs is 
skewed by several different signals originating from tumour cells (e.g. chemokine 
secretion), B cells (immune complexes) and stromal cells (e.g. IL1), leading to a 
diverse and heterogeneous population of TAMs (Biswas and Mantovani 2010).  
Despite the opposing functional populations of TAMs that exist within a primary 
tumour (pro- vs. anti- tumour), clinical data largely support a high density of 
Figure 1.10 Precursors of tumour-associated macrophages in cancer 
Monocytes and M-MDSCs from the blood are recruited in response to chemoattractant secreted from 
both tumour and host cells within the primary tumour. In some tumours, local tissue-resident 
macrophages (of embryonic origin) can contribute to the TAM population through in situ proliferation 
(adapted from Mantovani et al. 2017). 
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macrophages in tumours with poor prognosis as 80% of studies indicate a higher 
macrophage density is associated with inferior patient prognosis (Bingle, Brown, and 
Lewis 2002). In PDAC, TAMs are thought to be typically protumourigenic (as defined 
by CD163) and relate to progression and treatment resistance (Ino et al. 2013; 
Kurahara et al. 2013). This observation supports the widely accepted view that TAMs 
mainly promote several different aspects of tumour progression (Nielsen and Schmid 




Figure 1.11 The pro-tumourigenic effects of tumour associated macrophages  
Macrophages drive tumour progression within the primary tumour and in metastatic sites. These effects 
include supporting pro-survival and treatment resistance, evasion of immune cell cytotoxicity, 
supporting the expansion of the cancer stem cell (CSC) population, assisting in blood vessel formtaion, 







1.4.2.1 Macrophages and Chemoresistance  
Macrophages are important determinants of the efficacy of chemotherapeutic agents, 
but whether they enhance or counteract the anticancer effect is highly dependent on 
the drug used and tumour type (Mantovani et al. 2017).  
In syngeneic orthotopic pancreatic tumour mouse models, direct targeting of 
macrophages through inhibition of either colony-stimulating factor-1 receptor 
(CSF1R) or chemokine receptor (CCR) 2 decreased the number of tumour-initiating 
cells, and thus improved gemcitabine efficacy (Mitchem et al. 2013). Similarly, using 
a transgenic mouse model with reduced macrophage recruitment and activation, 
Weizman et al. demonstrated improved response to gemcitabine treatment augmented 
by the CSF1R receptor antagonist, GW2580. The proposed method for driving 
chemoresistance in this study was upregulation of cytidine deaminase, the enzyme that 
metabolises gemcitabine following its transport into the cell (Weizman et al. 2014).  
Interestingly, recent clinical data in PDAC suggest a dual prognostic significance of 
TAMs in the adjuvant setting; in patients not treated with chemotherapy, density of 
TAMs at the tumour-stroma interface (as defined by CD206, CD163 expression and 
IL10 expression) was associated with worse prognosis and distant metastasis (Di Caro 
et al. 2015). However, a high density was also associated with better prognosis for 
patients who received postsurgical adjuvant chemotherapy. In vitro data supported this 
finding, with gemcitabine treated macrophages becoming tumouricidal following 
treatment, implying chemotherapy ‘re-educated’ macrophages by inhibiting protumour 
functions and driving cytotoxic activity (Di Caro et al. 2015). This study implies 
therapeutic targeting of macrophages in the TME, especially in the adjuvant setting, 
should not only focus on decreasing TAMs density, but suggest developing agents that 






1.4.2.2 Macrophages and Cancer Stem Cells 
Emerging data support a novel role for macrophages in supporting the ‘CSC niche’ in 
breast and PDAC, either through direct or indirect interaction with CSCs. Lu et al. 
demonstrate a juxtacrine (i.e. cell-cell) interaction between breast CSCs and 
monocytes / macrophages that drives and maintains stem-like properties such as 
sphere formation in vitro and tumour formation in vivo (Lu et al. 2014). Published data 
from our laboratory have shown that macrophages can drive CSC properties in PDAC 
through secreted factors, IFN-stimulated gene 15 (ISG15) and human cationic 
antimicrobial protein 18 (hCAP-18) / leucine leucine 17 (LL37). These factors 
reinforce pancreatic CSC self-renewal, expansion and tumourigenicity in vitro and in 
vivo. A ‘crosstalk’ between the cancer cells and macrophages was determined, with 
CSCs secreting TGFβ, nodal, activin and IFNβ leading to ISG15 and hCAP-18 
secretion from the macrophages respectively (Sainz et al. 2014, 2015).  
The ability of TAMs to drive stem-like properties in cancer would support the other 
pro-tumourigenic roles described, as the traits of CSCs are also associated with other 
TAM driven phenotypes such as metastases formation and treatment resistance 
(Hermann et al. 2007). Further understanding of what is driving this relationship is 
therefore of importance. 
 
1.4.2.3 Macrophages and Angiogenesis 
Tumour angiogenesis is essential for allowing vessel growth to enable nutrient and 
oxygen supply to malignant tissue. TAMs play an essential role in driving the 
‘angiogenic switch’, during which formation of high-density vessel networks leads to 
malignant transformation. This is observed in data from Lin et al. in which 
macrophage depletion, through homozygous null mutation of the macrophages growth 
factor CSF1, led to an attenuated angiogenic switch and a delay in malignant 
transformation (Lin et al. 2006).  
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One key contribution of macrophages to support angiogenesis is through cytokine 
secretion in response to hypoxic conditions, mainly vascular endothelial growth factor 
(VEGF). In mice depleted of macrophages, VEGF overexpression restored 
angiogenesis and accelerated malignant transformation (Lin et al. 2007).  
A specific ‘angiogenic’ TAM subpopulation is likely to exist in cancers. For example, 
in RIP-Tag2 transgenic mice (in which pancreatic islets spontaneously develop 
adenomas and invasive adenocarcinomas), TIE2 expressing monocytes were shown to 
be recruited to tumour tissue and found in a perivascular location and this same 
population of cells mediated neovascularisation in a glioblastoma xenograft model (De 
Palma et al. 2005).  
1.4.2.4 Macrophages and Immune Suppression 
Despite functioning in normal tissues to initiate and support adaptive immunity, TAMs 
within the TME are believed to play a mainly immunosuppressive role. TAMs do not 
behave as their regular homeostatic counterparts: they lack the capacity to present 
antigens, trigger anti-tumour responses from T and NK cells and lyse tumour cells 
(Lewis and Pollard, 2006).  Several different mechanisms for how TAMs perform this 
function have been demonstrated, and can loosely be divide into either indirect effects, 
i.e. through secretion of factors that create an immunosuppressive environment, or 
direct effects i.e. by contact dependent immune cell interaction. 
Several indirect immunosuppressive effects of macrophages are likely to exist in the 
TME. In murine lung carcinoma models, macrophages produced arginase which led to 
impaired T cell function within tumours (Rodriguez et al. 2004). In addition, TAMs 
have been shown to increase the presence of established immunosuppressive 
cytokines, such as IL10 in hepatocellular cancer patient tissue (Kuang et al. 2009), 
TGFβ and prostaglandin E(2) in breast cancer mouse models (Torroella-Kouri et al. 
2009).  
In order to self-regulate the immune system has developed ‘checkpoints’ which are 
receptors on specific immune cells that can be activated or inactivated to generate an 
immune reaction. Cells within the TME are known to manipulate this system, by 
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expressing ligands to these checkpoints that then inhibit immune cell function and thus 
allow tumour evasion from immune recognition. Macrophages themselves are known 
to express some of these ligands, such as programmed death ligand-1 (PDL-1).  
Binding of this ligand to PD-1 on T cells triggers loss of activity function. In the KPC 
mouse model of PDAC, TAMs have been shown to express very high levels of PDL-1 
(Winograd et al. 2015). In turn, CSF1R blockade in syngeneic orthotopic PDAC 
mouse models led to upregulation of PDL-1 and another T-cell checkpoint inhibitor, 
CTLA4. The use of CSFR1 blockade and PD-1 and CTLA4 antagonists led to potent 
tumour regression, even in large established tumours, and thus provides a rationale for 
targeting of innate myeloid cell populations in PDAC to improve adaptive immune 
cell checkpoint inhibition (Zhu et al. 2014). 
1.4.2.5 Macrophages and Cancer Cell Migration and Invasion 
TAMs are found in close proximity to migratory cells on the invasive edge 
of tumours (Wyckoff et al. 2004) and therefore implicated in the ability of cancer cells 
to form distant metastasis.    
There are certainly data supporting the need for macrophages in metastasis formation. 
The most widely cited evidence is in breast cancer, using the 
PyMT mouse model. In this model, removal of macrophages, through a homozygous 
null mutation of CSF1, resulted not only in reduced rate of tumour progression but 
also less invasion and metastases (Nielsen and Schmid 2017). Conversely, 
overexpression in wild type tumours accelerated progression and metastatic 
potential (Lin et al. 2001).  
As in breast cancer models, ablation of macrophages through CSF1R inhibition or 
inhibition of CCR2 results in decreased metastasis in pancreatic cancer mouse 
models (Mitchem et al. 2013). In vitro studies have shown that both GMCSF-polarised  
and MCSF-polarised macrophages can induce EMT in pancreatic cell lines (H6c7 and 
Colo357), but intriguingly the GMCSF-polarised cells became more MCSF-like (as 
characterised by greater CD163 expression) with subsequent co-culture (Helm et al. 




It is now understood that this pro-metastatic role of macrophages is likely to involve 
several different stages and interactions. TAMs not only promote the 
invasion and intravasation of tumour cells from the primary tumour site, but also 
promote survival within the circulation and eventually generate a metastatic niche at 
the site of dissemination (Nielsen and Schmid 2017).  
The importance of EMT as an initial stage in metastasis has been previously discussed 
(section 1.2.1), and thus a likely pro-metastatic role of TAMs is an ability 
to induce this process in cancer cells residing in the primary tumour. There are data 
supporting this effect in several tumour types (Zhang et al. 2015), but how TAMs are 
initiating this process varies according the cell type and has yet to be fully elucidated 
in PDAC. One likely mechanism is through secretion of cytokines, which are 



















Cytokines are secreted or membrane-bound proteins that regulate growth, 
differentiation and activation of immune cells. In normal immunity, these proteins 
form a complex network with pleotropic effects. Within the TME, there is a rich mix 
of cytokines produced by malignant and non-malignant cells, and this network is often 
dysregulated. These secreted factors influence the malignant properties of cancer cells 
and non-cancer cells alike. 
TAMs are one of the most prolific producers of cytokines within the TME. As 
described, TAMs can influence malignant cell behaviour through secretion of 
cytokines that activate oncogenic intracellular signalling pathways. But cytokines 
within the TME also influence macrophage activity, for example cytokines such as 
IL6, IL10 and TNF-α have been shown to regulate PDL-1 expression on macrophages 
(Kryczek et al. 2006; Kuang et al. 2009; Wang et al. 2017). 
In pancreatic cancer, many different cytokines are present within the TME and are 
believed to drive tumour progression (Wörmann et al. 2014). One cytokine can 
influence many different cancer cell functions, thus inhibiting these small molecules 










1.6 Targeting Immunity in Cancer 
 
A paradigm shift in cancer treatment is emerging; instead of only targeting cancer 
cells, there is now a transition to target non-cancer cells that are supporting these cells 
and driving tumour progression. In particular, targeting immune cells has led to 
unprecedented outcomes in the treatment of metastatic disease. The intention of this 
strategy is to ‘switch on’, the immune system to recognise and kill cancer cells, thus 
providing long lasting immunity against the cancer, resulting in better long term 
outcomes compared to conventional chemotherapeutics.  
In recent years, the use of immunotherapy in cancer has made exciting progress in 
several different cancer types. Current agents mainly focus on the adaptive immune 
system, most notably the immune checkpoint inhibitors in the form of antibodies 
against PDL-1, PD-1 and CTLA-4. These drugs have been extremely effective in 












Table 1.4 FDA approved immunotherapies in cancer 
CTLA-4 = cytotoxic T-lymphocyte-associated protein 4; mAb = monoclonal antibody; NSCLC = non–small-cell 
lung cancer; PD-1 = programmed death 1; PD-L1 = programmed death ligand 1. 
 




mAb targeting PD-L1 March 15, 2016: previously treated locally 
advanced or metastatic NSCLC (Fehrenbacher et al. 
2016)  
May 18, 2016: first-line treatment locally advanced 
or metastatic urothelial carcinoma (Powles et al. 
2014)  
Avelumab mAb targeting PD-L1 May 9, 2017: locally advanced or metastatic bladder 
cancer after progression on platinum-containing 
chemotherapy  (Heery et al. 2017) 
Durvalumab 
 
mAb targeting PD-L1 01 May 2017: locally advanced or metastatic 
bladder cancer whose disease has progressed during 
or after platinum-containing chemotherapy or 
within 12 months of neoadjuvant or adjuvant 
chemotherapy.  
Ipilimumab  mAb targeting CTLA-4 March 25, 2011: unresectable or metastatic 
melanoma (Hodi et al. 2010; Robert et al. 2011)  
September 30, 2015: BRAF V600 wild-type 
unresectable or metastatic melanoma (in 
combination with nivolumab) (Postow et al. 2015) 
October 28, 2015: adjuvant therapy to lower 
recurrence risk of stage III melanoma after surgery 
(Eggermont et al. 2015) 
Pembrolizumab  mAb targeting PD-1 September 4, 2014: advanced or unresectable 
melanoma (Hamid et al. 2013; Robert et al. 2014)  
October 2, 2015: metastatic NSCLC with tumors 
that express PD-L1 and disease progression on or 
after platinum-containing chemotherapy (Garon et 
al. 2015) 
December 18, 2015: First-line treatment of 
unresectable or metastatic melanoma (Robert et al. 
2015) 
May 18 2017: locally advance/ metastatic urothelial 
carcinoma progression after platinum 
chemotherapy 
(Bellmunt et al. 2017) 
Nivolumab  mAb targeting PD-1 December 22, 2014: unresectable or metastatic 
melanoma that has progressed following 
ipilimumab and, if BRAF V600 mutation positive, 
a BRAF inhibitor (Weber et al. 2015) 
March 4, 2015: metastatic squamous NSCLC with 
progression on or after platinum-based 
chemotherapy (Borghaei et al. 2015) 
September 30, 2015: BRAF V600 wild-type 
unresectable or metastatic melanoma (in 
combination with ipilimumab) (Postow et al. 2015) 
October 9, 2015: metastatic NSCLC that has 
progressed during or after platinum-based 
chemotherapy (Borghaei et al. 2015) 
November 23, 2015: metastatic renal cell 
carcinoma after prior anti-angiogenic therapy 
(Motzer et al. 2015) 
January 23, 2016: BRAF V600 wild-type and 
BRAF V600 mutation-positive 
unresectable/metastatic melanoma (in combination 
with ipilimumab) (Larkin et al. 2015) 
February 02, 2017: Advanced bladder cancer  




However, studies involving immune checkpoint blockade have yet to be universally 
successful in all tumour types, and in PDAC this approach has shown no clinical 
efficacy thus far; Single agent ipilimumab, an anti–CTLA-4 therapeutic, in locally 
advanced or metastatic PDAC, showed no responses and only one “delayed” response 
(Royal et al. 2010). Anti–PD-L1 therapy had no efficacy in 14 PDAC patients treated 
in Phase I testing (Brahmer et al. 2010). One could argue these trials were limited by 
small patient numbers and therefore results from ongoing larger checkpoint trials will 
provide more conclusive evidence. Nonetheless, several reasons have been proposed 
for why immunotherapeutic agents may be ineffective in PDAC. One is a relatively 
low mutational load in PDAC tumours, leading to T cell exclusion due to a lack of 
antigen presentation (Bailey et al. 2016). Others have suggested that PDAC is a ‘non-
immunogenic cancer’, insofar as the tumour-infiltrating effector T lymphocytes are not 
a histopathological hallmark of disease as in other tumour types (Von Bernstorff et al. 
2001). Lack of T cell infiltration could be due to inhibition from the dense TME, for 
example by T cells (T regulatory), MDSCs, TAMs and inhibitory cytokines such as 
TGFβ and IL10 within the PDAC milieu (Byrne et al. 2015; Wachsmann, Pop, and 
Vitetta 2012). Most recent data show there may be a subpopulation of PDAC 
tumours with high cytolytic T cell activity despite low neoepitope load and that 
these tumours have a high expression of checkpoint inhibitors other than PDL-1 
(Balli et al. 2017).  Thus, targeting other immune regulators and cells to boost T cell 
activity as well as exploring inhibition of other checkpoint inhibitors in PDAC could 
prove successful in improving outcomes of immunotherapy. 
 
1.6.1 Targeting Macrophages in Cancer  
Due to the large infiltration of macrophages in cancers, their ability to influence 
adaptive immune cells, their association with poor prognosis and involvement in 
tumour progression, TAMs are emerging as targets of immunotherapy in cancer.  
Existing chemotherapeutic agents may already have effects on TAMs, for example the 
chemotherapeutic drug trabectadin has been reported to have an additional action of 
selective cytotoxicity to human monocytes (Germano et al. 2010) as well as its direct 
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anti-cancer cell properties. In soft tissue sarcoma patients treated with trabectadin, 
decreased circulating monocytes and a reduction in TAMs were seen on biopsy 
specimens (Demetri et al. 2016). This drug is now approved for treatment of soft tissue 
sarcoma and is being tested in several other tumour types and thus its anti-macrophage 
properties may be further explored (Table 2). 
An emerging target for direct macrophage toxicity is macrophage CSF1. The 
monoclonal antibody, RG7155, targets the CSF1 receptor and has shown a 74% 
objective clinical response in tenosynovial giant cell tumours (in which the CSF1 is 
overexpressed) (Ries et al. 2014). As part of this study, the use of RG7155 was 
extended to other solid malignancies, and a reduced macrophage infiltration on biopsy 
was correlated with an increased CD8+/CD4+ T cell ratio. This finding supports the 
combination of an adaptive and innate immunotherapy approach, and this agent is now 
being trialled in other solid malignancies (Table 1.5).  
Specifically in PDAC, targeting TAMs pose a novel therapeutic strategy. Efficacy for 
this approach has been demonstrated in the Phase I setting, in which a CD40 agonist, 
CP-870,893, showed an overall response rate of 19% in patients with metastatic 
disease (Beatty et al. 2013). This drug works by up regulating co-stimulatory 
molecules on macrophages to shift them from pro-tumour to an anti-tumour 
phenotype, thus re-polarising TAMs towards an anti-tumour phenotype could be 
beneficial in treating cancer. In addition, a further Phase I trial has shown promising 
results in the adjuvant setting, through blocking recruitment of TAMs by targeting the 
CCL2-CCR2 axis using PF-04136309, a CCR2 inhibitor, in combination with 
FOLFIRINOX.  In this study, primarily testing for safety and toxicity, 49% of patients 
in the combination arm underwent objective tumour response compared to 0% in the 






Table 1.5 Completed trials in agents targeting macrophages in cancer 
 
Agent Target Mechanism of Actions Study types / Tumour type 
Trabectadin TAM 
Selective monocyte / 
macrophage cytotoxicity 
Phase III Sarcoma  (Demetri 






PLX3397: Small molecule 
inhibitor CSF1R and KIT 
RG7155: Phase I 
Tenosynovial giant cell 
tumour (Ries et al. 2014), 
Phase I Diffuse-type 
tenosynovial giant cell tumour 
(Cassier et al. 2015) 
PLX3397: Phase II GBM 
CP-870,893 CD-40 
Human CD40 agonist 
antibody 
Phase I Pancreatic (Beatty et 
al. 2011, 2013) 
PF-04136309 CCR2 
Inhibition of CCL2-CCR2 
recruitment 
Phase Ib Pancreatic 
(Nywening et al. 2016) 
Maraviroc CCR5 
Antiretroviral CCR5 receptor 
antagonist 
Pilot metastatic CRC (Halama 
et al. 2016) 
 
Despite these data, the clinical effectiveness of macrophage targeting agents has so far 
been modest in early phase trials, and they have yet to prove effective in the Phase III 
setting. Currently there are no approved therapeutic agents in clinical use that target 
TAMs specifically, and therefore further development is needed into novel ways to 
target the pro-tumourigenic functions of TAMs which may then translate to better 
clinically efficacy. Advancing our understanding of the relationship between TAMs 
and cancer cells could help identify better therapeutic approaches. 
 
1.6.2 Targeting of Cytokines in Cancer 
Due to the pleiotropic effects of inflammatory cytokines in tumour progression, 
selective inhibition of specific cytokines have been trialled, with the aim of disrupting 
the already dysregulated tumour cytokine network in cancer to achieve both systemic 
as well as tumour-specific therapeutic effects. 
Several approved and novel agents targeting cytokines have been or are being tested in 
early phase cancer trials (Table 1.6). Some of these act on TAM function also, for 
example CCL2 inhibitors would limit macrophage recruitment (Brana et al. 2015; 






Table 1.6 Completed trials in cytokine targeting agents in cancer  
 
Target Agent Mechanism of Actions Study types / Tumour type 
TNFα Infliximab Chimeric TNF-specific antibody 
Phase I/II RCC (Harrison et al. 
2007; Larkin et al. 2010) 
TNFα Etanercept Human TNFR2–Fc fusion protein 
Phase II Breast (Madhusudan et 
al. 2004), Ovarian 
(Madhusudan et al. 2005); 
Phase I/II Pancreatic (Wu et al. 
2013) 
IL6 Siltuximab Chimeric anti-IL6 antibody 
Phase I Castleman’s disease  
(approved for use) (Kurzrock et 
al. 2013); Phase I/II advance 
solid tumours (Angevin et al. 
2014), Prostate (Dorff et al. 
2010; Hudes et al. 2013), RCC 
(Rossi et al. 2010); Phase II 
Ovarian (Coward et al. 2011) 
CCL2 Carlumab Human anti-CCL2 antibody 
Phase I (Sandhu et al. 2013); 
Phase 1b (Brana et al. 2015) 
Phase II prostate (Pienta et al. 
2013) 
IL1α MABp1 True human anti-IL2α antibody Phase I (Hong et al. 2014);  
 
Cytokine targeting agents have been trialled in PDAC, but little benefit has been seen, 
with anti-TNFα (Wu et al. 2013) and anti-IL6 agents (Angevin et al. 2014). One of the 
reasons for lack of efficacy could be because these cytokines are not key players in 
driving PDAC tumour progression, and thus inhibiting their activity has little clinical 
efficacy. It may also be due to the stage of treatment, as giving a cytokine agent in the 
setting of metastatic disease could be ineffective due in an already established 









There is mounting evidence for the role of TAMs in driving tumour progression. Thus, 
understanding the functions they play in PDAC could provide a novel immune 
mediated therapeutic target to treat an otherwise devastating disease. 
The basis of this project is formed on previous published data from our laboratory 
showing the ability of TAMs to create a pro-tumour paracrine niche for PDAC CSCs. 
Following microarray analysis of macrophages co-cultured with PDAC cells, two 
upregulated macrophage genes were investigated as important players in the crosstalk 
between the cell types: ISG15 and hCAP-18 / LL37 (Sainz et al. 2014, 2015).  
ISG15, a protein normally secreted by cells to stimulate the production of type II IFN, 
was secreted by TAMs in response to IFNβ produced by PDAC cells. This factor 
enhanced the inherent stem cell-like properties of self-renewal and tumourigeneicity 
(Sainz et al. 2014). In turn, hCAP-18 (biologically active in its cleaved form of LL37) 
was found to be exclusively secreted by TAMs induced again by CSC derived factors 
(TGFβ, Nodal and Activin). LL37 similarly enhanced CSC properties and inhibition of 
its receptors (formyl peptide receptor 2 and purinoceptor 7 receptor) negatively 
impacted tumour growth and circulating tumour cell numbers.  
The focus of these previous publications was that of the ‘CSC-niche’ promoting 
effects of macrophages derived factors. Results also demonstrated other potential pro-
tumourigenic effects of TAMs on primary PDAC cells such as cell survival, migration 
and metastases formation; PDAC cells cultured with condition media from MCSF-
polarised macrophages had upregulation of the pro-survival protein phospho-ERK, 
modulation of EMT-associated genes (E-cadherin, Zeb1 and Vimentin) and enhanced 
migratory capacity. In addition, cells treated with recombinant LL37 were found to 
have an increased CXCR4+ expression, which is a marker that defines a subpopulation 
of CSCs that drives metastasis (Hermann et al. 2007). Supporting this finding, cells 
pre-treated with LL37 generated more micrometastases in vivo (Sainz et al. 2015).  
Although both ISG15 and LL37 were shown to be important in driving tumour 
progression through the mechanisms described, the basis of these findings were 
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determined through analysis of TAMs, and effects were mainly focussed on the CSCs. 
As yet, there are no clinical drugs to target macrophage-derived factors LL37 and 
ISG15 in patients; therefore clinical applications for inhibiting this pathway are not yet 
achievable.  
Supporting the protumourigenic effects of TAMs in PDAC, our laboratory has also 
shown that conditioned media from macrophages can induce expression of the 
immune checkpoint inhibitor PDL-1 on the surface of treated PDAC cells, mediated 
by miR-93/106b. Thus, factors secreted by macrophages could also be inducing 
immune evasion in PDAC cells (Cioffi et al. 2017). 
Therefore, the hypothesis of this thesis is that further factors induced by interaction 
with TAMs are driving PDAC progression. By analysing the effects of this interaction 
in PDAC cells specifically, these factors and their associated molecular pathways can 
be identified. In doing so, a better understanding of how TAMs drive tumour 
development can be achieved. Identifying novel approaches to inhibit these factors and 































2.1 Cell Culture 
2.1.1 Primary Pancreatic Cancer Cells 
Human PDAC tissues were obtained with written informed consent from all patients. 
Primary tumours were processed and cultured in vitro and expanded in vivo as patient-
derived xenografts (PDX) as previously described (Mueller et al. 2009) and are 
referred to herein as PDX derived primary PDAC culture cells (Panc185, Panc215, 
Panc253, Panc354, Panc10953, Panc12560 Panc140114). Circulating tumour cells 
(CTC) were collected using the IsoFlux System (Fluxion) using Dynabead selection, 
and acquired cells were processed and cultured in vitro and expanded in vivo as per 
PDX derived primary PDAC culture cells (M.Yang, in submission). CTC derived 
cultured are referred to herein as CDX derived primary PDAC culture cells (C75 and 
C76). Mutational characteristics for each cell type were defined through gene and 
protein analysis (Table 2.1). 
Table 2.1 Mutational characteristics of PDX and CDX cultured cells 
Mutational characteristics of Panc185, 215, 253 and 354 cells were determined through Serial Analysis 
of Gene Expression (SAGE) (Jones et al. 2008). Mutational characteristics of Panc10953, 12560, 
140114, C75 and C76 were determined through digital PCR droplet analysis and western blot (M.Yang, 
in submission). WT, wild-type; uk, unknown.  
 
Cell Type KRAS SMAD4 P53 
Panc185 mutant mutant mutant 
Panc215 mutant WT mutant 
Panc253 mutant WT mutant 
Panc354 mutant mutant mutant 
Panc10953 uk mutant uk 
Panc12560 mutant mutant wt 
Panc140114 uk uk uk 
C75 mutant mutant wt 






All cells were cultured at 37° in a humidified atmosphere of 5% CO2. Cells were 
maintained in endotoxin free-RPMI (Gibco Life Technologies) supplemented with 
10% heat-inactivated fetal bovine serum (FBS; Gibco Life Technologies) and 50 
U/mL penicillin–streptomycin and used in vitro to passage 10 only.  
Cells were maintained at 70% confluence, and for collection, flasks were treated with 
trypsin-EDTA 0.05% (Sigma) until the majority had detached and then quenched by 
the addition of equal volume RPMI containing FBS. Live cells were counted using 
trypan-blue staining at a ratio of 1:1 and seeded for experiments. When required, cells 
were pelleted by centrifugation for 5 minutes at 1500rpm. Cell were tested monthly for 
mycoplasma infection.  For experiments with macrophage conditioned media, control 
media was DMEM:F12 (Gibco) supplemented with B-27 (Invitrogen), β-FGF 
(PeproTech), Penicillin-streptomycin (Sigma) and fungisome (Sigma). 
 
2.1.2 Human Monocyte-derive Macrophages (and Differentiation) 
In order to test the effects of tumour-associated macrophages on primary PDAC 
cultures, healthy donor monocytes were polarised to a more ‘tumour-associated’ 
phenotype in vitro using the methods stated below. The PBMCs used to generate these 
cells were from at least 10 different donors, ensuring heterogeneity in the macrophage 
populations, which was likely to better represent the clinical situation than using one 
donor alone.  
Buffy coats of lymphocyte-rich peripheral blood from healthy volunteers were 
obtained from the National Blood Service (Tooting, London) (City and East London 
Research Ethics Committee 17/EE/0182). Leucocyte cones were stored at 4°C and 
used within 24 hours of delivery to maintain cell viability. In T175cm
2
 flask (Corning) 
the combined 100ml volume of the two ‘buffy coats’ was added to 180mls of sterile 
PBS and mixed. 20mls of Ficoll-Paque
 
PLUS (GE Healthcare) was added to eight 
50ml capacity Falcon tubes (Corning). 35ml volumes of ‘buffy coat’ mixture were 





PLUS at an oblique angle. Samples were then spun at 2200rpm for 15 
minutes with decelerate without a break. 
Following centrifugation, separation occurred as per Figure 2.1. The lymphocyte–rich 
white layer (interphase) was collected and mixed with sterile PBS into 50ml Falcon 
tubes. The tubes were spun at 1500rpm for 10 minutes, supernatant aspirated and a 
repeat wash of the pellet with PBS was performed as per previous. The final cell pellet 
was then re-suspended in IMDM (Life Technologies) supplemented with 10% human 
serum (Sigma) for differentiation into mature macrophages. A density of 
approximately 5x 10
5
 PBMCs / cm
2




For macrophages intended for co-culture with tumour cells, flasks were incubated for 
4 days to allow full differentiation in IMDM and 10% human serum. After 4 days, 
cells were washed with PBS and gently detached using Accutase (Sigma). Viable 
mature macrophages were then counted ready for immediate use in co-culture 
experiments (section 2.1.3).  
To generate ‘tumour associated’ monocyte-derived macrophages, PBMCs were 
polarised the day after initial seeding with 0.5ng/ml of macrophage colony-stimulating 
factor (MCSF; R&D). The rationale for using MCSF for polarisation stems from the 
typical elongated ‘TAM’ morphological appearance following treatment (Figure 2.2)  
(McWhorter et al. 2013) and based on expression of the classical TAM marker, 
CD163; MCSF treated macrophages have similar CD163 expression to macrophages 
Figure 2.1 Ficoll separation of blood  PBMC, peripheral blood monocyte. 
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treated with media conditioned with PDX derived primary PDAC culture cells (Figure 
2.3) (Sainz et al. 2014).  
 











Figure 2.3 CD163 expression of macrophage cultures 
Cytometric analysis of cell surface CD163 expression in PBMCs cultured in GMCSF (M1), MCSF 
(M2), Panc354 conditioned media and Panc185 conditioned media (taken from Sainz et al. 2014) 
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2.1.2.1 Macrophage Conditioned Media (MCM) 
After 4 days of culture in MCSF, macrophages were washed twice with PBS and 
media was replenished with DMEM:F12 (Gibco) supplemented with B-27 
(Invitrogen) and β-FGF (PeproTech) to produce macrophage conditioned media 
(MCM). This media was collected after 48 hours, thus enriched with TAM secreted 
factors, and centrifuged at 1500rpm for 5 minutes to remove cell debris. Aliquots of 
MCM were stored at -80°C and defrosted to treat primary PDAC cells, using 
DMEM:F12 (Gibco) supplemented with B-27 (Invitrogen) and β-FGF (PeproTech) 
media alone as control.  
 
2.1.2.2  In vitro Macrophage Culture Experiments 
5x 10
5 
mature macrophages were seeded per well to 6 well adherent plates in 2mls of 
IMDM (Gibco) supplemented with 10% Human Serum (Sigma). In parallel, 1.6x 10
5 
primary PDAC cells (i.e. ratio of 3:1) were seeded to pre-soaked 6 well 0.4μm 
permeable polycarbonate membrane transwell (Corning) in RPMI. Following 
attachment overnight, PDAC transwells were added to wells containing macrophages, 
and media was changed to control media (1ml top of transwell / 2ml below), or added 
alone to empty wells containing control media / MCM for comparison (Figure 2.4). 
After 4 days culture, cells were trypsinised and live cells counted. Cells were then 
seeded for further experiments, collected for flow cytometry (section 2.7), collected 
for RNA (section 2.5) or protein (section 2.6). 
 




For macrophage phenotypes experiments, following 4 days of culture, 5x 10
5 
mature 
unpolarised macrophages were seeded per well to 6 well adherent plates in 2mls of 
IMDM (Gibco) supplemented with 10% Human Serum (Sigma). The next day, media 
was changed to either 0.5ng/ml of macrophage colony-stimulating factor (MCSF; 
R&D) or 1ng/μl transforming growth factor-β1 (TGFβ1; R&D). 
 
2.1.3 3D-Matrix Culture 
To assess cell morphology without the limitations of a monolayer cell culture, cells 
were grown in a three-dimensional model to better recapitulate the ECM and tissue 
organisation in vivo. This was based on methods used by Godinho et al (Godinho et al. 
2014) whereby a matrix of Collagen-I (Invitrogen) supplemented with 62.5μl 10X 
FBS and 62.5μl 0.1M NaOH per 500μl Collagen-I, corrected to physiological pH of 7-
7.5 was then mixed to Matrigel (Corning) at a 1:1 ratio to form an ‘ECM’.  
42μl of matrix was added to the center of each well in an 8-well chamber slide plate 
(Falcon), avoiding high meniscus on the border. Slides were incubated for 1 hour at 
37°C to allow the matrix to set, and then cell suspension in 400μl assay medium 
containing 2% Matrigel was added to each chamber (4x 10
4
 cells per chamber) (Figure 
2.5). Cells were incubated for 2-4 days at 37° in a humidified atmosphere of 5% CO2. 
On completion of the experiment, cells were fixed in 5% Formalin (Sigma), 
permeabilised in 0.5% Triton X-100 PBS and immunofluorescence analysis was 




 Figure 2.5 3D Matrix Culture 
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2.1.4 Sphere Formation  
To test for enrichment of cancer stem cells, cell spheres were generated by culturing 
1x 10
5
 PDX derived primary pancreatic cancer cells per ml of DMEM:F12 (Gibco) 
supplemented with B-27 (Invitrogen), βFGF (PeproTech), Penicillin-streptomycin 
(Sigma) and fungisome (Sigma) in anchorage-independent suspension conditions for 7 
days. A CASY Cell Counter (Roche) was used to quantify spheres. 
 
2.1.5 Treatments Used in Cell Culture 
To determine the effects of soluble factors on PDAC cells, 100ng/ml and 200ng/ml of 
recombinant human serpinB3/SCCA1 (R&D systems), 100ng/ml of human 
recombinant oncostatin M (OSM) (PeproTech), 100ng/ml of human interleukin 6 
(IL6) (PeproTech) and 100ng/ml of human recombinant leukaemia inhibitory factor 
(LIF) (PeproTech) were dissolved in control media.  
To test agents disrupting the PDAC-TAM crosstalk, cells were cultured in for up to 48 
hours in MCM or control media supplemented with soluble factors described above 
along with 10μg/ml of anti-OSM neutralising antibody (R&D systems), 2μg/ml of 
anti-gp130 human antibody (R&D systems) or 250nM of ruxolitinib (Sigma). In the 
case of anti-gp130 antibody, a pre-incubation of 30mins was performed prior to 
culture in experimental conditions.  
For cytotoxicity assays, gemcitabine (Sigma) chemotherapy was added to selected 






2.2 Cell viability  
2.2.1 Crystal Violet Staining 
Crystal violet staining is a method of quantifying survival cells based on cell staining 
in adherent conditions (Drysdale, Zacharchuk, and Shin 1983). 4x 10
3
 cells per well 
were seeded in 96 well plates and left to adhere overnight. The following day, cells 
were pre-treated with control media / MCM or OSM. Following 48 hours of treatment, 
media was supplemented with assay drug therapy if required. For collection on desired 
days (including a ‘day 0’ control), cells were fixed for 10 minutes in 100µl/well of 
0.2% Crystal Violet and 20% Ethanol. Wells were then washed twice with water and 
photographed after drying. To read the crystal violet stain, 100-200µl/well of 1% 
Sodium Dodecyl Dulfate (SDS) was added simultaneously to each assay plate and left 
to dissolve. Optical density (at 570nm) was then read using the FLUOstar OPTIMA 












2.3 Cell Migration and Invasion  
2.3.1 Invasion Assay 
Invasion assays were performed using 24-well 8.0μm PET membrane invasion 
chambers coated with growth factor reduced Matrigel (Corning 354483). Primary 
PDAC cells were pre-treated for 48 hours in adherent cultures. Following treatment, 
cells were trypsinised, live cells counted and re-suspended in serum free media (300μl 
per well) and seeded to coated inserts. 700μl of serum-free medium supplemented with 
20% FBS was added to the lower chamber, creating a serum gradient to attract cells 
(Figure 2.6). Assay chambers were incubate for 12-24 hours at 37°C in a humidified 
atmosphere of 5% CO2. Invaded cells were fixed with 4% paraformaldehyde (PFA), 
and matrigel coating was removed by wiping with cotton buds. Invaded cells were 
stained with DAPI and imaged on the Olympus Fluorescence microscope (model 









Figure 2.6 Invasion Assay 
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2.3.2 Scratch Wound Cell Migration Assay 
In vitro scratch assay is an established method to study cell migration, based on 
creation of an artificial ‘gap’ in a confluent cell monolayer, leading to cell movement 
towards the opening to close the scratch and thus allowing determination of rate of cell 
migration (Liang, Park, and Guan 2007).  
An automated system was used to perform this technique using IncuCyte ZOOM 
technology and analysis software (EssenBioscience).  Cells were seeded in a 96-well 
plate ImageLock plate and incubated at 37°C, 5% CO2 until confluency was achieved. 
Following the WoundMaker protocol, wounding procedure was performed to 
simultaneously create precise and reproducible wounds in all wells. Wounds were 
washed twice with PBS and inspected. 100μl of control media or MCM (supplemented 
with 1:1000 doxycycline for experiments with SerpinB3 knockdown transduced cells) 
were added to corresponding wells. The plate was placed in the IncuCyte ZOOM and 
repeat scanning was scheduled for every hour using 10x objective. After 24hrs, wound 











Figure 2.7 SerpinB3 shRNA and overexpression constructs 
A) shRNA construct: TLHSU2300-6317  B) overexpression construct: TOLH-1515456 Human 
Lentiviral ORF clone 
 
2.4 Transfection and Transduction of Lentiviral Constructs 
2.4.1 SerpinB3 shRNA Transfection 
Three human SerpinB3-GFP lentiviral shRNA clones (pZIP-TREG3) and a non-
targeting control were purchased from Transomic, USA (Figure 2.7A). Plasmids were 
recovered using the QIAGEN Plasmid Maxi kit (Qiagen - 12165). To make lentivirus, 
293T cells were plated to 10cm dishes, and transfected at 80% confluence using 
Lipofectamine 2000 to deliver 22.5μg lentiviral shRNA construct, 14.6μg packing 
plasmid (Pax2) and 7.9μg envelope plasmid (pCNA3.1-VSVG). Virus-containing 
supernatant was collected 48 hours post transfection, filtered through a 0.45μm filter 
(BD Bioscience) and concentrated by centrifugation for 45 minutes at 1500rpm, 
aliquoted, frozen and subsequently titrated by flow cytometry analysis of GFP 
expression in 293T cells infected with increasing dilution of virus. Primary PDAC 
cells were infected in suspension and following expansion, doxycycline (1:1000) 
selection was carried out 48 hours prior to FAC sorting for GFP positivity to achieve 
>90% knock-down of gene expression.  








2.4.2  SerpinB3 Overexpression 
Human SerpinB3 and empty vector lentiviral cDNA (pLX304) were purchased from 
Transomic USA (Figure 2.7B). Plasmids were recovered using the QIAGEN Plasmid 
Maxi kit. Transfection of 293T, virus production and infection of PDAC cells were 
carried out as per protocol section 2.4.1. Transfected cells were grown through 


















2.5.1 RNA Extraction and Quantification 
Cells were washed in PBS and TRI Reagent (Sigma-Aldrich T9424) added as per 
manufacturer’s instructions. Samples were stored at -80°C until further use. Once 
defrosted, phase separation with 100μl chloroform per 500μl of TRI Reagent was 
performed; following vigorous shaking for 15 seconds, samples were centrifuged at 
12000g for 30 minutes at 4°C. Phase separation resulted in: a red organic phase 
(containing protein), an interphase (containing DNA), and a colourless upper aqueous 
phase (containing RNA). The colourless aqueous phase was transferred to a fresh tube 
and 200μl isopropanol was added per 500μl of TRI Reagent. Samples were mixed and 
stored overnight at -20°C. The next day, samples were centrifuged at 12000g for 
30 minutes at 4°C. The resultant RNA precipitate pellet was washed in 800μl of 80% 
ethanol and followed by 800μl of 100% ethanol. Following washes, the RNA pellet 
was left to air-dry for 15 minutes, ensuring the pellet did not completely dry. 
According to the cell pellet size, an appropriate volume of RNA-ase free water was 
added to dissolve (approximately 15-30μl).  
Purity and quantity of RNA was analysed using the NanoDrop ND1000 UV-Vis 
spectrophotometer (Thermofisher, USA), measuring absorbance at 260 and 280 nm. 
Pure and contaminant free RNA was determined by 260/280 ratios of approximately 2 
and concentration was determined by the software, which automatically calculates the 
nucleic acid concentration. For microarray analysis, RNA was run on the Bioanalyser 
for integrity and quality. 
 
2.5.2 Complementary DNA (cDNA) Synthesis 
Using the QuantiTect Reverse Transcription Kit (Qiagen - 205314), 1μg of total 
purified RNA diluted in RNA-se free water was used for cDNA synthesis as per 
manufacturer’s instructions. For initial DNA wipeout: 2µl of DNAse was added per 
sample. Samples were then incubated for 5 minutes at 42ºC on the Eppendorf 
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Mastercycler Thermal Cycler (Eppendorf, UK).  
Reverse transcriptase (RT) mastermix was prepared (containing 1µg Quantiscript 
Reverse Transcriptase, 4µg Quantiscript RT Buffer, 1µg RT Primer Mix per sample) 
and gently added to 1μg of sample. cDNA synthesis reaction was performed using the 
following thermal cycling conditions: 
- Step 1: 95ºC for 20 minutes 
- Step 2: 60ºC for 30 minutes 
- Step 3: 95ºC for 15 minutes 
- Step 4: 4ºC overnight 
cDNA sample was diluted with 180µl RNA-ase free water, to give a final 
concentration of 5ng/μl. 
 
2.5.3 Quantitative Real Time Polymerase Chain Reaction (qRT-PCR) 
Real time qRT-PCR reactions were prepared to a 10µl volume by adding 10ng of 
cDNA to 8µl master mix per well (master mix 2.8µl RNAse free water; 5µl 
MasterMix PerfeCTa SBYR green (Applied Biosystems); 0.2µl of 10µM forward and 
reverse primer mix of gene of interest) (Table 1.1). 
Table 2.2 Primers List 
 
Gene Primer sense Primer antisense 
HPRT TGACCTTGATTTATTTTGCATACC CGAGCAAGACGTTCAGTCCT 
ubiquitin C AGTAGTCCCTTCTCGGCGAT GCATTGTCAAGTGACGATCACAG 
zeb1 GATGATGAATGCGAGTCAGATGC CTGGTCCTCTTCAGGTGCC 
vimentin GACAATGCGTCTCTGGCACGTCTT TCCTCCGCCTCCTGCAGGTTCTT 
slug ATGCCGCGCTCCTTCCT TGTGTCCAGTTCGCT 
loxl2 GGCACCGTGTGCGATGACGA GCTGCAAGGGTCGCCTCGTT 
OSMR TACGCGTCAGAGTTTGCACT GTGCTGTAATTCCCCACCCA 
IL6R ATCCCTGACGACAAAGGCTG CTGGCAGGAGAACTTCTGGG 
LIFR GGGAGCGTACCGACTGACTG CCAGAGGGTGCTTTCCAAGA 
KLF4 TCTCCACGTTCGCGTCTGGC TCCCGCCAGCGGTTATTCGG 
OCT 3/4 CTTGCTGCAGAAGTGGGTGGAGGAA CTGCAGTGTGGGTTTCGGGCA 
SOX2 AGAACCCCAAGATGCACAAC CGGGGCCGGTATTTATAATC 




The reaction was set up in a MicroAmp optical 384-well reaction plate (Applied 
Biosystems 4309849) and amplified in QuantStudio 7 Flex System (Applied 
Biosystems, USA). Thermal cycling conditions were as follows: 
- Step 1:  95°C for 20 seconds 
- Step 2:  40 cycles of 95°C for 3 seconds / 60°C for 30 seconds 
- Step 3:  95°C for 15 seconds 
- Step 4:  60°C for 1 minute 
Data were collected and analysed using the QuantStudio 7 Flex System software, 
version 1.0 in order to determine Ct (threshold cycle) values for each sample. Relative 




RNA from treated Pan215, 253 and 354 cells were analysed by Professor Stephan 
Hahn, University of Bochum, Germany. In summary, 100ng of each total RNA sample 
were hybridized to Agilent whole genome expression microarrays (Human GE 4x44K, 
v2 G4845A, AMADID 026652, Agilent Technologies). Array data analysis was 
undertaken using the AFE algorithm to generate the total gene signal (TGS), which 
was then used for further data analyses using the GeneSpring GX software package 
version 11.0.2. AFE-TGS were normalised by the quantile method. Subsequently, data 
were filtered on normalized expression values. Only entities where at least 2 out of 4 
samples had values within the selected cut-off (50th-100th percentile) were further 
included in the data analysis process. Differentially expressed genes were identified by 





 2.5.4.1 Gene Set enrichment 
The quantile-normalised expression dataset derived from Agilent whole genome 
microarrays and 186 gene sets derived from KEGG pathway database were used as 
input for Gene Set Enrichment Analysis (GSEA). Only those gene sets with significant 
enrichment levels (FDR q < 0.25) were considered. 
 
2.5.5 Tissue Cancer Genome Atlas 
To evaluate the expression activity level of genes in pancreatic cancer, the RNA seq 
database of pancreatic adenocarcinoma from The Cancer Genome Atlas (TCGA) was 
analysed by Dr Meng-Lay Ling (https://portal.gdc.cancer.gov/). Patient survival was 
estimated using R 3.3.3 software with the non-parametric product limit method 
(Kaplan-Meier). Additional software packages (survival 2.41.3 and survminer 0.4.0) 
were downloaded from the Comprehensive R Archive Network (CRAN). Gene 
expression data were categorised into high expression or low expression group, based 










2.6 Protein Analysis 
2.6.1 Western Blotting 
Cells grown in adherent 6-well plates were washed with PBS and placed on ice. 50µl 
of RIPA buffer (Sigma) supplemented with a protease inhibitor cocktail (Roche) was 
immediately added directly to washed cells. After 5 minutes on ice, cells were 
harvested using a cell scraper (BD Falcon) and collected to 1.5ml eppendorf tubes. 
Samples were vortexed for 1 minutes and placed on ice for 10 minutes, for a total of 
three times. Following the third vortex, samples were centrifuged at 14000g for 30 
minutes at 4ºC to pellet cell debris. Supernatant was removed and stored at -20ºC until 
immunoblotting.  
Protein standards of diluted albumin (BSA 2µg/l Sigma-Aldrich) were prepared at the 
following concentrations: 0, 0.1, 0.25, 0.5, 0.75, 1 and 2µg/µl protein, in RIPA buffer. 
Cell lysate samples were diluted 1 in 5 and 10µl of diluted sample or reagent were 
plated in triplicates in a 96 U-bottom plate well (Corning) plate. 200µl of Peirce BCA 
Protein Assay Reagent (Thermo Fisher Scientific 23225) was added to each well and 
incubated at 37ºC for 30 minutes. Samples were read using the FLUOstar OPTIMA 
microplate reader (BMG labtech) at 595nm and protein quantification was calculated 
against BSA protein controls. 
15-30μg of sample protein diluted in distilled water was mixed with loading buffer 
(50μl β-mercaptoethanol in 1ml NuPAGE sample buffer (Invitrogen NP0007)) at a 
ratio of 1 to 4 (buffer to sample). Samples were denatured by heating at 95ºC for 10 
minutes and then spun and cooled.  
Protein was separated in pre-cast 4-12% Bis-Tris NuPAGE gels (Invitrogen NP0321) 
using 10µl of Novex Sharp Pre-stained Protein Standard (Invitrogen LC5800). 
Samples were run in 1X MOPS SDS buffer (Invitrogen NP0001) at 150V for 1 hour, 
or until bromophenol blue marker ran off the bottom of the gel.  
Protein was transferred to nitrocellulose membranes (Amersham Pharmacia) using the 
wet transfer apparatus (Bio-Rad) and Tri-glycine with 20% ethanol transfer buffer 
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using pre-soaked Extra ThickBlot Paper (Bio-Rad).  
Membranes were subsequently blocked with 1X TBS containing 5% BSA (w/v) and 
0.05% Tween20 (v/v) for 1 hour at room temperature, and then incubated with 
primary antibody (see Table 2.3) overnight at 4ºC, followed by 3 washes with TBS 
containing 0.05% Tween20 (v/v). Incubation with horseradish peroxidase-conjugated 
secondary antibody at a concentration of 1:1000 was carried out at room temperature 
for 2 hours. Membranes were washed again with PBS and bound antibody complexes 
were detected with Enhanced Chemiluminescence Western Blotting Detection 
Reagent Kit (GE Healthcare RPN 2232). 
 





Target Host species 
Clonality / 
Isotype 
Supplier Dilution used WB 
SerpinB3 Mouse Monoclonal IgG2 Santa Cruz 1:500 








Vinculin Mouse Monoclonal IgG Sigma 1:1000 
Tubulin Mouse Monoclonal IgG Sigma 1:1000 
Secondary antibodies 
Target Conjugate Host species Supplier Dilution used 
Anti-Mouse IgG HRP* Rat DAKO 1:1000 
Anti-Rabbit IgG HRP* Donkey DAKO 1:1000 








2.6.2 Enzyme Linked Immunosorbent Assay (ELISA) 
Enzyme linked immunosorbant assay (ELISA) for OSM cytokine was carried out 
using the DuoSet Development kit (R&D DY295) in 96-well plates.  
 
2.6.2.1 Plate Preparation 
Mouse anti-human OSM capture antibody was prepared to the working concentration 
in PBS without carrier protein (1:180). A 96-well microplate was immediately coated 
with 100μl per well of the Diluted Capture Antibody, sealed and incubated overnight 
at room temperature. 
Wells were aspirated and washed three times with Wash Buffer (0.05% Tween 20 in 
PBS) the following day. Plates were then blocked with 300μl/well Reagent Diluent 
(1% BSA in PBS) and left to incubate for 1 hour at room temperature. Following 
aspiration/wash, plates were then ready for sample addition. 
2.6.3 Cell Supernatants 
Cellular supernatants were collected and centrifuged at 1500rpm for 5 minutes to 
remove cellular debris. Samples were then snap frozen and stored at 80ºC until ELISA 
analysis as per protocol above.  
2.6.4 Human Plasma / Serum 
Blood samples of treatment naïve metastatic PDAC patients were obtained with 
consent according to the Barts Pancreatic Tissue Bank Protocol from treatment naïve 
patients treated at Barts NHS Trust Hospital (City and East London Research Ethics 
Committee 13/SC/0592). Following centrifugation of the EDTA samples for plasma 
(as per section 2.1.2), and clotting of blood in SSTII bottles for serum, samples were 
snap frozen and stored at -80ºC until ELISA analysis.  
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2.7 Flow Cytometry 
Tumour cells were harvested using 1% trypsin-EDTA, centrifuged at 1500rpm for 5 
minutes and washed with PBS. Cells were re-suspended in 1ml of immune globin 
intravenous (Human) flebogamma 5% (Grifols Biologics) and incubated at 4°C for 30 
minutes. Cells were centrifuged at 1500rpm for 5 minutes and supernatant aspirated. 
Selected antibody was then added diluted in flebogamma 5% (Table 2.5). After 
incubation, cells were centrifuged and re-suspended in PBS with DAPI (1:1,000).  
Specific antibody protocols were as follows; For AnnexinV, 400µl of AnnexinV 
binding buffer (eBiosciences 556454) was added per sample post antibody incubation.  
For Ki67, cells were vortexed and 5mls of cold 70% ethanol was added dropwise to 
each sample (1-5x10
7
 cells). Cells were incubated overnight in ethanol at -20ºC, 
washed in PBS and incubated with antibody as per protocol above.  
Table 2.4 FACS antibody 
 






AnnexinV (550474 eBiosciences) APC 5μl 30  
CD133 (Miltenyi 130-090-826) APC 0.2μl 30 
Ki67 (556026 eBiosciences) FITC 20μl 30 
CD274 (B7-H1, PD-L1) (Biolegend 329707) APC 0.2μl 15 
 
2.7.1 Cell Sorting  
Cultured cells were harvested in trypsin-ETDA and pelleted at 1500rpm for 5 minutes. 
Cells were then re-suspended in PBS. Cells were re-suspended in 1ml of immune 
globin intravenous (Human) flebogamma 5% (Grifols Biologics) and incubated at 4°C 
for 30 minutes. Cells were then centrifuged at 1500rpm for 5 minutes, and supernatant 
aspirated. RFP / GFP positive cells proceeded straight to re-suspension in 100-200μl 
Sorting Buffer (1x PBS; 3% FBS (v/v); 3mM EDTA (v/v)) containing DAPI for the 
exclusion of dead cells (1:10,000). Cells requiring staining were incubated in 
appropriate antibody diluted in flebogamma at 4°C for 30 minutes (Table 2.5). 
Following antibody incubation, cells were re-suspended in Sorting Buffer and 
centrifuged. Samples were sorted using the BD FACS ARIA Fusion Cell Sorter (BD 
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Bioscience). Gates were created against unstained and isotype controls for accurate 
analysis. Samples were immediately re-suspended in cell culture medium and live 
cells counted prior to seeding for experiments. 
 
2.7.2 FACS analysis  
Samples were read using the BD LSR Fortessa
 
Cell Analyser platform (BD 
Bioscience). All samples were analysed with unstained and isotype controls for 
accuracy, and compensation was performed with positive stained samples. Data was 














2.8 Animal Studies 
2.8.1 Cell Culture  
Firefly luciferase expressing human Panc354 cells were established by infecting cells 
with CMV-Luciferase-RFP-TK Lentivector system from BioCat GmbH (Heidelberg, 
German). Cells were sorted for RFP expression with FACS and expanded in vitro as 
per section 2.1.1 in adherent conditions.  
For in vivo assays, cells were pre-treated for 48 hours in desired media (control / 
MCM / OSM) with or without 2μg/ml of human gp130 receptor antibody. Cells were 
then trypsinised and live cells counted. Cells for injection were suspended in 50μl of 
1:1 growth factor reduced Matrigel and RPMI media.  
 
2.8.2 Animals  
Mice were housed in the Biological Services Unit of the Barts Cancer Institute, Queen 
Mary University of London. Animals were maintained in a pathogen-free environment 
according to institutional welfare guidelines under the authority of the UK Home 
Office Project License (70/8129) subjected to the Guidance on Operations of Animals 
scientific Procedures – Act 1986. Protocols and procedures were performed under the 
personal license number: IB7529564.  







nude mice were purchased from Charles Rivers (L'Arbresle, France). Mice used in 
experiments were at least 6 weeks old. 
Three experimental set ups were used to assess metastases: 
 For experiment ‘A’, 1x 105 cells injected to NSG mice 
 For experiment ‘B’, 0.5x 105 cells injected to nude mice 




2.8.3 Metastasis Assay  
Mice were anaesthetised with Isoflurane (Baxter Healthcare FDG9623) delivered at 
2% v/v for induction and 1 % v/v for maintenance in oxygen. 
Intrasplenic injections of cells suspended in 50μl ‘matrix’ were administered using a 
0.3ml capacity syringe and 30-gauge needle (BD microlance). 
7 days post injections, mice were anaesthetised as above, and splenectomy was 
performed (Figure 2.8). 
Mice were checked and imaged weekly from week 6 post initial injection using IVIS 











2.8.4 Bioluminescence Imaging  
IVIS Spectrum Imaging System was used for analysis of in vivo luciferase activity. 
Mice were anaesthetised and injected intraperitoneally with 150mg/kg of luciferin 
(Promega) diluted in PBS. Sequential images were obtained with mice positioned on 
the left (maximum light emission, ~ 16 and 21 minutes after luciferin injection). 
Luciferase activity was detected as photons per second per square centimetre per 
steradian (p/s -1 cm-2 sr-1). Living Image software (Caliper Life Sciences) was used 
for image analysis.  
 
2.8.5 Sacrifice and Organ Removal  
Once a minimum of 1x10
6 
ROI bioluminesce was achieved in at least 3 mice on IVIS 
imaging, or if signs of ascites developed in any mice (suggestive of liver 
decompensation), all experimental mice were sacrificed using CO2 and cervical 
dislocation. Livers were harvested, imaged on collection and fixed in 4% PFA. Organs 







2.9 Histology and Immunostaining 
2.9.1 Immunohistochemistry 
2.9.1.1 In vivo Tissue Staining 
Tissue staining for in vivo samples was undertaken with the assistance of Mr George 
Elia, Barts Cancer Institute UK. Formalin-fixed paraffin-embedded (FFPE) mice livers 
were serially sectioned (3μm thick). Sections were dewaxed in xylene and immersed 
in 100% ethanol for 5 minutes. Endogenous peroxidase was blocked using 100% 
methanol and 3% hydrogen peroxide for 10 minutes. Rehydration was then carried out 
using graded alcohols. Antigen retrieval was undertaken using microwaving in pre-
heated 0.1M Citrate Buffer (2.84g Tri-sodium Citrate in 1L distilled water, pH 6) for 
10 minutes. Sections were blocked using horse serum (1:75) for 15 minutes. CK19 
antibody (Table 2.6) was applied for 1 hour at room temperature. After incubation, 
slides were washed in PBS and incubated with horseradish peroxidase-conjugated 
avidin (ABC Standard: Vector Laboratories). Antigen was visualised using 
3,3’diaminobenzidine (DAB+) chromogen (DakoCytomation) for 2 minutes and then 
sections were counterstained in Mayer Haematoxylin for 2 minutes. Histological 
quantification of digitalised slides was performed using Panoramic Viewer 
(3DHistech). Following manual optimisation of antibody, automated staining was 
achieved using the Ventana Classic Automated system.  
 
2.9.1.2 Tissue Microarray Staining 
Patients were consented for use of tissue biopsy samples under the Barts Pancreas 
Tissue Bank. Tissue microarrays (TMAs) of pancreatic tissues from hepto-
pancreatico-biliary patients were constructed at Barts Health NHS Trust (City and East 
London Research Ethics Committee 07/0705/87). Following review for tissue core 
loss / inadequate staining, 33 PDAC tissue samples were available for analysis. 
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TMA staining was undertaken by Mr Andrew Clear, Barts Cancer Institute, UK and 
staining analysis was performed with his assistance. Paraffin sections were placed in a 
60°C oven for 1 hour and then dewaxed in xylenes. Rehydration was undertaken in a 
series of graded alcohols to distilled water. Antigen retrieval was then performed; 10 
minutes (high power) microwaving in citrate based Antigen Unmasking solution 
(Vector Laboratories), followed by cooling to room temperature. Endogenous 
peroxidase was quenched in 3% hydrogen peroxide for 10 minutes and rinsed in 
TBST. Tissue was then incubated with antibody for 40 minutes at room temperature 
(Table 2.6).  
Prior to immunostaining, tissue was stained with hematoxylin followed by bluing in 
0.5% ammonium. Serial rounds of staining on a single tissue section were optimised to 
ensure no loss of tissue antigenicity and were performed in order to maximise use of 
tissue cores and enable concurrent analysis of stained sections (Glass, Papin, and 
Mandell 2009). In addition, appropriate control sections were run in parallel with each 





Each primary antibody detection was performed with the Biogenex Super sensitive 
polymer detection system and VIP (Vector Laboratories). Slides were coverslipped in 
DPX and imaged following each stain in high resolution using Ariol computerised 
imaging software (Leica Microsystems).  
Destaining was undertaken by removing coverslips in xylene, and slides were then 
taken back to distilled water through a graded series of alcohols. Antibody and 
coloured reaction products from previous staining cycles were stripped by repeating 
the heat-induced epitope retrieval step (pressure cooking with citrate based Antigen 
Unmasking Solution). Complete stripping of antibody and chromogen was determined 
with comparison of non-stripped control sections and antibody omission controls. 
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Tissue was then re-stained, beginning with the primary antibody incubation step, as 
described previously.  
 
Table 2.5 Immunohistochemistry antibodies  
 
Antibody Concentration 
CD68 (M0814 Dako) 1:8000 
CK19 (ab9221 Abcam) 1:2000 
pSTAT3 (9145 Cell Signalling) 1:100 
OSMR (HPA017278 Sigma) 1:250 
 
2.9.1.2.1 Microscopy and Image Analysis 
Full-slide scans of stained tissue were obtained after each round of staining on the 
ARIOL imaging system (Leica Microsystems) and software was used to quantify 
antibody staining. For tissue analysis of CD68 staining, software was trained to 
automatically select and measure the area of purple (VIP) CD68 stained tissue per 
core. This was then calculated as a percentage of total tissue stained (i.e. coloured 
pixels above background white threshold) and a mean percentage area of CD68 
staining was taken per patient, as per validated methodology (Greaves et al. 2013). 
For staining of pSTAT3, software was first trained to detect and count the number of 
CK19 stained cells. Then, on linked images, software automatically counted cells 
positive for nuclear pSTAT3 within the previously determined CK19 stained area. 
pSTAT3 positive stained cells were then quantified as a percentage of the total CK19 
cells and an average of the three cores per patient was calculated. 
For OSMR staining, software quantified the pixel intensity of OSMR staining within 
the CK19 cell population per core. This value was then normalised to the number of 






Immunoflourescence was carried out cells in grown in adherent plates or embedded in 
three dimensional matrix. Following fixation and permeabilisation, cells were rinsed in 
IF Wash Buffer (PBS, 0.1% BSA; 0.2% Triton X-100; 0.05% Tween-20 pH 7.4) for 
10 minutes at room temperature.  
Samples were then blocked in Blocking Buffer (IF Wash Buffer with 10% goat serum) 
for 1 hour. Following blocking, antibody diluted in Blocking Buffer was added (Table 
2.6) and incubation undertaken at room temperature. Antibody was then aspirated and 
3x PBS washes completed.  Hoechst (33342) diluted in Blocking Buffer 1:2500 was 
added to each chamber for 15 minutes. A final rinse with PBS was carried out. For 3D 
matrix samples, removal of chamber walls was carried out and slides were mounted 
using ProLong Antifade. Slides were stored in darkness at 4°C and imaged on the 
Zeiss LSM 510 Confocal Microscope. 
 
Table 2.6 Immunoflourescence antibodies  
 
Antibody Concentration Incubation 
time (mins) 
Phalloidin 488 (A12379 Life Technologies) 5μl/ml 15 









2.10 Statistical Analysis 
In general, all experiments were performed at least 3 independent times, unless stated. 
Statistical analyses were performed as an estimation of the associated probability to a 
student’s t-test (95% confidence interval), or one-way analysis of variance (ANOVA) 
depending on the involved conditions. Fisher’s exact test was used for analysis of in 
vivo studies to compare groups. Data were represented as means ± standard error of 
the mean (SEM) unless stated. In all cases statistical calculation was developed using 



















3 CHAPTER THREE: PRO-TUMOURIGENIC 














3.1 Introduction and Aims 
Published data support macrophage driven tumour progression in various tumour types 
and models (Nielsen and Schmid 2017; Ruffell and Coussens 2015). Data from our 
laboratory has focussed on TAMs aiding PDAC progression by creating a CSC niche, 
but also touched on other mechanisms such as promotion of cell survival and 
metastasis formation (Sainz et al. 2014, 2015). Therefore the initial aims of this thesis 
will be to explore these phenotypes further in both the CSC and non-CSC populations. 
The majority of existing in vitro data exploring TAM driven tumourigenesis in PDAC 
from other groups has been carried out in cell line models. It is known that cell lines 
do not fully represent all tumour subtypes and these cultures loose heterogeneity over 
time as a result of major irreversible alterations in biological properties, including 
genetic gains and losses, growth and invasive properties and loss of specific cell 
populations (Gillet et al. 2011).  Therefore by using primary cancer cells, both 
macrophages and PDAC cells, a more representative model could be applied for 
experimental testing that incorporates a more heterogeneous population of cells, 
resulting in more clinically relevant biological findings (Hidalgo et al. 2014) . 
The aims of this chapter are: 
 To explore the pro-tumourigenic effects of TAMs in the primary PDAC model 









3.2  Results 
 
3.2.1 EMT, Invasion and Metastases 
 
To determine the effects of TAM secreted factors on primary PDAC cells, a panel of 
primary PDAC cells were cultured with standard control media (DMEM:F12 (Gibco) 
supplemented with B-27 (Invitrogen) and β-FGF (PeproTech)) or standard control 
media that had been conditioned by MCSF-polarised macrophages for 48 hours 
(MCM) (see methods section 2.1.2.1). PDAC cells were treated for 48hrs in 2D and 
matrix-based 3D conditions and compared to control media alone.  It was noted that 
cells adopted a more myofibroblast-like morphology, with an elongated shape, and 
appeared detached / scattered, with less colony formation in MCM (Figure 3.1), 
suggestive of cells undergoing EMT.  
 
Figure 3.1 Primary PDAC cell morphology in MCM 
A) Brightfield microscopy images of primary PDAC cells cultured in MCM or control media for 48hrs 
B) Immunoflourescent images of primary PDAC cells grown in a 3D matrix in the presence of control 




Morphological changes were confirmed to be transition from an epithelial to a 
mesenchymal state by RT-qPCR gene analysis of cells cultured in MCM. Consistent 
upregulation of mesenchymal-associated genes (zeb1, vimentin, loxl2 and slug) were 
seen in all cell types compared to treatment with control media alone (Figure 3.2). Of 
note, a difference in the degree and pattern of each gene upregulation between cell 
types was seen throughout the primary cell panel and when using different donor 
macrophages to generate conditioned media and through use of different in vivo and in 
vitro passages of primary PDAC cells. This was expected, as the cancer cells tested 
represent a group of heterogeneous primary PDAC tumours and primary macrophage 
were derived from different donors. This model would therefore be reflective of the 
heterogeneity likely to be seen in the ‘real’ PDAC tumour. Upregulation of EMT 
genes was consistent across all cell types despite heterogeneity of tumour and 
macrophage cells, thus indicating a true finding likely to be relevant to a 






Figure 3.2 EMT gene expression in MCM culture 
RT qPCR of Panc185, 215, 253, 354, 10953, 12560 (n=9 per cell type) and Panc140114, C75, C76 (n=4 
per cell type) treated with MCM over 48hrs. Results represent a compilation of experiments normalised 
to control, with values representing the mean (+/- SEM). Statistical significance: Wilcoxian signed-rank 
test * = p<0.05, ** p<0.005 
 
 
Zeb1 Loxl2 Vimentin Slug 
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To confirm effects of TAMs on the induction of EMT in PDAC cells, a ‘direct’ co-
culture of unpolarised macrophages was undertaken in Panc215, 354 and 10953 using 
transwell co-culture. These results confirmed upregulation of EMT genes in ‘direct’ 




Figure 3.3 EMT gene expression in ‘direct’ macrophage and MCM coculture 
RT qPCR of Panc215, 354, 10953, (n=6 per cell type) co-cultured with unpolarised donor macrophages 
or MCM for 72hrs. Results represent a compilation of experiments normalised to control, with values 
representing the mean (+/- SEM). Statistical significance: Wilcoxian signed-rank test * = p<0.05 
 
Effects in direct culture were less pronounced than with MCM, for example Zeb1 was 
not consistently upregulated as with experiments using MCM alone (Figure 3.2). This 
could be as a result of different PDX in vivo passages used for in each experiment or 
due to the different experimental set up: for cells tested in Figure 3.2, primary cultures 
were treated for 48hrs in adherent plates with either control media on MCM. For 
experiments using co-culture, cells were treated in transwells, either with MCM or 
with macrophages plated on inserts (as described in section 2.1.2.2). Thus for co-
culture experiments, there was regulatory feedback between the two cell types when in 
direct culture that would not be present in conditioned media treating PDAC cells 
alone. As the cells types are in constant feedback with one another in co-culture, 
factors inducing EMT being secreted by macrophages could be regulated through a 
negative feedback loop when in direct culture, leading to lower EMT gene expression. 
Alternatively, the lesser effects could be explained by time points: macrophages used 
Zeb1 Loxl2 Vimentin Slug 
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in this experiment were ‘unpolarised’ at the time of seeding and only underwent 
‘TAM’ polarisation once culture with PDAC cells began. Thus, in these conditions, 
the secretion of any EMT-inducing factors by TAMs may be delayed, unlike in MCM 
where the factors are present from the start. To try to compensate for this, both co-
cultures were left for longer (72 hours) than the usual 48 hours with MCM alone. 
However, this presumes that polarisation of TAMs takes up to 72hrs in co-culture, and 
this has not been confirmed. One therefore cannot be certain of when the maximum 
‘EMT’ inducing effects of the eventually polarised macrophages was taking place, and 
therefore it would have been better to perform a time course assay with cells in co-
culture, first examining when macrophages were being polarised in direct culture with 
PDAC (for example using FACS analysis of CD163 or qPCR of ‘TAM’ gene 
expression in the macrophages) and then examining when the PDAC cells were 
undergoing EMT. By performing these kinetic experiments, time points could have 


















































Having now confirmed an EMT phenotype in PDAC as a result of TAM interaction, it 
was necessary to show functional effects. For all invasion assays, primary PDAC 
cultured cells were pre-treated with either non-conditioned control media (Ctl) or  
media conditioned by macrophages (MCM) for 48 hours and then seeded in transwell 
invasion assay (at least 2 transwells per condition per experiment). The number of 
invaded cells in each well was then counted and the mean number of cells per 
condition was calculated. The average number of invasive cells with MCM pre-
treatment was then calculated as a fold-change against the average number of invasive 
cells with control media pre-treatment. Cells pre-treated with MCM showed consistent 
increased invasive ability towards serum-rich conditions compared to control treated 
cells (Figure 3.4). This finding indicated functional consequence that macrophage 
derived factors were activating invasion in PDAC cells, possibly through transition to 










A) Panc215, 354 and 10953 (n=6 experiments per cell type) cells cultured with macrophage conditioned 
media (MCM) or control media (Ctl) for 48hrs and seeded for transwell invasion assay. For each 
experiment, the average number of invaded cells with MCM pre-treatment was then calculated as a fold 
change compared to control treated cells. Results represent a compilation of experiments normalised to 
control, with values representing the mean (+/- SEM). Statistical significance: Wilcoxian signed-rank 





Figure 3.4 Transwell invasion assay of MCM pre-treated cells 
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3.2.1.1 EMT and Invasion in Cancer Stem Cells 
Having now confirmed cells cultured with TAM secreted factors display an EMT 
phenotype and are more invasive, it was important to assess the effects of MCM on the 
cancer stem cell population specifically. Previous data from the laboratory has 
confirmed that factors within MCM enrich for cancer stem cells (Sainz et al. 2014, 
2015). For the purpose of this thesis, differential effects of EMT and invasion between 
the CSC and non-CSC population were examined. Cancer stem cells were defined by 
sorting for the cancer stem cell marker, CD133 (Human prominin-1, PROM1). This 
protein is a transmembrane cell-surface protein that localises to the plasma 
membrane. CD133 is expressed in cancer progenitor cells, including pancreatic cancer 
cells, and is an essential marker for detecting and enriching for CSCs in PDAC 
(Hermann et al. 2007). 
In the first instance, cells sorted for CD133 expression were cultured with control 
media or MCM for 48 hours and displayed differences in EMT gene regulation: at 
baseline (in control media) CD133+ cells had a significantly higher expression of the 
loxl2, and a trend for higher gene expression in zeb1 and vimentin (but not significant) 
(Figure 3.5). With MCM treatment, both the CD133- and CD133+ cells underwent a 
significant increase in all EMT genes, as seen in the ‘bulk’ mixed population of cells. 
Of interest, CD133+ cells had a significantly higher expression of zeb1, vimentin and 
loxl2 following MCM treatment when compared to upregulation of these genes in 
CD133- MCM treated cells. This finding would suggest that the invasive effects of 
CSCs were being potentiated by MCM, making them the most ‘EMT’ population 




Figure 3.5 EMT gene expression in CD133- & CD133+ Panc354 cells 
RT qPCR of CD133- and CD133+ Panc354 (n=8) cultured with MCM for 48hrs. Results represent a 
compilation of experiments normalised to control, with values representing the mean (+/-SEM). 










Confirming this result, CD133+ cells were more invasive at baseline compared to 
CD133- cells in invasion assay, but the most invasive population was the CD133+ 
MCM treated cells (Figure 3.6).  
 
Figure 3.6 Transwell invasion assay of CD133- and CD133+ Panc354 
Panc354 (n=6) cells cultured with MCM in transwell invasion assay. Results represent a compilation of 
experiments normalised to control, with values representing the mean (+/-SEM). Statistical significance: 
Wilcoxian signed-rank test * = p<0.05. 
 
 
Thus, collective in vitro results confirmed activation of EMT and invasion in primary 
PDAC cells when exposed to TAM secreted factors. In particular, these factors had the 





































1.8.1.1 In vivo metastasis 
Following in vitro data supporting the invasive effects of MCM in the primary PDAC 
model, the systemic relevance of these effects were tested using the in vivo model. 
Cells used for in vivo injection were Panc354 cells transduced with the CMV-
Luciferase-RFP-TK Lentivirus. Prior to preparing cells for injection, the effects of 
MCM were tested on this cell type to ensure similar effects were seen as with non-
transduced cells. Results confirmed typical changes in cell morphology and increased 
mesenchymal gene expression in Panc354-Luc cells following culture in MCM as 























Figure 3.7 Effects of MCM on Panc354-Luc cells  
A) Brightfield microscopy confirming EMT morphology in MCM cultured Panc354-Luc cells prior to 
in vivo injection B) RT qPCR of Panc354-Luc cells (n=2) cultured with MCM for 48hrs. Results 






In vivo experiment ‘A’ was performed using Panc354-Luc cells pre-treated with 
control media or MCM in vitro (see methods). Cells were then injected 
intrasplenically to mice after 48 hours. 1x 10
5
 cells were injected to NSG mice and 
splenectomy performed 1 week later. Animals were sacrificed at 6 weeks post 
injection, by which point the BLI signal was 1x10
6
 in 3 mice. Livers were dissected 
and imaged. Absence of metastatic spread was confirmed in livers with 
macrometastases by fixing organs and staining serial sections with CK19 antibody. On 
collection of organs, 3/5 livers treated with control media had macrometastasis and 5/5 
in MCM pre-treated cells (Figure 3.8 and Table 3.1). The number of mice treated in 
this experiment was not enough to determine significant differences on the effects of 
metastases formation in MCM pre-treated cells compared to control media treated 
cells in vivo. Therefore, this experiment would need to be powered calculated and 
repeated in more animals in order to make definitive conclusions about the differences 


























Figure 3.8 Liver macrometastasis in vivo 
Liver macrometastasis experiment ‘A’ following intrasplenic injection of 1x 10
5
 Panc354-Luc cells 
pretreated with control or MCM for 48hrs in vitro. Animals were sacrificed and livers imaged 6 weeks 








In order to further investigate the effects of TAM on PDAC progression, proliferative 
state was next assessed. Using FACS assessment of Ki67 staining, the percentage of 
positive stained cells (in G1 and S/G2-M phase) were quantified for both control 
media and MCM treated cells (Figure 3.9A). These results showed no significant 
difference between the percentage of Ki67 positive cells in control media or MCM 












Positive for liver metastasis / total number 
animals (%) 
Control 3/5 (60%) 

























Figure 3.9 Ki67 FACS analysis of MCM cultured cells 
A) Representative FACS plots of Panc215 and 354 stained with isotype control and Ki67 antibody 
after 48hrs of treatment in control media or MCM. Key: Q1=Ki67 +ve cells in G1 phase, Q2= Ki67 
+ve cells in S/G2-M phase, Q4=Ki67 –ve cells. At least 10,000 events were recorded for each 
condition. B) Quantification of Panc185, 215, 253 and 354 positive cells (G1 and S/G2-M phase) in 
control media compared to MCM treated cells (n=3 per cell type). Results represent a compilation of 
















































































Crystal violet proliferation assay was also undertaken for culture over longer time 
periods. Following 4 days and 7 days treatment, there was again no significant 









Figure 3.10 Crystal violet proliferation of MCM cultured cells  
A) Crystal violet analysis of Panc215, 354 and 10953 treated with MCM for 4 days (n=3 per cell type). 
Staining of crystal violet was normalised to day 0 control (i.e. pre-treated cell density). B) Crystal violet 
analysis of Panc354 and 10953 treated with MCM for 3 and 7 days (n=2 per cell type). Staining of 
crystal violet was normalised to day 0 control (i.e. pre-treated cell density).  
 
Cell death was next analysed using annexin V FACS staining of cells pre-treated in 
each condition. Quantification of live cells analysed using annexin V showed no 











Panc185 Panc215 Panc253 Panc354
Ctl
MCM





















A) Representative FACS plot of Panc215 and 354 stained with Annexin V antibody after 48hrs of 
treatment in control media or MCM. Key: Q1=DAPI +ve dead cells +, Q2= DAPI+ve and annexin 
V +ve dead cells (apoptosis), Q3=annexin V + live cells (undergoing apoptosis), Q4= live cells. At 
least 10,000 events were recorded for each condition. B) Quantification of Panc185, 215, 253 and 
354 live annexin V positive cells (Q4) in control media compared to MCM treated cells (n=4 per 
cell type). Results represent a compilation of experiments in normalised to control, with values 
representing the mean (+/- SD). 






















Thus, when cells were cultured in MCM, there was no differences seen in the number 
of cells undergoing cell death compared to control treated cells. Taken together, these 
results show factors within MCM do not confer a proliferative or survival advantage 
on PDAC cell growth in basal conditions. 
3.2.3 Chemoresistance 
Following data already published in PDAC (Di Caro et al. 2015; Mitchem et al. 2013; 
Weizman et al. 2014), it was pertinent to test the effects of MCM on cell survival in 
context of stress, particularly chemotherapy. As gemcitabine is the backbone of 
current therapy, cells were pre-conditioned with MCM or control media for 48 hours 
and media was then refreshed to contain 300nM of gemcitabine or no drug. 
Analysis by crystal violet staining showed no survival advantage against 
chemotherapy with MCM pre-conditioning (Figure 3.12). No differences were noted 
between control and MCM gemcitabine treated cells, with an almost identical pattern 
of decreased crystal violet staining between the two conditions.   
 
Figure 3.12 Crystal violet analysis of gemcitabine treated cells 
Panc215, 354 and 10953 were pre-conditioned with MCM for 48hrs and then media was refreshed with 
the addition of 300nM gemcitabine. Cells were grown for a further 4 days. Results represent n=1 per 
cell types and values are normalised to day 0 control (i.e. pre-treatment cell density) and plotted relative 




FACS analysis of annexin V staining was performed to determine cell death following 
treatment with gemcitabine. Again no significant differences were noted in MCM pre-
treated cells (Figure 3.13). 
 
Figure 3.13 Quantification of annexin V stained cells in MCM 
Quantification of Panc185, 215, 253 and 354 live annexin V positive cells (Q4) in control media 
compared to MCM pre-treated cells with gemcitabine treatment (n=4 per cell type). Results represent a 
compilation of experiments normalised to control, with values representing the mean (+/- SD). 
 
Taken collectively, results indicate factors within MCM do not confer a survival 








3.2.4 Microarray Gene Analysis of Panc253 and 354 
Having determined that cells cultured with macrophage derived factors were driving 
epithelial-to-mesenchymal transition, leading to invasion in vitro and metastasis in 
vivo, the factors and pathways generating this phenotype in primary PDAC cells 
needed to be determined. To do this, Agilent microarray gene analysis of cells treated 
with MCM was performed in collaboration with Professor Stephan Hahn of the Ruhr-
University Bochum, Germany. Initially, Panc253 and 354 were sent for analysis. 
To validate microarray samples sent to collaborators, RT qPCR of the treated Panc253 
and 354 was performed and confirmed upregulation of EMT genes (Figure 3.14). 
 
Figure 3.14 EMT gene validation of microarray samples 
RT qPCR of EMT genes in Panc253 and 354 cells (n=1) cultured with MCM for 24hrs and sent for 








3.2.4.1 Gene Regulation 
Microarray data were analysed as follows: fold change differences of gene expression 
in conditioned media compared to control treated cells was determined. Moderated t-
test was applied and significant gene fold differences were determined (p<0.05). 159 
genes were found to be significantly upregulated and 94 downregulated in Panc354. 
41 genes were significantly upregulated and 34 downregulated in Panc253 (Figure 
3.15).  
 
Figure 3.15 Venn diagram of microarray gene expression 
Gene expression fold change profile in Panc253 and 354 comparing control media treated cells with 
conditioned media. A) Significantly downregulated genes B) Significantly upregulated genes. Statistical 










6 commonly downregulated genes in MCM culture were found between Panc253 and 
354 (Figure 3.15 and 3.16).  
 
Figure 3.16 Common downregulated genes on microarray 
 
14 commonly upregulated genes in culture with MCM were found between Panc253 
and 354 (Figure 3.15 and 3.17). Of these genes, the serine proteases SerpinB3 and B4 
were the most highly upregulated genes in both cell types. 
 





3.2.4.2 Gene Set Enrichment Analysis 
To determine which pathways were likely to be activated by macrophage-derived 
factors, microarray data was analysed, with the assistance of Dr Meng-Lay Lin, using 
KEGG pathway mapping. Agilent microarray gene expression profiles were uploaded 
to software, and based on the transcriptomic profile of Panc253 and 354 cultured in 
MCM, 10 common gene sets were found to be significantly enriched between the two 
cell types (FDR q-val <0.25) (Table 3.2).  
Table 3.2 KEGG gene set enrichment Panc253 and 354 
(NES = normalised enrichment score. FDR= False Discovery Rate: p-val <0.25) 




COMPLEMENT_AND_COAGULATION_CASCADES 1.4998453 1.7503108 
FOCAL_ADHESION 1.5119898 1.3321809 
LEISHMANIA_INFECTION 1.5941939 2.384698 
NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY 1.5958716 1.8420589 
CYTOSOLIC_DNA_SENSING_PATHWAY 1.6120821 2.0001507 
CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 1.6617507 2.2095013 
OLFACTORY_TRANSDUCTION 1.6780441 1.600173 
JAK_STAT_SIGNALING_PATHWAY 1.7079959 2.1062407 
ECM_RECEPTOR_INTERACTION 1.7152467 1.7317232 
HEMATOPOIETIC_CELL_LINEAGE 1.97643 2.1082714 
 
 
Of these gene enrichment sets, two were noted to be of potential of interest: Cytokine 
receptor interaction was deemed important, as macrophages are known to be abundant 
producers of cytokines within the TME. In addition, the JAK-STAT signalling 
pathway was of interest, as this pathway is known to be activated by cytokines, 
dysregulated in many different cancers and relates to metastasis (Frank 2007).   
Therefore, based on microarray analysis of Panc254 and 354, SerpinB3/B4 were 
determined as factors of interest and cytokine receptors / JAK-STAT signalling were 
gene sets of interest to take forward for investigation in relation to the invasive / 





3.3 Discussion  
When exploring the pro-tumourigenic effects of TAMs on primary PDAC cells, the 
most striking finding was that of TAMs inducing EMT, invasion and metastatic spread 
in primary PDAC cells. Results demonstrated an upregulation of mesenchymal genes 
associated with the process of EMT (zeb1, vimentin, loxl2 and slug) when primary 
cells were treated with conditioned media from MCSF-polarised macrophages. This 
finding was supported by transwell culture of the two cell types, confirming that this 
effect is seen in ‘real-time’ when macrophages are polarised through transwell 
interaction with the cancer cells rather than by MCSF. In keeping with transition from 
an epithelial-to-mesenchymal state, cells were more invasive in vitro and formed more 
metastases when injected in vivo.  
Previous studies have published similar phenotypic changes in cancer cells following 
interaction with macrophages (summarised in section 1.4.2.5). In pancreatic cancer, 
Mitchem et al. first demonstrated a requirement for TAMs in metastatic spread. Focus 
of this study was on the effects of macrophage depletion on tumour initiating cells (i.e. 
a subpopulation of cells akin to CSCs), but when using orthotopic injections of mouse 
tumour cells, authors demonstrated a decrease in peritoneal metastases with two kinase 
inhibitors against the macrophage survival factor CSFR1 (PLX6134 and PLX3397) 
(Mitchem et al. 2013). No mechanism of action for how macrophages were inducing 
these metastatic effects was generated in this study, but these finding support our 
results that TAMs are important for tumour cell dissemination. 
Our experimental model used conditioned media from MSCF-polarised macrophages 
and transwell co-culture, suggesting secreted factors from TAMs were likely to be 
driving EMT, leading to invasion and metastasis formation. Several publications have 
described TAM derived cytokines can mediate EMT and invasion in different cancer 





Table 3.3 Macrophage derived cytokines inducing EMT 
 
Cytokine Cancer Type Reference 
CCL18 Breast (Chen et al. 2011; Su et al. 2014) 
IL4, IL6, IL10, TNF-α and 
TGF-β1 




(Gal et al. 2008; Bonde et al. 2012; 
Mikiko et al. 2012) 
CCL18 Pancreatic (Meng et al. 2015) 
IL10 Pancreatic (Liu et al. 2013) 
CCL20 Pancreatic (Liu et al. 2016) 
TGF-β Gastric (Shen et al. 2013) 
 
In pancreatic cancer cell line models, several cytokines have been implicated in 
driving EMT;  
- IL10 induced EMT in Panc1 and BxPC3 cell lines, in response to activation of 
toll-like receptor (TLR) 4 in IL-4 polarised macrophages ( Liu et al. 2013).  
- CCL18 derived from TAMs (using macrophage cell lines, U937 and THP-1) 
induced EMT in Panc1, BxPC3, Capan2 and SW1990 cells and was suggested 
as a potential clinical biomarker in PDAC, but no mechanism of action was 
implicated in this study (Meng et al. 2015). 
- CCL20 expression in macrophages promoted EMT and invasion in pancreatic 
cancer cells lines Panc1, MiaPaCa2, and SW1990 and metastasis in vivo. RNA 
interference of its receptor in pancreatic cells, chemokine receptor 6 (CCR6), 
led to decreased invasion (Liu et al. 2016). 
Therefore there are pre-clinical data implicating macrophage-secreted cytokines in the 
process of EMT and invasion in pancreatic cancer. These studies were predominantly 
undertaken in cell line models, although CCL18 was verified in clinical samples. 
When exploring data using patient derived cells, in vitro results of this chapter are 
validated by Helm et al. whereby transwell co-culture experiments were performed 
using both patient tissue derived TAMs and healthy donor GMCSF- and MCSF-
polarised macrophages with PDAC cell lines (H6c7 = premalignant PDAC cell line, 
Colo357 = malignant PDAC cell line) (Helm et al. 2014). In the first instance, 
transwell co-culture using both patient tissue derived macrophages and healthy donor 
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macrophages revealed a change in PDAC cell lines to a more mesenchymal-like cell 
morphology along with increased RNA and protein expression of vimentin and the 
adhesion molecule L1CAM. In turn, Colo357 cells were more invasive following co-
culture with both subsets of polarised macrophages. The authors did not deduce the 
specific cytokines or factors that could be inducing these effects, only speculated that 
it could be TGFβ1. These findings are in keeping with results from this chapter, which 
demonstrated increased expression of EMT genes (zeb1, vimentin, slug, loxl2) and 
invasion following exposure of primary PDAC cells to primary TAM secreted factors 
as well as transwell co-culture. The secreted factors inducing these changes in the 
primary culture model have yet to be identified. 
In this first chapter, other published pro-tumourigenic effects of TAMs were explored. 
Proliferation and cell survival was assessed and showed no significant difference in 
cells treated with control media or conditioned media. Mitchem et al, showed 
inhibition of TAMs (through CSF1R and CCR2 inhibition) led to a decrease in 
orthotropic tumour burden, suggesting an effect on tumour cell proliferation in vivo 
through the loss of macrophages. However, the in vivo model used in this setting 
differs from our in vitro proliferation based platforms and it would be too simplistic to 
directly compare the two findings. TAMs have effects on pro-survival, angiogenesis 
and on the ECM, which effect the growth of tumours in the in vivo setting and not of 
cells grown in vitro. There are data to suggest cells undergoing EMT are less 
proliferative, .for example in colorectal tumour tissue, cells on the invasive front of 
tumours displaying a more mesenchymal profile were found to have less Ki67 staining 
as they were undergoing ‘dedifferentiation’ to invade and metastasise (Brabletz et al. 
2001). However, we did not find a significant difference in proliferation rates in our 
cell cultures treated with macrophage conditioned media compared to control. 
No survival advantage was demonstrated with chemotherapy in cells pre-treated with 
macrophage-secreted factors. Mitchem et al. showed better efficacy of gemcitabine in 
vivo when given concomitantly with TAM inhibitors (CSF1R and CCR2 inhibitors) 
(Mitchem et al. 2013). Weizman et al. have also tested the chemoprotective effects of 
TAMs and used similar in vitro assays to ours, whereby conditioned media from 
healthy donor ‘TAM’ macrophages was supplemented with gemcitabine and used to 
treat Panc01 cells. These data show a significant reduction in apoptosis and activation 
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of the caspase-3 pathway during gemcitabine treatment, and was supported by in vivo 
inhibition with the CSF1R antagonist GW2580. Smaller tumours were seen in mice 
treated with both gemcitabine and GW2580 compared to gemcitabine alone. Authors 
determined that TAMs were chemoprotective by inducing expression of the cytidine 
deaminase (CDA) gene in cancer cells, a gene responsible for resistance to 
gemcitabine and cisplatin, through paracrine signalling. It should be noted that the in 
vitro data for this study was limited to only one cell line (Panc01). Certainly from our 
limited data, FACS staining for annexin V showed a slight increase in live cells 
following gemcitabine treatment in Panc185 and 215 cells pre-treated with MCM, 
although this was not a significant increase. This finding could suggest heterogeneity 
of responses dependent on PDAC cell type, possibly due to differences in CDA 
expression in different cell types. However, our results are too limited to definitively 
conclude chemoprotective effects of macrophages in the primary PDAC model and 
would require further testing in vitro and in vivo on a wider panel of cell types. 
The second aim of this chapter was to determine factors regulated by TAM interaction 
in primary PDAC cells. In microarray gene analysis of Panc253 and 354, the highest 
upregulated factors were protease inhibitors, SerpinB3 and B4. These genes encode for 
proteins known as squamous cell carcinoma antigens (SCCAs) and form part of the 
clade B subset of serpins. They bind to enzymes such as cathepsins via an irreversible 
interaction. The first variant of the SCCAs to be identified was SerpinB3 (aka 
SCCA1), which was elevated in squamous cell carcinoma (Kato and Torigoe 1977) 
and has since been proven to be highly expressed in several other cancers including 
lung, head and neck and liver (Vidalino et al. 2009). SerpinB3 drives EMT and 
invasion in hepatocellular carcinoma and breast cancer (Quarta et al. 2010; Sheshadri 
et al. 2014). In pancreatic cancer, SerpinB3 is expressed at higher levels in malignant 
tissue compared to non-malignant, and expression relates to the progression of cancer 
(Catanzaro et al. 2014). A function for this protein has yet to be established in PDAC. 
It would therefore be of interest to explore SerpinB3 in the context of macrophage 
induced expression in our primary models in the context of the metastatic phenotype 
identified. 
As well as exploring specific genes of interest, activated signalling pathways in PDAC 
cells driven by TAM interaction were generated using microarray data. The JAK-
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STAT and cytokine receptor pathways were noted to be enriched based on GSEA. The 
signal transducer and activator transcription (STAT) family comprises of seven genes; 
STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B and STAT6. Activation of 
these transcription factors crucially require phosphorylation by Janus kianses (JAKs). 
These tyrosine kinases are frequently coupled with receptors upstream of STATs and 
their kinase activity initiates downstream intracellular signalling. More than 40 
different polypeptide ligands cause STAT phosporylation, either through cytokine 
receptor association with JAK kinases or growth factors acting through intrinsic 
receptor tyrosine kinase activity. Hence, it would not be unexpected that the JAK-
STAT and cytokine receptor gene sets were both found to be enriched on GSEA as 
they are likely share similar genes in their assosciated expression profiles. 
Of the seven different STAT family members, STAT3 is the most commonly 
described in cancer and is itself recognised as an oncogene (Bromberg et al. 1999). 
This STAT is commonly associated with inflammatory transcription pathways and is 







Under basal conditions, cytoplasmic STAT3 is activated by phosphorylation on a single tyrosine kinase 
residue 705 (Y705) in the C-terminal domain of STAT3. Phosphorylation of the STAT3 Y705 residue 
can be induced by cytokines, growth factors via non-receptor tyrosine kinases (such as JAK and Src). 
Following phosphorylation, STAT3 homodimers (or heterodimers with STAT1) translocate to the cell 
nucleus. Once in the nucleus, dimerised STAT3 binds to DNA, recognising bases in the major groove, 
and binds specific DNA response elements in the promoter regions of  target genes.  
Figure 3.18 STAT3 activation and translocation  
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STAT3 protein is constitutively activated in many cancers without mutation of the 
gene itself (Yu et al. 2014), is associated with cancer related inflammation (Yu et al. 
2014) and plays an activate role in pancreatic tumourigensis (Scholz et al. 2003). 
Pioneering work by Lesina at el. has demonstrted the vital role of STAT3 in 
progression of PaNIN to PDAC, and linked activation fo this transcription factor to the 
inflammatory cytokine interleukin-6 (IL6) (Lesina et al. 2011). The downstream target 
effects of STAT3 in other cancers are many, and vary according to tissue type. 
Experimental data of the direct binding targets of STAT3 demonstrate involvement in 
a large variety of potential cancer pathways (Carpenter and Lo 2014). Based on direct 
binding alone, STAT3 is implicated in tumour metastases and mediates transcription 
of several genes involved in metastasis formation, including EMT (Zeb1, Twist, 
Vimentin), ECM degradation (MMPs) and cell survival (Bcl-2, Survivn, Bcl-x) 
(Carpenter and Lo 2014). Therefore, investigating further how activation of STAT3 
may play a role in PDAC tumour progression as a result of TAM interaction would be 
of interest in determining the intracellular mechanisms that could then be targeted for 
































4.1 Introduction and Aims 
Microarray gene analysis of primary PDAC cells revealed SerpinB3 and B4 as the 
highest upregulated genes in Panc253 and 354 in the presence of macrophage 
conditioned media. There is a high degree of homology between the two proteins, 
however there are important differences in function, with analysis showing SerpinB3 
as a potent cross-class inhibitor of papain-like cysteine proteinases such as cathepsins 
L, S and K, whereas SerpinB4 is an inhibitor of chymotrypsin-like serine proteinases 
such as cathepsin G and mast cell chymase and derp1 and 2 (Schick et al. 1998).  
In both cell types, microarray analysis showed SerpinB3 to be the highest expressed 
following MCM treatment: in Panc253, the gene was upregulated 23 times more in 
conditioned media than control media (p=0.000867) and in Panc354 upregulation was 
218 times higher (p=0.003938). In addition, SerpinB3 has been described as playing a 
role in regulating epithelial-to-mesenchymal state and invasion in other tumour types 
(Quarta et al. 2010; Sheshadri et al. 2014; Sueoka et al. 2005), a phenotype similar to 
that induced by MCM culture in this PDAC model. How this protein directly induces 
invasion and migration specifically has yet to be characterised. In HCC, a direct 
mechanism of action has not been proven, but SerpinB3 transfected cells have down-
regulation of E-cadherin and upregulation of β-catenins, which are both known to be 
linked to the process of EMT, thus leading authors to speculate that these proteins 
could be playing a role. There is also upregulation of MMP activity in transfected 
cells, therefore SerpinB3 could also be regulating these enzymes resulting in more 
invasion (Quarta et al. 2010). In PDAC, SerpinB3 has already been identified as a 
marker of progression (Catanzaro et al. 2014).   
Overexpression of the SerpinB3 gene results in an EMT phenotype in HCC (Quarta et 
al. 2010). As macrophage-conditioned media is upregulating this gene in PDAC 
treated cells, we hypothesised that expression of SerpinB3 in PDAC cells following 
MCM treatment could be directly regulating the resultant EMT phenotype. Therefore, 





The aims of this chapter are: 
 To confirm upregulation of SerpinB3 in PDAC cells treated with media 
conditioned by macrophages 
 To characterise the role of SerpinB3 expression following TAM interaction 

















Although the aim of this chapter was to determine the function of SerpinB3 in the 
context of PDAC tumour progression, there was not enough experimental evidence to 
define its role. Several of the experiments in this chapter were initially performed 1-2 
times in the three cell types respectively to test for an overall trend across cell types 
prior to further investigation. However, these preliminary experiments showed a lack 
of consistent findings across all cells types, therefore I stopped pursuing the role of 
SerpinB3 in PDAC. Conclusions presented are therefore speculative and it would 
require further investigation to definitively understand if the upregulation of SerpinB3 
in response to macrophage secreted factors helps drive PDAC progression.    
 
4.2.1 SerpinB3 upregulation 
In order to confirm SerpinB3 gene was upregulated in MCM treated PDAC cells, RT 
qPCR was performed on a selection of primary PDAC cells treated for 48 hours 
(Figure 4.1). When normalising to control media, a consistent increase of SerpinB3 
was seen across all cell types using several donor macrophages to generate MCSF-
polarised macrophage conditioned media. These findings confirmed the microarray 
results and showed effects were consistent using different macrophage donors and 




Figure 4.1 Gene expression of SerpinB3 
SerpinB3 mRNA through RT qPCR of Panc185, 215, 253 and 354 cells cultured with MCM from 4 
different donors over 48hrs (n=4 per cell type). Results represent a compilation of experiments in each 
cell type was normalised to control, with values representing the mean (+/- SD). Statistical significance: 
Wilcoxian signed-rank t test * = p<0.05. 
 
Increased expression at the protein level was demonstrated on one western blot only of 
Panc354 cell lysate using anti-SerpinB3 antibody (Figure 4.2). This result could not be 
repeated, and this could relate either to lesser protein expression levels in subsequent 
cell lysates or due to suboptimal antibody detection methods (e.g. polyclonal antibody 
rather than monoclonal). Therefore further optimisation or investigation into 
alternative antibody for detection would be required to prove this result further.  
 
Figure 4.2 Protein expression of SerpinB3 
SerpinB3 protein expression in Panc354 cells treated with MCM for 48hrs. Western blot was cut 
following transfer and incubate with relative antibody simultaneously. 
 Ctl         MCM 
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4.2.2 Effects of recombinant SerpinB3  
In relation to EMT and invasion, Quarta et al. have previously linked SerpinB3 to 
increased invasion and migration, as well as proliferation, in the HepG2 cell line 
following treatment with recombinant protein (Quarta et al. 2010). Thus, initial testing 
to determine the effects of SerpinB3 in PDAC were undertaken using recombinant 
human SerpinB3 (rhSerpinB3). Based on experimental data from Quarta et al, 
100ng/ml and 200ng/ml were used to treat Panc185 and Panc354 cells. 
After 48 hours of treatment, no difference in cell morphology was noted (Figure 4.3), 
and no consistent changes in EMT gene expression were seen (Figure 4.4). 
 
Figure 4.3 Cell morphology with recombinant human SerpinB3 
Panc185 and Panc354 cells treated with 0ng/ml, 100ng/ml and 200ng/ml of recombinant SerpinB3 for 








Figure 4.4 EMT gene expression with recombinant human SerpinB3 
Panc185 and Panc354 cells treated with recombinant human SerpinB3 over 48hrs were analysed using 
RT qPCR for EMT gene expression (n=1). Results represent normalisation to control (0ng/ml). 
 
This lack of effect suggested that treatment of PDAC cells with recombinant SerpinB3 
protein had no effect on EMT as seen with MCM treated cells. However, it could be 
questioned whether the recombinant protein underwent endocytosis (to then have an 
intracellular effect) in our model of primary PDAC cells. Quarta et al. were able to 
demonstrate extracellular effects using recombinant human SerpinB3 protein in 
HepG2 cells (through immunofluorescence staining for EMT-related proteins), but 
also confirmed effects altering gene overexpression, indicating both an extracellular 
paracrine and an autocrine effect in HepG2 cells.  
Therefore in order to further investigate a function of SerpinB3 in the primary PDAC 
model, it would be necessary to manipulate intracellular gene, and thus protein 




4.2.3 SerpinB3 knockdown  
SerpinB3 gene silencing was performed using doxycycline inducible lentiviral 
SerpinB3 shRNA constructs in Panc185, 215 and 354 cells. 
Sorted GFP+ cells were cultured and maintained as stably transduced populations. 
Expression of the SerpinB3 transcript was assessed using RT qPCR and compared to 
the level of gene expression in cells transduced with the non-targeting ‘scrambled’ 
shRNA (‘SCR shRNA’) and non-transduced cells (‘NT’) treated with MCM (Figure 
4.5). Results showed a trend for knockdown of MCM induced SerpinB3 expression in 
all three primary transduced cells compared to non-target shRNA control, however 





Figure 4.5 Confirmation of SerpinB3 knockdown 
RT qPCR of SerpinB3 mRNA expression in Panc185, 215 and 354 cells (n=2 per cell type) transduced 
with lentiviral shRNA constructs (SB3 shRNA1 and SB3 shRNA 2) and treated with MCM for 48hrs. 
Comparison was made with both non-transduced control cells (NT) and non-targeting shRNA 
transduced cells (SCR shRNA). Results represent a compilation of duplicate experiments in each cell 
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4.2.3.1 SerpinB3 knockdown and EMT / migration / invasion 
Having shown less SerpinB3 gene in transduced primary PDAC cells, it was necessary 
to assess if this loss of gene resulted in a decrease of EMT genes/ migration/ invasion 
following MCM culture. 
SerpinB3 has been shown to be critical in the process of EMT in other cells types 
(Quarta et al. 2010; Sheshadri et al. 2014). As PDAC cells undergo an upregulation of 
EMT associated genes following treatment with MCM, knockdown cells were treated 
with both control and MCM media, with the expectation that should SerpinB3 play an 
active role in the transition to a more mesenchymal state, less upregulation of EMT-
related gene expression in MCM would occur. However, data showed that in Panc185 
and 215 there was little difference in EMT gene expression in knockdown cells, with 
MCM treatment inducing increased expression of Zeb1, Vimentin and Slug in MCM 
in both non-transduced control cells, non-targeting shRNA transduced cells and 
knockdown cells (Figure 4.6A and B). In Panc354, interestingly the cells with 
SerpinB3 knockdown had a greater expression of EMT-related genes compared to 
both the non-transduced controls and the non-targeting shRNA control cells (Figure 
4.6C).  However, no firm conclusions can be made regarding impact of loss of 
SerpinB3 on EMT gene expression, and further experiments would be required to 




Figure 4.6 EMT gene expression in SerpinB3 knockdown PDAC cells 
mRNA expression of zeb1, vimentin and slug in A) Panc185 (n=2), B) 215 (n=2) and C) 354 (n=2) 
cultured with control media and MCM for 48hrs. Results represent a compilation of experiments in each 
cell type, with values representing the mean (+/- SD). 
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Using IncuCyte ZOOM live-cell imaging, wound-healing analysis of Panc354 cells 
grown in MCM demonstrated a greater migratory potential in SerpinB3 shRNA 
knockdown over 24hrs compared to non-transduced cells. However, control non-
targeting shRNA cells also showed increased migration, suggesting this effect was not 
specific to knockdown rather than vector transduction (Figure 4.7).  
 
   
Figure 4.7 Migration of SerpinB3 knockdown cells 
Scratch assay (n=1) was performed on Panc354 non-transduced (NT), non-targeting shRNA (SCR 
shRNA) and SerpinB3 knockdown transduced (SB3 shRNA 1 / SB3 shRNA 2) cells in the presence of 
MCM over 24hrs. Measurements from wounds made from monolayer cells were analysed for relative 
wound density using Incucyte Zoom software. Results represent pooled analysis of 3 technical 





































Testing functional invasion in a ‘3D’ system, one experiment using SerpinB3 shRNA 
2 knockdown cells was performed and showed greater invasion compared to non-
transduced and non-targeting shRNA cells using transwell invasion assay (Figure 4.8). 
However both the migration and invasion experiments would need to be repeated to 


















Figure 4.8 Invasion of serpinB3 knockdown cells 
Transwell invasion assay was performed on non-transduced (NT), non-targeting shRNA (SCR shRNA) 
and SerpinB3 shRNA knockdown (SB3 shRNA 2) Panc354 cells seeded in MCM or control media over 
16hrs (n=1). Values representing the mean count of 4x images per well (+/- SD). 
 
4.2.4 SerpinB3 overexpression  
To further determine the autocrine effects of SerpinB3 expression in primary PDAC 
cells, overexpression of the gene was next performed using lentiviral SerpinB3 
constructs in Panc185 and 354 cells. 
Blasticidin selected cells were cultured and maintained as stably transduced 
populations. Expression of the SerpinB3 transcript was assessed using RT qPCR and 
compared to the level of expression in non-transduced cells and with empty PLX304 
vector cells (Figure 4.9). Results confirmed upregulation of SerpinB3 gene in both 
transduced cells types (significant in Panc185) compared to control and empty vector 





Figure 4.9 Confirmation of serpinB3 gene overexpression 
RT qPCR of SerpinB3 mRNA expression in Panc185 (n=3) and 354 cells (n=2) transduced with 
lentiviral serpinB3 construct (SB3 – clone 1). Comparison was made with both non-transduced control 
cells (NT) and empty PLX304 vector transduced cells (Mock). Results represent a compilation of 
experiments in each cell type, with values representing the mean (+/- SD). Statistical significance: 1 
way ANOVA * = p<0.05. 
 
 
4.2.4.1. SerpinB3 overexpression and EMT / invasion 
To assess if there was a link between upregulation of SerpinB3 and EMT / invasion, 
cells overexpressing SerpinB3 were tested for EMT gene expression along with 
invasive ability. 
Expression of EMT genes again showed non-specific upregulation of EMT genes with 
empty vector control transduced cells (Figure 4.10), although these experiments would 
need to be further repeated to be able to make firm conclusions on the effects of  EMT 




Figure 4.10 EMT gene expression in cells overexpressing Serpin3 gene 
RT qPCR analysis of EMT genes in A) Panc185 (n=2), B) 354 (n=2) in non-transduced controls (NT), 
empty PLX304 vector transduced cells (Mock), or SerpinB3 construct (SB3 – clone 1). Results 
represent a compilation of experiments in each cell type, with values representing the mean (+/- SD).  
 
Exploring functional activity, Panc354 cells with SerpinB3 overexpression showed 
greater invasion with transduction in both empty vector and SerpinB3 construct 
compared to wild type alone (Figure 4.11). Cells overexpressing the gene had no 
greater invasive ability as the empty vector control cells. However, this experiment 
was only performed once and would need to be repeated to deduce the effects of 








Figure 4.11 Invasion of cells overexpressing SerpinB3 gene 
Transwell invasion assay was performed on non-transduced (NT), transduced empty PLX304 vector 
(Mock) and SerpinB3 overexpression (SB3- clone 1) Panc354 cells over 16hrs (n=1). Values 
representing the mean count of 4x images per well (+/- SD). 
 
In conclusion, there were not enough experimental repeats to be able to make 
definitive conclusions on how the overexpression SerpinB3 is linked to EMT / 
invasion and gene expression. However the results did suggest that that cells undergoing 
the process of transduction, even with empty vector, are in themselves different to 








Agilent microarray results showed significant upregulation of SerpinB3 in response to 
TAM secreted factors in Panc253 and 354 cells. This protein acts as a cysteine 
protease inhibitor in normal cells (Schick et al. 1998), however its function in cancer 
progression remains unclear. Cumulative data suggest both pro- and anti-tumourigenic 
activity of SerpinB3 in cancer cells, including mediating invasion and migration, pro-
survival and treatment resistance (Table 4.1).  
Initial results confirmed consistent upregulation of SerpinB3 gene and protein in 
MCM treated cells across different types of primary PDAC cells tested with different 
macrophage donors. However, recombinant SerpinB3 showed no functional effects 
when administered to cells. Testing with recombinant protein was based on data from 
Quarta et al. who showed intracellular effects in HepG2 cells following treatment with 
recombinant SerpinB3 (Quarta et al. 2010). In addition, the protein has been detected 
in patient plasma of various malignant and non-malignant diseases and reports suggest 
squamous cancer cells actively secrete it into the circulation or culture medium 
(Hirakawa et al. 2004; Numa et al. 1996; Tsuyama et al. 1991). Thus, one would have 
assumed an extracellular effect of the protein based on these data alone. However, 
when examining studies testing the activity of SerpinB3, only Quarta et al. have 
demonstrated an extracellular effect of the protein in HepG2 cells. Contrary to this 
finding, when specifically examining inhibitory cathepsin activity, Uemura et al. 
showed a lack of inhibitory activity of extracellular SerpinB3, but did detect activity 
within the cytosol (Uemura et al. 2000). In addition, the majority of reports in Table 
4.1 describe cytoplasmic activity for SerpinB3, thus suggesting a predominant intrinsic 
mechanism of action. This does not explain why the protein is so abundant in the 
serum of patients, but Uemura et al. postulate that the presence of SerpinB3 in patient 
sera may be due to passive release rather than active secretion, especially as the 
protein lacks a recognisable secretory sequence.  
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Table 4.1 Molecular mechanisms of action of SerpinB3  
Compiled list of publications relating to the cancer related functions of SerpinB3 and proposed molecular mechanisms of action (MOA). All cell types human unless stated. 
SCC = squamous cell carcinoma 
Cell type Activity Proposed MOA Reference 
SCC (SKG-IIIa) Resistance to drug (7-ethyl-10-hydroxycamptothecin, etoposide), 
cytokine (TNFα) and effector cell (IL-2 activated NK cell) induced 
apoptosis 
Caspase 3 and or/upstream proteases (Suminami et al. 2000) 
Kidney (293T) Resistance to radiation induced apoptosis Decreased caspase 3 and 9 activity / decreased p38 MAPK (Murakami et al. 2001) 
SCC (SKG-IIIA) Tumour growth Decreased apoptosis / Inhibition of Natural Killer cell recruitment (Suminami et al. 2000) 
Cervical Cancer (SiHa) Inhibition of invasion E1AF transcription factor activating SCCA promoter  (Iwasaki et al. 2004) 
Hepatoma (HepG2) Resistance to drug induced apoptosis (pro-oxidant chemotherapy) Inhibition of ROS generation at Complex I of mitochondria (Ciscato et al. 2014) 
Oral SCC (MISK81-5, sMISK) Resistance to TNFα induced death  Inhibition of cytochrome c release from mitochondria (Tsuyama et al. 1991) 
Cervical Cancer (CaSki, SKG-IIIa) Cell invasion Increased MMP9 (Sueoka et al. 2005) 
Mouse fibroblasts (3TC-J2) Keritanocytes 
(HaCaT) 
Resistance of UV-induced apoptosis Supresses c-Jun NH2- terminal kinase-1 (JNK1) (Katagiri et al. 2006) 
Head and Neck SCC (YCU-N) Inhibition of tumour growth and invasion  ? inhibition of cathespins (Nakashima et al. 2006) 
Head and Neck SCC (HN13) 
Prostate Cancer (DY145)  
Mammary (MCF7)  
Breast Cancer (231)  
Cell survival STAT3 /IL6 (Ahmed and Darnell 
2009) 
Hepatoma (HepG2, Huh7) Induction of EMT Increased MMP 2 and MMP 9 (Quarta et al. 2010) 
Mouse kidney (BMK) Inhibition of cell death induced by lysosomal injury (DNA 
alkylating agents and hypotonic shock) / Promotion of apoptosis in 
response to ER stress 
Inhibition of cell death through blocking cathepsin activity / 
Promotion of apoptosis through aggregation of lysosomal 
caspase-8 
(Ullman, Pan, and Zong 
2011) 
Fibroblast (IMR90)  
Pancreatic Cancer (Panc-1, CF-PAC-1, 
HPAF-II, L3.6, CAPAN-1) 
Inflammatory cytokine production  Ras mutation / UPR dependent induction of NF-κB / IL6 (Catanzaro et al. 2014) 
Mammary (MCF10A)  Oncogenic transformation / Induction of EMT UPR dependent induction of NF-κB and IL6  (Sheshadri et al. 2014) 
Primary human liver cirrhosis and 
progenitor / C57BL/6J mice 
Pro-survival in progenitor cells ?inhibition of caspase 3 (Villano et al. 2014) 
Hepatoma (HepG2) Increased pro-oncogenic c-myc  Inhibition of calpain (Turato et al. 2015) 
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There is no evidence in the literature of a specific SerpinB3 receptor or that the protein 
has the ability to undergo endocytosis to cross the cell membrane and have 
intracellular effects as seen in HepG2 cells. This could therefore explain the lack of 
effects of recombinant protein in our primary PDAC model, as the treated cells were 
unlikely to have taken up SerpinB3 to then have intracellular effects. 
Intrinsic function through silencing and overexpression of the SerpinB3 gene was used 
instead to asses function. Firm conclusions cannot be made from these experiments 
due to lack of experimental repeats, but the preliminary data collected here of 
knockdown and overexpression data of SerpinB suggest that the EMT / migratory / 
invasive effects were not specific to the SerpinB3 expression, but more likely due to 
the process of vector transduction. This is reflected in findings that control transduced 
cells (with non-targeting RNA in knockdown cells and empty PLX304 vector in 
overexpression cells), also had high EMT gene expression profile and invasive 
capacity despite no loss or gain in SerpinB3 gene expression.  
Differences in the non-transduced versus transduced cell populations in these 
experiments would suggest a change in biological behaviour as a result of lentiviral 
gene transfer. This concept has been described in one study of Diffuse Large B Cell 
Lymphoma (DLBCL), in which lentiviral transduction with a control vector interfered 
with response to rituximab by increasing drug tolerance compared to non-transduced 
cells (Ranjbar et al. 2016). In this thesis, knockdown cells were treated with 
doxycycline and FACS sorting for GFP positivity, and overexpression cells were 
selected with blasticidin, a drug known to be highly toxic to mammalian cells. The 
processes would have applied more cellular stressors to the transduced cell 
populations (including control vector) than non-transduced cells. Some of these 
process are associated with the induction of EMT, such as mechanical compression 
(Tse and Kalluri 2007), potential hypoxia (Jiang, Tang, and Liang 2011) and unfolded 
protein response (UPR) (Dejeans et al. 2015) and therefore in turn a more invasive and 
migratory cancer cell population could have been induced. Thus, the experimental 
processes involved in transduction could have inadvertently resulted in selection of a 
more ‘aggressive’ cell population that was able to survive more stressors and become 
more mesenchymal, explaining why transduced control cells in both experiments were 
also seen to be functionally more invasive.  
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Although the data from this chapter on SerpinB3 are not robust enough to confirm the 
effects of SerpinB3 on EMT and invasion, its expression as a result of MCM treatment 
in PDAC does not have to be specifically related to this phenotype of interest and one 
cannot rule out other pro-tumorigenic functions for the protein yet to be discovered, 
especially when reviewing the many other roles it plays in other cancer types (Table 
4.1). Recent data have shown a link between Serpins and responses to immunotherapy 
in melanoma, in which mutations of SerpinB3 and SerpinB4 are commonly seen. 
Patients with specific mutations derived clinical benefit from anti-CTLA4 therapy 
(Riaz et al. 2016). No mechanistic actions were provided for this observation, however 
authors speculated that because the types of mutations included missense, the protein 
activity could be lost, which in some autoimmune diseases results in autophagy, 
thereby enhancing autoantigen presentation, or leads to inflammatory aggregates 
formation, resulting in more immunogenic neopeptides. In our model the expression of 
SerpinB3 was increased, therefore based on this hypothesis one could speculate that 
increased SerpinB3 expression would lead to less immune aggregates and neopeptides, 
thus providing decreased immune cell recognition of tumour tissue as a result of 
macrophage driven expression. Based on the growing literature on SerpinB3 in the 
field of cancer biology, an as yet unknown function for this gene in tumourigenesis in 
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5.1 Introduction and Aims 
 
GSEA of MCM cultured Panc253 and 354 indicated enrichment of the JAK-STAT 
pathway and cytokine receptor gene sets. These two pathways are linked, with 
cytokine receptors commonly coupled with JAK kinases to allow phosphorylation of 
downstream STATs, thereby initiating intracellular signalling. Of the STAT family 
members, persistent activation of STAT3 is frequently detected in cancer cell lines and 
tumour tissues (Bowman et al. 2000; Buettner, Mora, and Jove 2002). In addition, 
STAT3 has been linked to invasion and metastasis (Huang 2007) and is implicated in 
PDAC tumourigenesis (Corcoran et al. 2011; Lesina et al. 2011). Crucially, targeting 
activation of STAT3 can inhibit tumour growth and metastasis both in vitro and in 
vivo without affecting normal cells (Niu et al. 1999), and JAK-STAT inhibitors are 
already in clinical use for treatment of patients with myeloproliferative disease 
(Harrison et al. 2017; Mesa et al. 2013). Therefore further investigation of STAT3 in 
PDAC following pathway activation by TAM secreted factors could be a valid 
therapeutic approach in decreasing the pro-tumourigenic effects of TAMs. 
The aims of this chapter are: 
 To confirm activation of the JAK-STAT3 pathway in PDAC following TAM 
conditioning 
 To determine the likely macrophage-derived cytokines activating the JAK-
STAT3 pathway in primary PDAC cultures 
 To deduce whether cytokine activation of JAK-STAT3 is driving EMT, 








5.2.1 Microarray Gene Analysis of Panc215, 253 and 354 
In addition to microarray of treated Panc253 and 354, Panc215 was also analysed. 
Analysis of all three cell types showed common gene upregulation in cells cultured 
with MCM (Figure 5.1). 
 
 
Figure 5.1 Venn diagram of microarray gene expression 
Gene expression fold change profile in Panc215, 253 and 354 comparing significantly upregulated 







The 7 common upregulated genes were noted between Panc215, 253 and 354 (Figure 
5.2). Of note, SerpinB3 was not present in this panel; despite being significantly 
upregulated in Panc253 and 354, upregulation in Panc215 did not reach significance.  
 





KEGG GSEA of collective microarray data for Panc215, 253 and 354 again revealed 
10 common gene sets between the three cell types. The complement cytokine receptor 
and JAK-STAT gene sets had significant normalised enrichment scores (Table 5.1 and 








Table 5.1 KEGG gene set enrichment Panc215, 253 and 354 
(NES = normalised enrichment score. FDR p-val <0.25) 
 






OLFACTORY_TRANSDUCTION 1.3116386 1.6780441 1.600173 
ECM_RECEPTOR_INTERACTION 1.5504879 1.7152467 1.7317232 
FOCAL_ADHESION 1.8077673 1.5119898 1.3321809 
HEMATOPOIETIC_CELL_LINEAGE 1.8510597 1.97643 2.1082714 
COMPLEMENT_AND_COAGULATION_CASCADES 2.0527737 1.4998453 1.7503108 
CYTOSOLIC_DNA_SENSING_PATHWAY 2.0718224 1.6120821 2.0001507 
JAK_STAT_SIGNALING_PATHWAY 2.1193426 1.7079959 2.1062407 
LEISHMANIA_INFECTION 2.2995777 1.5941939 2.384698 
NOD_LIKE_RECEPTOR_SIGNALING_PATHWAY 2.3498127 1.5958716 1.8420589 
CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 2.5795727 1.6617507 2.2095013 
 
 
Figure 5.3 Gene Set Enrichment Scores 
 
 
To determine which cytokines could be upstream of these genes set, the online 
analysis tool Ingenuity Pathway Analysis (IPA) was used with the assistance of Dr 
Matthieu Schoenhals; cumulative microarray results from Panc215, 253 and 354 were 
tested to determine candidate cytokines.  Through this, several cytokines of interest 
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were predicted and included several interleukins and interferons. One predicted 
cytokine of interest was oncostatin M (OSM). Review of microarray noted that the 
receptor for OSM, OSMR, was a common upregulated gene in MCM treated Panc215 
and 354 (Figure 5.1). Crucially, this cytokine belongs to the glycoprotein 130 (gp130) 
family cytokines, which are known activators of the STAT3 pathway. Thus, further 
investigation of OSM was taken forward. 
 
5.2.2 STAT3 
To confirm Agilent microarray data, western blot of pSTAT3 (specifically the Y705 
residue) was performed on a panel of primary PDAC cultures treated with MCM. 
Phosphorylation at this site is a surrogate marker of pathway activation, leading to 
nuclear translocation and target gene transcription. pSTAT3 protein was consistently 
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A) Representative western blots of pSTAT3 protein expression from cell lysates of PDAC cells cultured 
with MCM for 24hrs. B) Densitometry of pSTAT3 protein expression of Panc215, 354 and 10953 
cultured for 24hrs, normalised to density of loading control (vinculin) and total STAT3. Results 
represent a compilation of experiments in each cell type (n=4 per cell type), with values representing the 






Figure 5.4 STAT3 phosphorylation in cells cultured with MCM 
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Phosphorylation of STAT3 was also demonstrated when direct co-culture of TAMs 
with PDAC cells was performed (Figure 5.5), confirming the effects were applicable 
upon ‘direct’ interaction of the two cell types. For this experiment, cell lysates were 
collected at 48hrs rather than 24hrs as previously described with just MCM culture 
alone, in view of the speculated longer ‘time for tumour associated polarisation’ 
discussed in Chapter 3 with unpolarised macrophages. Expression was not as high as 
with MCM. This could be due to similar reasons discussed in Chapter 3 when 
determining EMT gene expression in PDAC with ‘direct’ macrophage co-culture 










Figure 5.5 STAT3 activation in ‘direct’ and ‘indirect’ coculture  
Western blot of pSTAT3, total STAT3 protein and control (vinculin) in Panc215 and 10953 cultured 
alone (Ctl), directly with unpolarised macrophages (‘+MΦ’) or with MCM for 48hrs. 
 
 
5.2.3 gp130 cytokines 
There are at least nine human gp130 family cytokines, so called because they all share 
gp130 as a common signal transducer in their receptor complex: interleukin-6 (IL6) 
(Taga et al. 1989), interleukin-11 (IL11) (Yin et al. 1993), interleukin-27 (IL27) 
(Phillips et al. 2004), leukemia inhibitory factor (LIF) (Ip et al. 1992), ciliary 
neurotrophic factor (CNTF) (Ip et al. 1992), OSM (Gearing et al. 1992), cardiotrophin-
1 (CT1) (Gearing et al. 1992), cardiotrophin-like cytokine (CLC/ CLCF1) (Elson et al. 
2000), and neuropoietin (NP) (Derouet et al. 2004).   
146 
 
Interest in the role of OSM in PDAC is based on IPA, suggesting this cytokine to be 
upstream of activated genes, and microarray gene analysis, revealing OSMR as a 
common upregulated factor. In addition, gp130 family members IL6 and LIF cytokine 
would also be important to investigate, due to their high predominance in the literature 




Table 5.2 PubMed search for gp130 family cytokines in cancer 
Results of PubMed search (up to December 2015) for ‘(cytokine of interest), cancer’. In addition, a 
search for ‘(cytokine of interest), cancer, EMT’ or ‘(cytokine of interest), cancer, PDAC’ was also 
carried out. 
Gp130 Family Cytokine 
 No. publications in 
‘Cancer’ 
No. publications in 
‘Cancer and EMT’ / 
‘Cancer and PDAC’ 
Interleukin 6 (IL6) 1690 
EMT 10 
PDAC 4 
Leukaemia inducing factor (LIF) 1133 
EMT 4 
PDAC 2 
Oncostatin M (OSM) 465 
EMT 2 
PDAC 0 
Interleukin 11 (IL11) 426 
EMT 6 
PDAC 0 
Ciliary neurotropic factor (CNTF) 202 
EMT 0 
PDAC 1 
Interleukin 27 (IL27) 132 
EMT 2 
PDAC 0 
Cardiotrophin (CT) 28 
EMT 0 
PDAC 0 







In the first instance, confirmation of STAT3 phosphorylation in the primary PDAC 
model with IL6, LIF and OSM was necessary. Recombinant proteins of each were 




Interestingly, only recombinant human OSM induced phosphorylation of STAT3 
similar to that seen with MCM (Figure 5.6). When quantified for Pan215, 354 and 
10953, IL6 also induced slight upregulation of protein expression (density normalised 
to control = 1.19), but the level was not as high or significant as with OSM (density 
normalised to control = 3.01 and MCM (density normalised to control = 3.41) (Figure 
5.7). Of note, recombinant human interleukin 8 (IL8) was also included in the initial 
panel of cytokines tested, as it is known to activate EMT via the JAK/STAT3 pathway 
in HCC (Fu et al. 2014), but as it showed little effect on pSTAT3 expression and was 








































Figure 5.6 STAT3 activation in primary PDAC cultured in MCM 
Representative western blots of pSTAT3 protein expression from cell lysates of PDAC cells cultured 











Figure 5.7 Quantification of pSTAT3 expression Panc215, 354 and 10953 
Densitometry quantification of pSTAT3 protein expression of Panc215, 253 and 10953 cultured for 
24hrs, normalised to density of loading control and total STAT3. Results represent a compilation of 
experiments in each cell type (n=4 per cell type), with values representing the mean (+/- SD). Statistical 
significance: Wilcoxian signed-rank test * = p<0.05. ** = p<0.005 
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Findings that OSM had greater effect on STAT3 phosphorylation compared to IL6 
were surprising. This was in part because IL6 is the most well described gp130 
cytokine, commonly cited as the principal activator of STAT3 in malignancy (Sansone 
and Bromberg 2012). An explanation of the lesser response of IL6 compared to OSM 
on STAT3 phosphorylation / activation in our primary PDAC model was sought. 
Expression of the relative co-receptors of each cytokine was first investigated, as 
difference in relative receptors expression could explain increased potency of different 
cytokines. Activation of the JAK/STAT3 pathway by gp130 family cytokines is reliant 
on heterodimer formation of the relevant cytokine subunit receptor with the gp130 






Classical IL6 signalling involves IL6 binding to the membrane bound IL6 receptor (IL6R) which then 
initiates homodimerisation of gp130 for downstream activation. In transignalling, IL6 interacts with a 
soluble form of IL6 receptor (sIL6R) and then activates of gp130 signalling. IL11 associates with α-
receptor IL11R with homodimerized gp130. CNTFRα requires heterodimerization of gp130 and LIFRβ 
and is bound not only by CNTF but also NP and CLC. CT1 also utilizes the gp130/LIFRβ 
heterocomplex for signalling through direct binding to LIFRβ but not gp130. OSM signalling is 
mediated either by the gp130/LIFRβ (type I complex) or gp130/OSMRβ (type I complex) 
heterocomplexes. IL27 requires the association of gp130 and WSX-1 for receptor complex formation 
and signal transduction. 
 
 
The relevant expression of the receptor genes both at baseline and following treatment 
with MCM were examined. For OSM, it should be noted that this cytokine can bind to 
both OSMR and LIFR (Figure 5.8), thus LIF could appear to have a lesser affect than 
OSM due to the competitive binding of both cytokines to LIFR and the ability of OSM 
Figure 5.8 gp130 cytokine receptors 
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to bind both receptors. Basal expression of the three receptor genes was first 
determined in Panc215, 354 and 10953. In the case of IL6, binding is through 
membrane bound IL6R or soluble IL6R (sIL6R) (Figure 5.8). sIL6R is generated 
through either proteolysis of the membrane bound protein (Mülberg et al. 1993) or 
through a transcript variant which lacks the transmembrane coding regions (Lust et al. 
1992). Thus, it was ensured that primers to detect mRNA of IL6R did not code for the 
transmembrane region (codon 356 – 387) and therefore detected both membrane 
bound and soluble receptor.  
Basal OSMR gene expression was significantly higher than both IL6R and LIFR in all 
three cell types (Figure 5.9).  
 
Figure 5.9 Basal gene expression of gp130 cytokine receptors 
RT qPCR of OSM, IL6 and LIF receptor mRNA in Panc215, 354 and 10953 (n=7 per cell type) in basal 
conditions (control media for 48hrs). Results represent a compilation of relative values in each cell type, 
with values representing the mean (+/- SEM). Statistical significance: Wilcoxian signed-rank test * 
p<0.05. 
 
In addition, only OSMR was significantly upregulated following MCM treatment in 
all three cell types, and not LIFR or IL6R (Figure 5.10). In fact LIFR was actually 




Figure 5.10 Gene expression of gp130 cytokine receptors with MCM culture 
RT qPCR of OSM, IL6 and LIF receptor mRNA in Panc215, 354 and 10953 (n=7 per cell type) in cells 
treated with control and MCM media for 48hrs. Results represent a compilation of relative values in 
each cell type, with values representing the mean (+/- SEM). Statistical significance: Wilcoxian signed-
rank test * p<0.05. 
 
These results explained the differential effect of each cytokine with regards to 
pSTAT3 activation following MCM treatment in primary PDAC: OSM is having a 
greater effect as there is more OSMR at basal levels than the other cytokine receptors, 
thus allowing more cytokine to initially bind compared to IL6 and LIF. The receptor 




potentiating the effects of downstream pathway activity and allowing for sustained 
pSTAT3 activation seen over time. These findings support that of microarray data in 
which the receptor for this cytokine, OSMR, was upregulated following treatment with 
TAM derived factors. 
Finally, to confirm the mechanism of action of pathway activation, nuclear 
translocation of STAT3 with both MCM and OSM were tested using 
immunofluorescence. Results confirmed that both MCM and OSM culture, pSTAT3 
was present in the nucleus of treated cells as soon as 10 min after treatment, and was 
not detected with control media (Figure 5.11). A shorter time frame was used for this 
experiment compared to the usual 24hrs used when collecting cell lysates for western 
blot analysis in order to capture the initial translocation of protein to the nucleus. 
Therefore, activation of the signalling pathway upon cytokine receptor activation leads 
to nuclear translocation for gene transcription. 
 
Figure 5.11 Immunoflourescence pSTAT3 
Immunofluorescence staining of pSTAT3 in Panc354 cells following 10 minutes treatment with control 




5.2.4 EMT and OSM  
Having confirmed pSTAT3 is upregulated and translocates to the nucleus in PDAC 
cells treated with OSM and MCM, confirmation of whether OSM also activates a 
metastatic phenotype was needed.  
Initial testing of Panc354 demonstrated a similar change in cell morphology with OSM 
treatment and MCM (mesenchymal elongation and cell scattering) (Figure 5.12). IL6 
and LIF did not appear to have these effects.  
 
 
Figure 5.12 Effects of gp130 cytokines on cell morphology 
Brightfield microscopy images of Panc354 cells treated with control media, MCM and gp130 cytokines 
for 48hrs 
 
Consistent with these morphological changes, genes associated with EMT were also 







Figure 5.13  EMT gene expression in Panc354 treated with gp130 cytokines 
RT qPCR of Panc354 (n=3) MCM and gp130 cytokines (OSM 100ng/ml, IL6 100ng/ml, LIF 100ng/ml) 
after 48hrs treatment. Results represent normalisation to control, with values representing the mean (+/- 
SEM). 
 
To ensure the effects of OSM on gene upregulation were consistent and applicable to 
the other primary PDAC cell types, EMT gene expression was further analysed in 
Panc354, Panc215 and 10953 cells treated concurrently with OSM and MCM. Results 
showed upregulation of genes in a similar pattern when cells were treated 





Figure 5.14 EMT expression of OSM treated cells 
RT qPCR of EMT genes in Panc215, 354 and 10953 (n=6 per cell type) treated with control media, 
MCM or OSM 100ng/ml for 48hrs. Results represent a compilation of experiments normalised to 
control conditions, with values representing the mean (+/- SEM). Statistical significance: Wilcoxian 






























































































Zeb1 Vimentin Slug Loxl2 
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5.2.5 Invasive effects of OSM  
Functional effects of OSM were tested using invasion assay. Results confirmed 
increased invasion of Panc215, 354 and 10953 cells pre-treated with OSM (Figure 
5.15).  
 
Figure 5.15 Invasive effects of OSM 
Transwell invasion assay of Panc215, 354 and 10953 (n=6 per cell type) treated with OSM 100ng/ml 
for 48hrs. Results represent a compilation of experiments normalised to control, with values 
representing the mean (+/- SEM). Statistical significance: paired t test * = p<0.05. 
 
When testing invasion of Panc354, one experiment showed less upregulation in 
invasion following treatment with IL6 and LIF compared to MCM and OSM (Figure 







Figure 5.16 Effects of gp130 cytokines on invasion 
Transwell invasion assay of Panc354 cells treated with control media, MCM, OSM 100ng/ml, IL6 
100ng/ml and LIF 100ng/ml  (n=1). Values representing the mean (+/- SD). 
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Taken collectively, it appeared that OSM was the most effective gp130 cytokine in 
activating the STAT3 signalling pathway, inducing EMT and is driving invasion in the 
primary PDAC cells, thus confirming its importance following initial analysis of 
microarray data using IPA pathway software. 
 
5.2.5.1 OSM and Macrophages  
Having concluded that OSM had similar effects on PDAC phenotype as MCM, it 
remained to be proven that this cytokine was being secreted within the conditioned 
media of TAMs. Through ELISA, OSM protein was detected in different macrophage 
donor MCM following culture with MCSF for 4 days (Figure 5.17). Levels ranged 
from 232-1557pg/ml, demonstrating heterogeneity in primary macrophage OSM 




Figure 5.17 ELISA of OSM in MCM 
ELISA of OSM protein in primary MCSF-polarised donor macrophage conditioned media (n=13). 















Although this result proved that OSM was being secreted by MCSF-polarised 
macrophages, this phenotype was artificially induced through MCSF. In other cancer 
models, a crosstalk between TAMs and cancer cells has been demonstrated within the 
TME to drive polarisation of macrophages towards a more pro-tumourigenic 
phenotype (Su et al. 2014). In PDAC, data from our laboratory has already shown that 
CSC-conditioned media can drive OSM gene expression in primary macrophages 
(Figure 5.18A), and it was speculated that the cytokine responsible for this was TGFβ1  
(Sainz et al. 2015), which is known to be secreted in large amounts by PDAC 
(Massagu J. 2008) and was confirmed to be secreted by our primary PDAC culture 






PDAC tumours are known to harbour inactivating mutations in the TGFβ signalling 
pathway rendering them unresponsive (Iacobuzio-Donahue et al. 2009), therefore this 
cytokine, secreted from PDAC cells, is likely to act primarily on other stromal cells 
within the TME.  
Therefore, to further test the theory that PDAC secrete TGFβ1 which then primes 
macrophages to be more ‘tumour-associated’, in turn secreting OSM, mature 
unpolarised macrophages were treated with either MCSF or TGFβ1 for 24 hours. 
Supernatant was then collected for ELISA analysis of OSM protein. Results confirmed 
Figure 5.18 OSM and TGFβ1 expression in primary PDAC 
A) RT qPCR analysis of hCAP-18/LL-37, OSM and vascular endothelial growth factor (VEGF) mRNA 
expression levels in human monocyte-derived macrophages cultured with control media or with CSC 
CM from three PDAC cultures *P=<0.05 B) ELISA analysis of TGFβ1 expression from primary 




the previous gene expression analysis, showing protein secretion of OSM in cells 
treated with TGFβ1 (Figure 5.19).  
 
Figure 5.19 ELISA of MCSF and TGFβ1 treatment macrophages 
ELISA of OSM protein in unpolarised macrophage treated with MCSF or TGFβ1 for 24 hours (n=6). 
Results represent individual values with mean. 
 
 
This finding implies a potential crosstalk between cancer and immune cells that could 
be driving the invasive phenotype, with the PDAC associated cytokine TGFβ1 
inducing OSM secretion in macrophages. 
 
5.2.5.2 Invasive effects of OSM on CSCs 
Previous results have shown that CSCs are more invasive in MCM compared to non-
CSCs, as defined by CD133 expression (see section 3.2.1.1). Thus, having proven that 
OSM mimicked the invasive effects of MCM on the ‘mixed’ PDAC population, 
effects on the CSC population were also investigated. Gene expression of Zeb1, Loxl2 
and Slug were higher in CD133+ cells treated with OSM compared to treated CD133- 

















Figure 5.20 EMT gene expression of CD133+/-  cells treated with OSM 
RT qPCR of EMT genes in Panc354 CD133-/+ cells treated with control media or OSM (100ng/ml) for 
48hrs (n=1). 
 
In keeping with this finding, the most invasive cell population was the CD133+ OSM 
treated cells in invasion assay (Figure 5.21).  
 
Figure 5.21 Invasive effects of OSM on CD133+/- cells 
Transwell invasion assay of Panc354 CD133+/- cells treated with OSM (100ng/ml) (n=3). Results 





To determine why the CD133+ CSC population was more responsive to the invasive 
effects of OSM, basal gene expression of OSMR was compared in both populations 
immediately after sorting. The baseline expression of OSMR was significantly higher 
in the CSC CD133+ population compared to the non-CSC CD133- population (Figure 
5.22). 
 
Figure 5.22 OSMR gene expression in CSCs vs non-CSC 
RT qPCR of baseline OSMR mRNA in Panc354 and Panc215 (n=3 per cell type) immediately after 
sorting in CD133+ (CSC) compared to CD133- (non-CSC) populations. Results represent a compilation 
of experiments normalised to control, with values representing the mean (+/- SD). Statistical 
significance: Wilcoxian paired t test * = p<0.05. 
 
Therefore, expression of OSMR is not only higher in the bulk population of cells 
compared to other gp130 cytokine receptor and positively regulated by MCM, but it is 
also more highly expressed in the CSC population compared to the non-CSC 
population at baseline. This expression leads to CSCs being the most invasive cell 































5.2.6 Stemness effects of OSM 
Previous data from our group have shown that macrophage derived factors LL37 and 
ISG15 potentiate stemness in Panc185 and 354 cells. Based on these findings, and 
having shown increased invasion of stem cells with OSM, it was pertinent to test if 
OSM also had similar effects on inducing stemness in PDAC cells. 
Panc215, 354 and 10953 were treated for 48 hours with OSM and RNA collected for 
analysis of the stemness genes Oct3/4, KLF and SOX2. Results showed variation in 
the expression of genes when normalised to control. Panc215 did not show 
upregulation of any genes and certainly fold change was decreased, suggesting cells 
were becoming less stem. In Panc354, upregulation of Oct3/4 was noted, and in 
Panc10953 slight increase in expression of KLF4 (Figure 5.23).  
 
 
Figure 5.23 Stemness gene expression in OSM treated cells 
RT qPCR of stemness genes in Panc215, 354 and 10953 (n=3 per cell type) following treatment with 
OSM 100ng/ml for 48hrs.  
 
 
In addition, OSM treated Panc215 were analysed for surface expression of the stem 
marker, CD133. Preliminary results showed a decrease in CD133+ cells after OSM 
treatment when compared with control (Figure 5.24), but this would need to be 










































Figure 5.24 FACS analysis of CD133 following OSM treatment 
FACS analysis of CD133 in Panc215 following 48hrs of OSM treatment (n=1). 
 
Finally, functional assessment was undertaken using sphere formation assay. This 
assay measures anchorage-independent growth in sphere-like 3D structures from the 
proliferation of one CSC in serum free conditions. Panc354 and 10953 cells derived 
from primary spheres (i.e. sample already enriched for CSCs) were reseeded in the 
presence control media, MCM or OSM in anchorage serum free conditions. Both cell 
types demonstrated slight increase in sphere formation following treatment with 
MCM, but this experiment would require further replicates to make conclusions on the 















Figure 5.25 Sphere formation assay 




Therefore, in order to definitively conclude the effects of OSM on the CSC 
subpopulation in PDAC, further experimental replicates would be required to gain 
more rigorous conclusions.  
 
 
5.2.7 Immuno-inhibitory effects of OSM 
Published data from our lab indicate culture with MCM induces immune checkpoint 
expression of PDL-1 in PDAC cells (Cioffi et al. 2015). Several cytokines are known 
to induce PDL-1 expression in various different cells types, for example IFNγ (Kondo 
et al. 2010). Therefore, OSM within MCM could also be having an immune 
modulatory effect by driving expression of PDL-1 on PDAC cells undergoing EMT to 
evade immune cell mediated T cell death. 
Panc215, 354 and 10953 were analysed for PDL-1 expression after culture with MCM 
and OSM treatment for 48 hours. Results showed a consistent upregulation in PDL-1 
expression compared to control treatment not only with MCM, as previously 
published, but also following OSM treatment (Figure 5.26A). Cumulative data of all 






Figure 5.26 FACS analysis of PDL-1 in PDAC  
A) Representative FACS plots of Panc215, 354 and 10953 stained with isotype control and PDL-1 
antibody after 48hrs of treatment in control media or MCM. Mean fluorescent intensity (MFI) for each 
condition is labelled on histograms. B) Pooled MFI analysis in Panc 215 (n=2), 354 (n=2) and 10953 
(n=2) treated with control media, MCM or OSM (100ng/ml).  Results represent a compilation of 





In PDAC tissue, PDL-1 is not only expressed on tumour cells but also infiltrating 
lymphocytes and stromal cells (Nomi et al. 2007). Certainly in some tumours, PDL-1 
expression within the immune component (consisting of macrophages, dendritic cells 
and T cells) is seen as a better predictor of outcome to anti-PDL-1 blockade than the 





shown to stimulate autocrine expression of another checkpoint inhibitor molecule, B7-
H4, indicating self-governing immune suppression by TAMs (Kryczek et al. 2006, 
2007). Therefore, having shown MCM and OSM induce PDL-1 expression in tumour 
cells, and because PDL-1 is known to be highly expressed on TAMs in PDAC 
(Winograd et al. 2015), PDL-1 expression on TAMs in response to OSM was analysed 
in case of autocrine effects. Results did not show a difference in the expression of 
PDL-1 by FACS analysis in control treated compared to OSM treated primary 
macrophages from 3 different donors (Figure 5.27). 
 
 
Figure 5.27 FACS analysis of PDL-1 in TAMs 
FACS plots of three healthy primary macrophage donors, unpolarised for 4 days and then treated with 
control or OSM (100ng/ml) for 24hrs. Cells were stained with isotype control and PDL-1 antibody. 
Mean fluorescent intensity (MFI) for each condition is labelled on histograms.  
 
Taken collectively, results show that OSM not only induce EMT and invasion, but 
also immune evasion of PDAC cells through regulation of PDL-1 expression. The 
effects of TAM derived OSM are primarily on PDAC cells, and there is no autocrine 







Collective results of GSEA in Panc215, 253 and 354 confirmed enrichment of the 
cytokine receptor and JAK-STAT pathway gene sets in primary PDAC cells. Western 
blot analysis proved that TAM secreted factors were inducing activation of the STAT3 
pathway via phosphorylation of Y502, and this finding was consistent across 7 
primary PDAC cultures tested. Culture with MCM lead to pSTAT3 translocation to 
the nucleus, as shown through immunofluorescence staining, thus further confirming 
the postulated mechanism of action. 
STAT3 is activated by growth factors and cytokine signalling. As the cytokine 
receptor pathway gene set was also enriched on microarray in Pan215, 253 and 354, 
investigation of potential cytokines secreted by TAMs that could activate STAT3 was 
undertaken. OSM was determined as a cytokine of interest, largely due to known links 
between its family of gp130 cytokines and STAT3, results of IPA analysis that 
predicted it to be upstream of activated genes, and because of the sigificant 
upregulation of its receptor gene, OSMR, in Panc253 and 354 determined by 
microarray analysis.  
The gp130 family cytokines are linked through the following signalling pathways 
(Figure 5.28): 
 JAK-STAT3 pathway  
 Src homology 2 (SH2)-containing protein tyrosine phosphatase-2 (SHP-2)-
Ras-Raf-MEK-extracellular signal-regulated kinase (ERK) pathway  


















Of these pathways, STAT3 is recognised as the major signal transducer downstream of 
gp130 signalling (Heinrich et al. 2003). Other signalling pathways can be activated 
downstream of gp130 receptor complexes, for example PI3K and MAPK pathways 
(Figure 5.28). However it is likely that in our primary PDAC model, STAT3 is highly 
activated downstream of gp130 receptor, as GSEA indicated this pathway was 
significantly enriched in all three primary PDAC cell types tested. PI3K-AKT pathway 
was not enriched in any cell type, and the MAPK pathway was only significantly 
upregulated in Panc215, not Panc354 and 253.  
Gp130 cytokines do not have intrinsic tyrosine kinase activity, therefore they engage 
with the receptor-associated tyrosine kinase JAK to activate phosphoyrlation of 
STAT3, allowing translocation of the protein to the nucleus leading to gene 
transcription. In cancer, gp130 receptor proteins are highly expressed in multiple 
tumour types, including pancreatic cancer cell lines (Corcoran et al. 2011), and are 
significantly associated with worse outcomes in patients (Xu and Neamati 2013).  
Having proven STAT3 activation following MCM, one could not overlook other 
gp130 family cytokines could be secreted by TAMs and contribute to signalling 
Figure 5.28 gp130 receptor signalling pathways 
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pathway induction. This was thought to be especially important as both IL6 and LIF 
activate STAT3 in PDAC cell lines (Corcoran et al. 2011). However, western blot data 
across seven primary PDAC cultures demonstrated STAT3 was being activated most 
strongly by OSM (similarly to MCM), to a lesser degree by IL6, and not by LIF. This 
pattern of STAT3 activation by each cytokine was similar to the pattern of invaision 
seen, with only OSM and MCM causing increased invasion of Panc354, but further 
replicates for this invasion assay would be required to confirm statistical significance . 
It was deduced the reason for this difference was due to upregulation of OSMR 
expression both at basal levels and in response to MCM in primary PDAC cultures 
compared to IL6R and LIFR, leading to a positive feedback loop and therefore greater 
downstream effects with OSM. One could question whether the experimental doses of 
recombinant protein used for each cytokine could have affected in vitro results. 
However, when referring to doses used in the literature, the most commonly used dose 
for all three cytokines was the same, (100ng/ml) (Klausen et al. 2000; Wang et al. 
2000), therefore cytokine concentrations are unlikely to have influenced the 
differences seen. Certainly, our findings that OSM induced stronger STAT3 activation 
in PDAC compared to IL6 have also been noted in melanoma and lung, whereby 
higher pSTAT3 expression with OSM was found in malignant cells compared to IL6 
treatment (Shien et al. 2017; Y. Wang et al. 2013). 
ELISA confirmed secretion of OSM by primary TAMs in their conditioned media. 
Although consistently secreted, there was a large range of concentrations noted, likely 
because of macrophage donor heterogeneity. This varibality in OSM concerntrations 
could in part explain the heterogeneity in reponses, such as gene expression, that is 
often seen when treating primary PDAC cells in this experimental model. In the 
inflammatory setting, macophages secrete OSM in response to several different 
stimuli, for example prostoglandin E2 and pathogenic bacteria (Ganesh et al. 2012). 
Our results, in conjunction with previous data from the laboratory, suggest PDAC 
secreted TGFβ1 could be driving TAMs to secrete OSM, as demonstrated through 
ELISA of primary macrophages stimulated with cytokine for 24 hours. This would 
imply a potential crosstalk between the two cells, by which cancer cells secrete 




A key finding of this chapter was the confirmation that OSM induces EMT and 
invasion of PDAC cells similar to that seen with MCM. This function of OSM has 
been noted in several different cancer types, including cervix (Kucia-Tran et al. 2016), 
breast (Guo et al. 2013; Lapeire et al. 2014) and lung (Argast et al. 2011). Therefore, 
should inhibitory mechanisms of blocking this pathway in PDAC be determined, there 
could be potential for application in other cancer types also.  
Previous data from our lab support a crosstalk between TAM and PDAC model 
driving the CSC niche (Sainz et al. 2014, 2015). Transition from an epithelial-to-
mesenchymal state has also been linked to stemness properties in some cancer models. 
Therefore, as OSM drives a more invasive phenotype in PDAC, the relationship 
between OSM and stemness was also investigated. No upregulation of stemness genes 
was seen, and further experiements would be required to confirrm the differences in 
surface markers or sphere formation following treatment with OSM. Current data is 
mixed as to whether OSM poetentiates stemness; West et al. show OSM not only 
induces EMT but also promotes stemness through SOX2 gene upregulation and CD44 
surface expression in breast cancer (West, Murray, and Watson 2014), whereas in 
HCC the cytokine actually induces differentiation rather than stemness, defined by a 
decrease in AFP and CK19 expression and decrease gene expression of KRT19, AFP, 
TERT, BMI1 and POU5F1 (Yamashita et al. 2010). Thus, the effects of OSM on 
stemness may be dependent on the tissue type and markers used to define the ‘stem’ 
population. Although no conclusions can be made regarding OSM potentiating 
stemness, when defined by CD133 surface expression, CSCs were the most invasive in 
response to OSM due to higher expression of OSMR. In animal models, mesenchymal 
stem cells are known to be more migratory following cytokine stimulation (Naaldijk et 
al. 2015), however the effects of specific cytokines in the context of cancer biology 
(particularly of OSM) have yet to be demonstrated in current literature.  
Our laboratory have already published data macrophages conditioned media induces 
PDL-1 expression on the surface of primary PDAC cells. A novel finding leading on 
from this was that OSM induces PDL-1 expression in PDAC. PDL-1 is an immune 
checkpoint inhibitor of great interest, as it is known to be expressed in many different 
tumours (Ghebeh et al. 2006; Hamanishi et al. 2007; Hino et al. 2010; Nomi et al. 
2007; Ohigashi et al. 2005) and is currently targetable through antibody therapies in 
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the clinic. In PDAC, expression of PDL-1 correlates with worse outcomes (Nomi et al. 
2007; Wang et al. 2010), and macrophages have to been linked to the regulation of 
PD1 and CTLA4 expression in PDAC tumours, with macrophage targeting agents 
enhancing the effects of checkpoint inhibitors in vivo (Zhu et al. 2014). PDL-1 
expression is known to be mediated by several different cytokines, therefore one could 
speculate that macrophages are inducing checkpoint expression in tumours by 
cytokine secretion. IFNγ is thought to be the most potent inducer (Kondo et al. 2010). 
No members of the gp130 family cytokines have previously been described in driving 
PDL-1 expression specfically in any cell type, but IL6 has also been implicated in 
expression of another checkpoint inhibitor, B7-H4, on monocytes and macrophages in 
ovarian cancer (Kryczek et al. 2006). Therefore our findings of OSM inducing PDL-1 
in PDAC cells is in keeping with a potential immune tolerance effect of this family of 
cytokines, but unlike IL6 the effects of OSM are only on PDAC and not TAMs. 
Nonetheless, it is appreciated that within the real PDAC TME it is unlikely that OSM 
is the only cytokine to dictate immune checkpoint inhibitor expression in malignant 
and stromal cells and more likely that many cytokines are inducing expression to 
produce an immune suppressive environment.  
There are links between EMT and immune suppression programming in other 
tumours. Chen et al. have shown that Zeb1 relieves miR-200 repression of PDL-1 in 
tumour cells, which leads to CD8+ T cell immunsupression and metastasis in lung  
cancer (Chen et al. 2014). However, Hirai et al. found that in more mesenchymal / 
invasive oral squamous carcinoma cells, PDL-1 was downregulated both in vitro and 
in patient tissue, and it was stromal cells that had upregulated PDL-1 in invasive tissue 
rather than the tumour cells (Hirai et al. 2017). Therefore the exact link between 
invasion and acquisition of immune evasion in tumours is not clear, but our data 
support an association between the two phenotypes in tumour cells following 
interaction with TAM secreted factors.  
Results from this chapter have so far shown upregulation of STAT3 activation and 
which appear to correlate with findings of more invasive and immune evasive 
phenotype. However, the link between STAT3 and the phenotypes described are only 
presumed based on previous literature and not yet directly proven. There are extesnive 
published data demonstrating that both invasive and immune tolerance pathways are 
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mediated by STAT3 (Table 5.3). In T cell lymphoma, STAT3 binds the PDL-1 gene 
regulators (Marzec et al. 2008) and in PDAC mouse models, ruxolitinib improved the 
efficacy of anti-PD-1 immunotherapy (Lu et al. 2017). In several different cancer 
models, STAT3 directly transcribes pro-tumourigenic genes known to contribute to 
metastasis in cancer such as Zeb1 and MMPs (Table 5.3). One could deduce that 
STAT3 activation in our model is therefore also driving EMT, as less potent activators 
of STAT3 (IL6 and LIF) having less EMT gene upregulation and were less 
functionally invasive when compared to stronger activators such as MCM and OSM. 
One way to confirm the involvement of this signalling pathway in TAM driven pro-
tumourgenesis of PDAC is by blocking this signalling pathway to determine the 
effects on both phenotypes. 
Table 5.3 Cancer related genes upregulated by STAT3 in human cells  
(adapted from Carpenter and Lo 2014) 
Gene Cell Type Reference  
Transcription Factors 
c-Fos HepG2, A431  (Lo et al. 2007; Seidel et al. 1995; Yang et al. 2003) 
HIF-1α A2058 (Niu et al. 2008) 
c-Myc HepG2, BAF-G277, KT-3,  (Kiuchi et al. 1999) 
Twist A431 (Lo et al. 2007) 
Zeb1 SW1116, LoVo  (Xiong et al. 2012) 
Oct-1 Eca-109  (Z. Wang et al. 2013) 
Apoptosis and Proliferation 
Bcl-2 Hela (Choi and Han 2012) 
Mcl-1 U266 (Becker et al. 2014; Epling-Burnette et al. 2001) 
Bcl-xL U266 Myeloma (Catlett-Falcone et al. 1999) 
Survivin MDA-MB-453  (Gritsko et al. 2006) 
Hsp70 VSM, HeLa  (Madamanchi et al. 2001) 
Hsp90α Jurkat  (Chen et al. 2007) 
Hsp90β VSM  (Madamanchi et al. 2001) 
Cyclin-D1 293T, 3YI, 2fTG  (Bromberg 2002; Leslie et al. 2006; Sinibaldi et al. 2000) 
Immune Suppression and Proliferation 
IL-10 RPMI-8226 B  (Schaefer et al. 2009) 
COX-2 U87MG  (Lo et al. 2010) 
PDL-1 SUDHL-1, JB6, SUP-M2, Karpas 299, 
and L-82 
(Marzec et al. 2008) 
Metastasis 
MMP-1 T24, HT-29 (Itoh et al. 2006) 
MMP-3 HBVE  (M. Liu et al. 2013) 
MMP-9 MCF7  (Song et al. 2008) 
Fascin 4T1 (Snyder, Huang, and Zhang 2011) 
Vimentin MDA-MB-231 (Wu et al. 2004) 
ICAM-1 HepG2 (Schuringa et al. 2001) 
NGAL Primary Macrophages (Jung et al. 2012) 
SAA1 HepG2  (Kesanakurti et al. 2013) 
p21CIP1/WAF1 MG63, A431, HT-29, WiDr, HepG2  (Bellido et al. 1998; Chin et al. 1996; Giraud et al. 2002) 
Cell Signalling 
AKT 293  (Hung and Elliott 2001) 
TNF-R2 SW480  (Hamilton et al. 2011) 
MUC-1 T74D, ZR-75-1  (Ahmad et al. 2011; Gaemers et al. 2001) 
Foxp3 293  (Zorn et al. 2006) 
Tumour Immune Surveillance 
IFN-γ T Cells (Cheng et al. 2003; Kusaba et al. 2005; Wang et al. 2004) 
RANTES PC3 (Cheng et al. 2003; Wang et al. 2004; Yang et al. 2007) 
CRP Hep3B (Zhang et al. 1996) 
STAT1 MDA-MB-468  (Han et al. 2013) 
Other 
TIMP-1 HepG2, WI38, CD4+ T  (Adamson et al. 2013; Bugno et al. 1995) 
JunB HepG2  (Seidel et al. 1995) 
iNOS A431  (Lo et al. 2005) 








6 CHAPTER SIX: TARGETING THE ONCOSTATIN 
















6.1  Introduction and Aims 
 
Having identified upregulation in activity of the OSM/ OSMR/ STAT3 pathway in 
primary PDAC cells, driven by TAMs, the next aim of this thesis is to explore this 
pathway in the clinical setting. By determining if this pro-tumourigenic pathway is 
present in the clinical setting, the prospect of inhibiting it for therapeutic benefit could 
then be taken forward. 
To date, few agents targeting TAMs specifically have reached clinical practice for 
treatment of solid tumours. This may be in part due the abundant presence of 
macrophages throughout the body, making it difficult to target TAMs specifically 
without causing systemic toxicity to non-malignant macrophages. Therefore, targeting 
the pathways activated by TAMs in cancer cells could pose a better therapeutic 
approach, as this would allow more specific activity towards malignant tissues. 
The aims of this chapter are: 
 To further explore the significance of OSM/ OSMR/ STAT3 pathway in 
PDAC patient samples 
 Identify agents that inhibit the activation of OSM/ OSMR/ STAT3 pathway in 
primary PDAC cells 

















6.2.1 Clinical relevance of OSM in PDAC 
Having demonstrated effects of OSM in vitro in our primary PDAC model, it was 
necessary to determine if this cytokine and its receptor had relevance in the clinical 
setting and is linked to pSTAT3 and EMT. 
 
6.2.1.1 Tissue Cancer Genome Atlas analysis of OSM 
Using the TCGA, expression of OSMR, along with the other gp130 cytokine receptor 
genes IL6R and LIFR, was analysed in a PDAC patient population. The patient 
population consisted of 177 patients with a diagnosis of PDAC (Appendix 1).   
Results showed expression of OSMR is prognostic in a PDAC patient cohort: patients 
with high gene expression had a significantly worse patient outcome than those with 
low expression (p=0.01433) (Figure 6.1). Interestingly, IL6R and LIFR expression 
was inversely related to survival, with high expression levels leading to better patient 




Figure 6.1 Prognostic analysis of gp130 cytokine receptors in PDAC 
Kaplan-Meier curves of OSMR, IL6R and LIFR gene expression in TCGA pancreatic data set showing 
the overall survival analysis in patients with high and low receptor expression (median expression cut 






As this patient cohort was mixed, patients were divided by stage of disease to 
determine of OSMR expression was relevant. Unfortunately, patient numbers were not 
high enough for meaningful analysis in Stage III and IV disease (n=3 and n=4 
respectively). However, when analysing localised disease only i.e. stage I and II 
patients (n=167), patients with high OSMR expression had a significantly worse 
outcomes (p=0.042) (Figure 6.2). Thus, patient data suggest that OSMR is an 
important prognostic factor in early stage disease for inferior survival. 
 
Figure 6.2 Prognostic analysis of OSMR in Stage I and II PDAC 
Kaplan-Meier curves of OSMR gene expression in early stage (i.e. localized disease) in TCGA 
pancreatic data (n=167) showing the overall survival analysis in patients with high and low expression 
of OSMR (median expression cut off). 
 
6.2.1.2 Serum levels of OSM  
In order to confirm the TCGA dataset, levels of OSM in patient serum was next tested. 
It was hypothesised that should OSM/ OSMR be an important pathway driving PDAC 
progression, then it would be elevated in patients with the disease compared to non-
diseased individuals. Detectable serum levels have previously been reported in PDAC 
patients, whereby elevated serum levels of OSM were found to be diagnostic as part of 
a panel of cytokines in response to combination therapy of gemcitabine and erlotinib 
(Torres et al. 2014).  
Levels of OSM protein were tested in treatment naïve metastatic PDAC patients and 




higher average level of serum OSM in healthy donor population compared to the 
diseased population.  
 
Figure 6.3 ELISA of OSM in healthy vs. PDAC patients 
ELISA of OSM protein in healthy (n=10) vs. PDAC patient serum (n=9) macrophage conditioned 
media (n=13). Results represent individual values with mean. 
 
One possible explanation for these results could be technical, as it was noted that 5/9 
patients in the disease population had undetectable levels; the time to collect and 
process PDAC patients was longer compared to the ‘healthy’ donor controls. Thus, 
should OSM have been unstable over longer periods of time, protein levels could have 
appeared falsely low. In addition, baseline differences in the patient populations could 
have led to the differences noted. In the first instance, healthy donor and PDAC 
patients were not age matched, and information of disease status for healthy donor 
populations was not available. Thus, as OSM levels are known to vary in disease 
states, for example higher levels in inflammatory conditions (Richards 2013), if a 
donor was suffering from an inflammatory condition at the time of testing, than 
circulating OSM would be raised and this bias could have affected results. In addition, 
all of the PDAC patients tested were treatment naïve and had metastatic or locally 
advanced disease.  Based on the TCGA analysis results, expression of OSMR is 
prognostic in the early stage patients and undetermined for late stage disease due to 















be more relevant in early stages of disease, rather than in this patient cohort of late 
stage metastatic disease.  
Should these low readings of circulating OSM be true however, it could be explained 
that the circulating levels are not reflective of the activity at the localised tumour, 
especially if the cytokine is secreted by local tumour infiltrating TAMs. Thus, these 
findings of lower levels of serum OSM in PDAC compared to healthy controls does 
not necessarily reflect the activity of the pathway described thus far. 
 
 
6.2.1.1 Tissue Microarray 
To investigate the pathway of interest at the local tumour site, TMAs of PDAC patient 
tissue were stained for OSMR, pSTAT3, CD68 and CK19. Zeb1 and OSM staining 
were also attempted, but antibodies could not be optimised for accurate analysis of 
IHC. 
Serial staining of a TMA panel of 33 PDAC tissue cores revealed a significant positive 
association between the expression of nuclear pSTAT3 staining and OSMR intensity 
of CK19 positive cells (Figure 6.4). This result not only shows that the degree of 
OSMR is related to pSTAT3 activation in human tissue samples, but also confirms 




























































Figure 6.4 Association of pSTAT3 and OSMR in patient tissue 
A) Correlation between nuclear pSTAT3 expression and OSMR intensity in CK19 cells of 33 PDAC 
tissue cores. Linear regression was conducted to evaluate the correlation between pSTAT3 percentage 
staining as a total CK19 cells compared to OSMR intensity in CK19 cells. Dotted lines represent the 
95% confidence interval B) Representation micrographs of CK19, pSTAT3 and OSMR stained PDAC 
tissue cores. 
 
Overall, this exploration of clinical data has revealed that OSMR is prognostic for 
worse survival in PDAC patients, and that staining of patient tissue has shown an 
association with this receptor and pSTAT3 in the primary tumour. These findings 
support in vitro data that OSM is likely to be initiating a pro-tumourigenic phenotype 
in PDAC cells via binding to its receptor, and driving STAT3 mediated pathways that 







6.2.2 In vitro inhibition 
To identify agents that inhibited activation of our pathway on interest, drugs had to be 
readily available and non-toxic to mammalian cells. In addition, a way in which to 
prove mechanism of action for each agent was needed. Inhibition of pSTAT3 through 
western blot analysis was selected for this purpose.  
Based on these criteria, three inhibiting agents were selected that covered all stages of 
the pathway: neutralising OSM antibody (anti-OSM), antibody against the gp130 
receptor (anti-gp130 antibody) and the small molecule inhibitor against JAK/STAT, 
ruxolitinib (Figure 6.5). It was recognised that antibody against gp130 receptor was 
not specific to OSM, however there is no commercial agent against OSMR therefore 
this antibody was selected to determine the effects of receptor inhibition. 
 





6.2.1.2 Inhibition of STAT3 phosphorylation 
Mechanism of action for each agent was confirmed through loss of STAT3 
phosphorylation in both MCM treated cells (Figure 6.6). Western blot for inhibition 
was only performed once in each cell type, and would have to be repeated to 
determine significant down regulation of protein, but the trend was seen across three 
different primary cultures tested. Of note, inhibition appeared stronger in all three cell 
types with the anti-gp130 receptor antibody compared to neutralising OSM antibody 
in MCM. Reasons for this finding could be that at the concentrations used, OSM 
antibody was not completely neutralising recombinant OSM protein / secreted OSM 
protein present in MCM, thus some was still able to bind the receptor complex to 





















Figure 6.6 STAT3 phosphorylation with antibody inhibition 
Western blot of pSTAT3 protein expression from cell lysates of PDAC cells cultured with MCM in the 
presence of anti-OSM antibody (10μg/ml), anti-gp130 receptor antibody (2μg/ml) or ruxolitinib 
(250nM). Relative densitometric quantification of protein bands, normalised to total STAT3 and 




6.2.1.1 Inhibition of immune evasion 
PDL-1 is known to be regulated by STAT3 in lymphomas (Marzec et al. 2008) and 
and in PDAC mouse model, ruxolitinib improves the efficacy of anti-PD-1 
immunotherapy (Lu et al. 2017). Therefore, PDL-1 expression in PDAC could be 
influenced by STAT3 pathway blockade. Upregulated expression in OSM and MCM 
was decreased by OSM/ OSMR/ STAT3 inhibitors, confirming the hypothesis that 
regulation of PDL-1 in PDAC cells is STAT3 driven (Figure 6.7).  
 
 
Figure 6.7 PDL-1 expression following OSM / OSMR / STAT3 inhibitors 
Mean fluorescence intensity (MFI) analysis for Panc354 (n=2) treated with control media, MCM or 
OSM (100ng/ml) +/- neutralising anti-OSM (10μg/ml), anti-gp130R antibody (2μg/ml) or ruxolitinib 
(250nM).  Results represent a compilation of experiments normalised to control media non-treated cells, 































































































































Anti-OSM +-+- +-+- +-+-
Anti-gp130R +-+- +-+- +-+-
Ruxolitinib +-+- +-+- +-+-
Ctl
MCM
6.2.1.2 Inhibition of invasion 
The effect of pathway inhibition on invasion was next determined. Treatments were 
applied to Panc215, 354 and 10953 and cells were subsequently used in invasion assay 
experiments, performed twice in each primary cell culture type (Figure 6.8). Of note, 
anti-gp130 receptor antibody showed the most consistent and the greatest decrease in 
fold change of invasion in MCM treated cells, but experiments would have to be 




































Figure 6.8 Invasion with OSM/ OSMR/ STAT3 inhibitors  
Transwell invasion assay of Panc 215, 354 and 10953 (n=2 per cell type) pre-treated MCM for 48hrs +/- 
anti-OSM antibody (10μg/ml), anti-gp130 receptor antibody (2μg/ml) or ruxolitinib (250nM). Results 





As antibody treatment against gp130 showed the strongest and most consistent 
downregulation in function with MCM treatment (i.e. invasion), this treatment was 
chosen to take forward for further testing. The effects of this antibody were confirmed 
in the presence of OSM treatment also, showing a decrease in EMT gene expression 
and invasion in the cells treated with OSM and anti-gp130 receptor antibody (Figure 
6.9 and 6.10). 
  
Figure 6.9 EMT gene expression with antibody inhibition 
RT qPCR of EMT genes in Panc354 treated with OSM (100ng/ml) for 48hrs with anti-gp130 receptor 
antibody (2μg/ml) (n=3). Results represent normalisation to control, with values representing the mean 














































Figure 6.10 Effect on invasion with anti-gp130 receptor  
Transwell invasion assay of Panc 215, 354 and 10953 (n=2 per cell type) pre-treated with OSM 
100ng/ml and MCM for 48hrs +/- anti-gp130 receptor antibody (2μg/ml). Results represent a 
compilation of experiments normalised to control, with values representing the mean (+/- SEM). 
Statistical significance: Wilcoxian paired t test * = p<0.05. 
 
In conclusion, in vitro testing revealed that anti-OSM antibody, anti-gp130 antibody 
and ruxolitinib blocked pSTAT3 expression and invasion in the presence of MCM. As 
anti-gp130 receptor antibody gave the most consistent downregulation in invasion 
with both OSM and MCM treatment cells, this agent was taken forward for inhibition 









6.2.3 In vivo inhibition 
Prior to in vivo testing, it was necessary to confirm that blocking the pathway using the 
gp130 receptor antibody had no detrimental effects on cell growth that could influence 
the in vivo metastatic assay results or growth of a primary tumour in situ.  
Anti-gp130 receptor antibody was tested on cells pre-treated for 48 hours with control 
media, MCM or OSM. After 3 days treatment, cumulative results from Panc215, 354 
and 10953 demonstrated a significant decrease in proliferation of OSM treated cells 
compared to control treated (Figure 6.11). There was a trend for decreased 
proliferation in MCM as seen previously, but this was not significant. The effects on 
proliferation were reversed with the antibody treatment as hypothesised, but this 
difference was only significant in the control treated cells and not in MCM or OSM 
pre-treated cells. 
 
Figure 6.11 Crystal violet proliferation with anti-gp130 receptor antibody 
Crystal violet analysis of Panc215, 354 and 10953 pre-treated with control, MCM of OSM (100ng/ml) 
for 48hrs, followed by 4 days treatment with corresponding media and antigp130 receptor antibody 
(2μg/ml) (n=2 per cell type). Staining of crystal violet was normalised to day 0 control (i.e. pre-treated 
cell density). Results represent a compilation of all experiments (n=6) normalised to control, with 




Applying this clinically, it would suggest that inhibiting the gp130 receptor alone in 
patients could theoretically lead to greater proliferation of PDAC cells within the 
primary tumour, especially those not under the influence of macrophage derived 
factors. However, independent inhibition of this pathway was never proposed, as there 
is no suggestion that targeting cells through this pathway would have cytotoxic effects 
that leads to tumour regression, an essential requirement for effective anti-cancer 
therapy. Thus, trying to mimic the potential clinical application of the agent, the 
antibody was tested in conjunction with gemcitabine in cells pre-treated with the 
MCM or OSM. The previous proliferative advantage seen with antibody blockade was 
not seen in combination treatment i.e. cells remained responsive to conventional 
chemotherapy when inhibiting the OSMR/ OSM/ STAT3 pathway (Figure 6.12). 
Therefore, when formulating a future clinical application for targeting this pathway, 
one would expect to give therapy in conjunction with a standard cytotoxic 
chemotherapy regime.  
 
Figure 6.12 Crystal violet proliferation with antigp130 receptor and gemcitabine 
Crystal violet analysis of Panc215, 354 and 10953 pre-treated with control, MCM of OSM (100ng/ml) 
for 48hrs, followed by 4 days treatment with corresponding media and antigp130 receptor antibody 
(2μg/ml) or gemcitibine (300nM) alone or in conjunction (n=1 per cell type). Staining of crystal violet 
was normalised to day 0 control (i.e. pre-treated cell density). Results represent a compilation of all 
experiments (n=3) normalised to control, with values representing the mean (+/- SD).  
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Prior to in vivo injection, as with MCM, effects of OSM and antibody treatment 
described thus far were found to be consistent in Panc354-Luc, which had undergone 
virus transduction and GFP sorting and therefore could have responded differently due 
to selection pressures. OSM treated cells displayed the typical morphological changes 
expected, which were reversed with antibody treatment (Figure 6.13A). pSTAT3 and 
invasion was upregulated with OSM treatment, and inhibited with anti-gp130 receptor 
antibody treatment, as with non-transduced cells (Figure 6.13B & C). These 
experiments were only done once for the purpose of confirming the pattern of effect 














Figure 6.13 Effects of OSM on Panc354-Luc cells 
A) Brightfield imaging of Pan354-Luc cells treated with OSM 100ng/ml +/- anti-gp130 receptor 
antibody 2μg/ml B)  Western blot of Panc354-Luc cell lysate following treatment with OSM and 
antibody C) Invasion assay of Panc354-Luc cells treated with OSM and antibody inhibitors (n=1). 




Having confirmed OSM and inhibitory antibody effects were applicable in Panc354-
Luc, further in vivo metastases experiments were next performed with OSM pre-
treated cells. For in vivo experiment ‘B’, Panc354-Luc cells were injected to nude 
mice. In addition to the different mouse model used, fewer cells were injected in this 
experiment (50,000) compared to experiment ‘A’, in an attempt to avoid ‘saturation’ 
of the system in the control conditions, as 3/5 mice had liver metastases in the control 
group for experiment ‘A’.   
After 9 weeks post injection, no macrometastases were noted at the time of animal 
sacrifice, despite the luciferase detection criteria being met on IVIS imaging as with 
experiment ‘A’ (i.e. at least 3 mice detecting 1x10
6
 BLI signal) (Figure 6.14).  
 
Figure 6.14 In vivo IVIS bioluminescence imaging and liver images 
IVIS bioluminecsnce imaging of animals at 9 weeks post injection, with corresponding livers dissected 




As macrometastases were not visible, livers were fixed, sectioned and serial slides 
were stained for CK19, using a human specific antibody, to detect micrometastases 
(Figure 6.15). Micrometastasis were taken as a colony of cells measuring at least 
150μm in maximum diameter. 
 
Figure 6.15 Examples of CK19 positive micrometastases 
Examples of histology from livers sectioned from two mice injected with pre-treated OSM (100ng/ml) 
Panc354-Luc cells and sacrificed at 9 weeks post injection 
 
Results of micrometastasis analysis showed that all animals in control and OSM 
groups had liver metastases (Table 6.1). This was unexpected, as control treated cells 
would not have been ‘primed’ to undergo EMT and be invasive as with OSM pre-
treated cells. However, the antibody treatment had inhibited invasion not only in the 
OSM pre-treated cells but also in the control group. This finding suggested that the 
metastases in the control group were being driven downstream of the gp130 receptor. 
As no direct stimulus was being applied in vitro to these cells, one would assume the 







Table 6.1 Metastasis results in vivo  





Reasons for a lack of visible metastases in experiment ‘B’ compared to ‘A’ could have 
been due to the different animal model used (NSG vs nude mice) or lower number of 
cells injected. Thus, for experiment ‘C’, NSG mice were used as per experiment ‘A’. 
Less cells than experiment ‘A’ (50,000) were injected again to try to minimise the 
possible ‘saturation’ in control animals. In this experiment, animals were sacrificed at 
week 12, when the BLI signal was >1x10
6
 in at least 2 mice. Visible metastases were 
counted (Figure 6.16). As with experiment ‘A’; in livers with no visible metastases, 
organs were fixed, sectioned and stained with CK19 antibody. Following this, one 
additional liver in the OSM group stained for micrometastasis (at least 150μm) that 
had no visible macrometastases (Figure 6.17 and Table 6.2) 
 
Figure 6.16 Macrometastasis in vivo  
Liver macrometastasis experiment ‘C’ following intrasplenic injection of 50,000 Panc354-Luc cells pre-
treated with control, OSM (100ng/ml) +/- antigp130 receptor antibody (2μg/ml) for 48hrs in vitro. 
Animals were sacrificed and livers imaged 12 weeks post injection.  
 
Pre-treatment 
Positive for liver 
metastasis / total number 
of mice 
Control 4/4 
Control + anti-gp130R antibody 2/5 
OSM 5/5 





















In this third in vivo experiment, control cells still induced liver metastases in 2/4 mice 
despite less cells injected. Anti-gp130 receptor antibody again inhibited metastases 
formation as seen in experiment ‘B’, in both the control and treatment groups. OSM 
induced metastases in all mice (Table 6.2).  
Table 6.2 Metastasis results in vivo  







Therefore, in vivo data using antibody against the gp130 receptor demonstrated a trend 
for a decrease in the number of mice with liver metastasis across the two models used. 
These data would require further experiments to be performed (in NSG mice using 
50,000 cells per injection as per experiment ‘C’) to prove significant differences with 
gp130 receptor antibody treated cell conditions.  
 
Pre-treatment 
Positive for liver 
metastases / total number 
of mice 
Control 2/4 
Control + anti-gp130R antibody 0/5 
OSM 3/3 
OSM + anti-gp130R antibody 0/3 
Figure 6.17 CK19 positive micrometastases in vivo 
Micrometastases detected through CK19 staining of serial sections in OSM pre-treated Panc354-






The first aim of this chapter was to determine the clinical relevance of the OSM/ 
OSMR/ STAT3 pathway in patient samples. Analysis of the TCGA database revealed 
OSMR gene expression to be prognostic for poor outcome, particularly in early stage 
disease. This finding supports our in vitro data, demonstrating OSMR expression to 
correlate with a more pro-tumourigenic phenotype. As macrophages induce OSMR 
expression, and the presence of macrophages in patient tissue confers with worse 
patient outcome (Ino et al. 2013; Kurahara et al. 2013), this result could be 
extrapolated and one could speculate that higher presence of OSMR in PDAC tissue 
relates to a more aggressive disease. 
Expression of OSM cytokine in circulation was next investigated in relation to disease. 
There was no correlation between levels of the cytokine in patient serum and disease 
status. This could have been due to technical reasons and lack of screening of ‘healthy’ 
controls for inflammatory conditions as discussed. As this thesis is investigating the 
effects of OSM on PDAC cells in the primary tumour tissue, staining of primary 
tumour was of more relevance. Unfortunately, staining of OSM and Zeb1 could not be 
optimised therefore a direct correlation between OSM, and the activated phenotype of 
interest in PDAC cells could not be determined. IHC analysis of PDAC TMAs did 
however establish an association between the presence of OSMR on malignant cells 
and pSTAT3 nuclear expression, supporting the hypothesis that upstream activation of 
pSTAT3 is through OSMR. 
The next aim of this chapter was to test inhibitors of OSM/ OSMR/ STAT3 pathway. 
Inhibition of the pathway was achieved using an OSM neutralising antibody, an 
antibody against the gp130 receptor or the JAK-STAT inhibitor ruxolitinib, and was 
confirmed in each cell type by blotting for pSTAT3 in MCM treated cells in vitro, but 
further experiments would be required to ensure consistent and significant reduction. 
Use of these inhibitors was also found to reduce levels of PDL-1 expression in the 
presence of OSM and MCM. This finding is supported by in vivo studies in transgenic 
mice by Lu et al. whereby ruxolitinib led to more cytotoxic T cell infiltration of mouse 
tumours and improved the efficacy of anti-PD-1 antibody treatment (Lu et al. 2017). 
These in vivo data can now be explained by our findings that ruxolitinib treatment 
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leads to less PDL-1 expression on tumour cells in vitro. Pathway inhibitors also 
showed a trend for decreased invasion when tested in vitro when tested in each cell 
type (n=2), and inhibition with gp130 receptor antibody was the most consistent, but 
further repeats would be required to determine significance. This co-receptor is shared 
with other gp130 family cytokines, therefore one could argue that in the presence of 
MCM the effects of this antibody may not be attributed to the effect of OSM alone and 
thus stronger inhibition could have occurred leading to significance over other 
inhibitors. However, OSMR was the most highly expressed gp130 co-receptor at 
baseline in PDAC and the most potent activator of STAT3 compared to IL6R and 
LIFR, therefore one would expect that the inhibitory effects of anti-gp130R would act 
predominantly on OSMR activation compared to the other gp130 family cytokine 
receptors, and thus inhibition of these receptors influencing the results would be less 
important.  
Panc354 cells pre-treated with OSM and anti-gp130 receptor antibody in vitro formed 
the less liver metastasis when injected in vivo in metastasis assay, but this would have 
to be definitively proven with further animal experiments. Interestingly, experiments 
testing the effects of this inhibitor demonstrated a large percentage of treated animals 
developed liver metastases even in the control groups. This had also been noted in first 
in vivo experiment ‘A’, in which 60% of animals in control group were positive for 
liver metastasis. The number of cells injected had been adjusted accordingly for 
subsequent experiments, however this did not appear to influence the result. This 
finding was unexpected, as cells injected in these control animals had not been 
preconditioned with factors that had not driven the process of EMT or invasion in vitro 
downstream of the gp130 receptor. Because antibody blockade in this control group 
led to decreased metastases forming in both animal models, it was hypothesised that 
the driving effect of metastasis formation therefore would have occurred in vivo. This 
can be explained by previous studies comparing tumour cells grown in vitro to those in 
vivo in which increased expression of genes that play a role in metastasis formation, 
such cell adhesion molecules and cytokines, occur in vivo and not in vitro (Creighton 
et al. 2003). Therefore, in animal experiments performed in this thesis, metastasis 
formation in the control groups could reflect non-specific pathway activation, coming 
from signalling from the environment for example, resulting in tumour cell 
dissemination that is otherwise not present in vitro.  
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Inhibitory agents against the OSM/ OSMR/ pSTAT3 pathway already exist in the 
clinic: ruxolitinib is currently approved for use in myeloproliferative disease (Harrison 
et al. 2017; Mesa et al. 2013). In PDAC, an interim analysis of phase II trial data 
comparing ruxolitinib plus the oral chemotherapy agent capecitabine versus 
capecitabine alone in refractory metastatic disease showed promise in patients with a 
high C-reactive protein (CRP), demonstrating better OS and PFS with combination 
treatment (Hurwitz et al. 2015). As CRP is a surrogate marker for systemic 
inflammation, this finding would support inflammatory STAT3 driven progression in 
PDAC. However, recruitment to the phase III trial of ruxolitinib in combination with 
capecitabine in metastatic PDAC patients (JANUS-2: NCT02119663) was 
discontinued due to an apparent lack of efficacy.  Nonetheless, other agents against 
STAT3 are currently in testing for PDAC, for example napabucasin (BBI608). This 
oral agent is designed to inhibit STAT3 and is believed to specifically target cancer 
stemness pathways. Phase 1b/II testing in metastatic PDAC patients has shown 
promise, with one patient undergoing a completed response (2%) and 26 patients 
(43%) having partial response (Bekaii-Saab 2017). A phase III trial will conclude 
efficacy in combination with nab-paclitaxel plus gemcitabine in patients with 
metastatic pancreatic cancer (NCT02993731). Ongoing development and application 
of STAT3 agents in PDAC support our findings that this pathway plays an important 
role in tumour progression. In addition, findings from this thesis provide a mechanistic 
reason as to why this may be an effective therapeutic strategy.  
An alternative therapeutic approach to target the OSM/ OSMR/ STAT3 pathway 
would be through targeting OSM. The apparent less consistent inhibitory effect with 
neutralising anti-OSM across the three cell types tested in this chapter could be due to 
low binding affinity of neutralising antibody to OSM, or that the concentrations 
needed for the agent to be effective were not fully optimised. A clinically developed 
anti-OSM antibody, GSK315234, has been tested in phase II trials in patients with 
rheumatoid arthritis and was deemed safe (Choy et al. 2013). However, it was noted 
that the antibody was not very potent, with only moderate binding affinity and rapid 
off-rate protein carrier effect. A more potent antibody has since been developed  
(GSK2330811) and is safe in healthy volunteers (Reid J, et al. 2016). A phase I trial of 
this agent in systemic scleroderma has been completed (NCT02386436) pending 
report, and a phase II is proposed (NCT03041025). Based on the findings from this 
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thesis, one could speculate that it would be of interest to apply these anti-OSM 







































7.1 Discussion and Future Work 
 
 
Pancreatic cancer is considered a highly desmoplastic tumour, composed of tumour 
and non-malignant cells within an ECM. Due to a current lack of effective treatment 
strategies, interest is growing in novel therapeutic interventions that target these other 
tumour components, such as the stromal cells (Carr and Fernandez-Zapico 2016). 
Tumour-associated macrophages are abundant within the PDAC TME, conferring 
worse survival outcomes (Ino et al. 2013; Kurahara et al. 2013). In an era of novel 
immunotherapies, current trials targeting TAMs in cancer have so far been limited and 
have failed to make real clinical impact. However, by gaining further insight into how 
TAMs interact with cancer cells to drive tumour progression, novel agents targeting 
their effects could be developed to produce better clinical efficacy. 
Results from this thesis have concluded that interaction with TAMs are vital in 
malignant progression by driving an epithelial-to-mesenchymal phenotype, promoting 
invasion and increasing metastasis of primary PDAC cells. This was concluded to be 
due to the secretion of the gp130 family cytokine OSM. This cytokine activates 
STAT3 driven pathways in cancer cells that result in a pro-tumourigenic phenotype. 
Crosstalk between cancer and immune cells are likely to be driving this phenotype, 
with the PDAC associated cytokine TGFβ1 shown to induce OSM secretion by TAMs 
(Figure 7.1). Of note, OSM has greater effects in PDAC than other gp130 cytokine 
family members, such as IL6 and LIF, due to the higher presence of its receptor, 
OSMR, in cancer cells. For the first time the importance of this receptor has been 
confirmed in patient samples, whereby patients with higher gene expression had a 
worse OS on TCGA dataset analysis and expression in the primary tumour was shown 
to correlate with pSTAT3 expression in cancer cells.  A higher expression of OSMR in 
PDAC CSCs explains the increased potency of MCM and OSM effects in this 
subpopulation of cells. In turn, OSM increases PDL-1 expression on PDAC, assisting 
in immune evasion. These two latter effects are likely to aid metastasis formation, as 
CSCs are believed to be key in dissemination of cancer to form heterogeneous 
tumours in distant sites (Hermann et al. 2007) and PDL-1 expression would protect 
cells from immune cell cytotoxicity when travelling away from the protective 
immunosuppressive PDAC TME.  
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Inhibition of the OSM/ OSMR/ STAT3 pathway using neutralising antibody against 
OSM, antibody inhibition of the gp130 co-receptor or by the JAK-STAT small 
molecule inhibitor ruxolitinib reversed the effects of STAT3 activation, induction of 
EMT, invasion and upregulation of PDL-1 by MCM and OSM in vitro.  Confirming 
systemic effects of this inhibition, PDAC cells treated with anti-gp130 receptor 
antibody formed less metastasis in vivo in two mouse models tested, but further 
experiments would be needed to determine if this reduction was significant. Thus, 
preliminary data provided here shows targeting this macrophage driven pathway could 
have therapeutic potential. 
 
      Figure 7.1 Schematic summary of thesis 
 
 
Recent publication supports results that OSM is a key cytokine in driving PDAC 
tumour progression: Smigiel et al. have shown that OSM not only induces 
mesenchymal transition in PDAC cells, but also a CSC phenotype (Smigiel, 
Parameswaran, and Jackson 2017). Similar to our findings, authors showed OSM 
activation of EMT factors (Zeb1 and Snail) and pSTAT3 in PDAC cell lines (HPAC, 
Panc04.03, 08.13, 05.04). Also, IL6 did not drive pSTAT3 and Zeb1 expression in 
these PDAC cell lines, once again supporting our data. Using clinical datasets, OSMR 
expression was shown to be greater in PDAC tissue compared to normal. Converse to 
our findings however, OSM potentiated the CSC population, with CSCs being defined 
by expression of CD44. Our results show that stemness genes were not increased 
following treatment with OSM in vitro, but further experiments are required to 
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determine if there are also effects on CD133+ expression and sphere formation. 
Different experimental assays were used to determine stemness in Smigiel et al. 
(CD24/CD44 expression and tumourigenicity assay in vivo). Authors generated PDAC 
cells that overexpressed OSM and found they produced larger tumours in vivo and that 
these tumours were more resistant to gemcitabine. In turn, when PDAC cells were co-
injected with fibroblasts overexpressing OSM in vivo, animals formed more metastasis 
and had worse survival outcomes. Overall, findings from this study support results 
presented in this thesis that OSM is a key cytokine in driving PDAC progression and 
metastasis. 
In this thesis, in vitro and in vivo assays were used to explore the interactions between 
TAMs and PDAC. However, it should be noted that there are limitations in applying 
these experimental results to actual PDAC patient tumours due to the complexity of 
the TME that is difficult to recapitulate through in vitro and in vivo models. In the first 
instance, other cytokines are likely to be present within the patient TME that could 
also be driving EMT and invasion. However, the pleotropic activity of OSM in 
immune modulation and invasion, particularly on the CSC population, suggest a wide 
range of effects in driving metastasis formation. In turn, expression of OSMR was 
shown to have clinical significance. Therefore, the data presented establishes a 
significant role for OSM amongst the many other cytokines likely to be present in 
patient tumours, and one would anticipate targeting OSM would be clinically effective 
as it would inhibit several aspects of PDAC progression that could culminate in 
improved patient outcome.  
Experimental findings of this thesis were based on exploring secreted factors from 
TAMs. However, in patient tumours cell-cell contact between macrophages and 
PDAC are likely to be taking place and influencing cell behaviour. This association is 
important in breast cancer, whereby direct binding of macrophages and CSCs 
potentiates the CSC niche (Lu et al. 2014). Therefore to confirm findings in more 
detail, it would be important to extend in vitro experiments to incorporate direct co-
culture of macrophages and PDAC. This would investigate if juxtacrine signalling 
effects TAM secretion of OSM, STAT3 pathway activation and OSMR expression on 
PDAC. For example, this could be done by growing cells in direct co-culture, sorting 
them and examining gene expression (e.g. testing for OSM in macrophages and EMT 
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genes in PDAC cells). By performing such experiments, the speculated pathway of 
interest in the setting of juxtacrine signalling could be confirmed.  
It is unlikely that macrophages are the only source of OSM within a patient tumour. 
Other cells are known to secrete OSM, such as monocytes, T cells and DCs (Richards 
2013). In cancer tissue, adipose cells and CAFs have both been shown to secrete OSM 
in breast and lung cancer respectively (Lapeire et al. 2014; Shien et al. 2017). To 
determine which cells are secreting the cytokine within PDAC, further staining of 
TMAs could be performed. Using techniques such as RNA scope, staining of OSM 
mRNA in addition to cell specific antibodies such as CD3 (T cells), CD11c (dendritic 
cells) and CD68 (macrophages) could be performed. This would then help determine 
which stromal cell population is responsible for most OSM secretion within the 
primary tumour. However, even if it were found that cells other than macrophages are 
producing OSM, the proposed targeting of the cytokine itself or of STAT3 activation 
within the malignant cells rather than macrophages directly would still be an effective 
way to modulate tumour progression. 
In vivo experiments of pre-treated cells suggest that targeting the OSMR-gp130R 
heterocomplex could decrease the metastatic effects of OSM. There are no drugs 
currently designed to directly bind and inhibit the gp130 co-receptor, mainly as 
complete inhibition could potentially cause severe side effects such as heart attack, 
coagulation, neuropathy and infection (Xu and Neamati 2013). No clinical agents exist 
against OSMR either. This receptor is expressed at high levels in normal tissue, 
including brain and muscle (Figure 7.2), therefore despite OSMR being overexpressed 
in PDAC tissue compared to normal (Smigiel et al. 2017), there would no doubt be 
toxicity to other organs following systemic inhibition. In addition, targeting of OSMR 
would not completely inhibit the STAT3 activation effects of OSM due to its ability to 





Figure 7.2 Human Protein Atlas tissue expression of OSMR 
Taken from Human Protein Atlas (http://www.proteinatlas.org) showing protein expression data of 
OSMR staining for each of the 44 tissues tested.  
 
When exploring other ways to inhibit the OSM/ OSMR/ STAT3 pathway, OSM-/- 
animals are viable and healthy (Hamada et al. 2007), suggesting that loss of OSM 
cytokine itself is not embryonically lethal and not vital for normal homeostatic 
activity. To date, two antibodies against OSM have been designed, GSK315234 and 
GSK2330811. These agents have already been safely trialled in humans (Choy et al. 
2013; Reid J et al. 2016) and are proposed for further testing in inflammatory 
disorders. Therefore, of the therapeutic strategies suggested for targeting this pathway 
in cancer, neutralisation of OSM appears to be the most viable in humans. To explore 
the potential clinical benefits of targeting OSM in PDAC, GSK2330811 (the more 
potent antibody) would need to be tested in conjunction with chemotherapy in vivo 
and assessed for toxicity, effects on metastatic spread and OS in animals. The 
preclinical models used to test this hypothesis should ideally be genetically engineered 
mouse models (GEMMs). This is because in vivo data presented thus far has been 
based on the use of PDX models as an in vivo read out of in vitro treatment of PDAC 
primary cultures. Although these PDX models better represent intratumour 
heterogeneity, cancer genetics and drug responses, they exclude the participation of 
stromal components in tumour progression, and crucially the effects of the adaptive 
immune system. Therefore, due the model used, the metastatic assay does not allow 
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for assessment of T cell effects on disseminating tumour cells in relation to the finding 
of increased PDL-1 expression following cytokine treatment and do not assess 
systemic toxic effects of pathway inhibition because the antibody was given only with 
local injection of tumour cells into the spleen. Using GEMM, such as the KPC mouse 
model, a better representation of the clinical course of PDAC from early to late stage 
disease in the context of a ‘true’ microenvironment could be assessed. Accordingly, 
complementing our studies using GEMM would provide indication of the 
effectiveness of anti-OSM antibodies in PDAC and also provide some data on 
systemic drug toxicity in combination with chemotherapy. The key question that could 
also be answered by using these models is at what stage would administering OSM 
treatment be clinically effective. One could argue that early treatment prior to cancer 
cell dissemination, possibly in the neoadjuvant setting, would be more important in 
preventing metastatic recurrence. This is also supported by TCGA findings that high 
OSMR expression leads to worse survival outcome in early stage disease. However, 
OSM inhibiting agents could also be of interest in ‘containing’ metastatic disease 
progression due to its other effects on immune cell evasion and CSCs, which may lead 
to less metastatic growth and better OS. By following up the in vivo investigation of 
OSM pathway inhibition in both PDX and GEMM, the real benefits of clinical 










In this exciting era of immunotherapy in cancer medicine, novel agents targeting the 
inflammatory drivers of cancer progression would allow for more effective treatment 
strategies.  Understanding the role of innate immune cells within the TME is now of 
interest to develop these approaches further. The work presented in this thesis 
indicates TAMs are driving STAT3 mediated metastatic spread of PDAC through 
secretion of the inflammatory cytokine, OSM. Further investigation of the clinical 
relevance of OSM is required, specifically whether blockade of the pleotropic effects 












































Adamson, Adewole et al. 2013. “Tissue Inhibitor of Metalloproteinase 1 Is 
Preferentially Expressed in Th1 and Th17 T-Helper Cell Subsets and Is a Direct 
Stat Target Gene.” PLoS ONE 8(3). 
Ahmad, Rehan et al. 2011. “MUC1-C Oncoprotein Promotes STAT3 Activation in an 
Autoinductive Regulatory Loop.” Science Signaling 4(160):ra9. 
Ahmed, Simi T. and James E. Darnell. 2009. “Serpin B3/B4, Activated by STAT3, 
Promote Survival of Squamous Carcinoma Cells.” Biochemical and Biophysical 
Research Communications 378(4):821–25. 
Almoguera, Concepcion et al. 1988. “Most Human Carcinomas of the Exocrine 
Pancreas Contain Mutant c-K-Ras Genes.” Cell 53(4):549–54. 
Angevin, E. et al. 2014. “A Phase I/II, Multiple-Dose, Dose-Escalation Study of 
Siltuximab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with 
Advanced Solid Tumors.” Clinical Cancer Research 20(8):2192–2204. 
Argast, Gretchen M. et al. 2011. “Cooperative Signaling between Oncostatin M, 
Hepatocyte Growth Factor and Transforming Growth Factor-β Enhances 
Epithelial to Mesenchymal Transition in Lung and Pancreatic Tumor Models.” 
Cells Tissues Organs 193(1–2):114–32. 
Assifi, M.Mura et al. 2011. “Neoadjuvant Therapy in Pancreatic Adenocarcinoma: A 
Meta-Analysis of Phase II Trials.” Surgery 150(3):466–73. 
Bailey, Peter et al. 2016. “Genomic Analyses Identify Molecular Subtypes of 
Pancreatic Cancer.” Nature 531(7592):47–52. 
Balli, David, Andrew J. Rech, Ben Z. Stanger, and Robert H. Vonderheide. 2017. 
“Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic 
Cancer.” Clinical Cancer Research 23(12):3129–38. 
Bardeesy, Nabeel and Ronald a DePinho. 2002. “Pancreatic Cancer Biology and 
Genetics.” Nature Reviews. Cancer 2(12):897–909. 
Barré, Benjamin, Arnaud Vigneron, and Olivier Coqueret. 2005. “The STAT3 
Transcription Factor Is a Target for the Myc and Riboblastoma Proteins on the 
Cdc25A Promoter.” The Journal of Biological Chemistry 280(16):15673–81. 
Beatty, Gregory L. et al. 2011. “CD40 Agnsts Alter Tumor Stroma and Show Efficacy 
Against Pancreatic Carcinoma in Mice and Humans.” Science 331(May):1612–
16. 
Beatty, Gregory L. et al. 2013. “A Phase I Study of an Agonist CD40 Monoclonal 
Antibody (CP-870,893) in Combination with Gemcitabine in Patients with 
208 
 
Advanced Pancreatic Ductal Adenocarcinoma.” Clinical Cancer Research 
19(22):6286–95. 
Becker, T. M. et al. 2014. “Mutant B-RAF-Mcl-1 Survival Signaling Depends on the 
STAT3 Transcription Factor.” Oncogene 33(9):1158–66. 
Bekaii-Saab, Tanios S. 2017. “A Phase Ib/II Study of Cancer Stemness Inhibitor 
Napabucasin (BBI-608) in Combination with Gemcitabine (Gem) and Nab-
Paclitaxel (nabPTX) in Metastatic Pancreatic Adenocarcinoma (mPDAC) 
Patients (Pts).” J Clin Oncol 35((suppl; abstr 4106)). 
Bellido, T., C. A. O’Brien, P. K. Roberson, and S. C. Manolagas. 1998. 
“Transcriptional Activation of the p21(WAF1,CIP1,SDI1) Gene by Interleukin-6 
Type Cytokines. A Prerequisite for Their pro- Differentiating and Anti-Apoptotic 
Effects on Human Osteoblastic Cells.” J Biol Chem 273(33):21137–44. 
Bellmunt, Joaquim et al. 2017. “Pembrolizumab as Second-Line Therapy for 
Advanced Urothelial Carcinoma.” New England Journal of Medicine 
376(11):1015–26. 
Von Bernstorff, Wolfram et al. 2001. “Systemic and Local Immunosuppression in 
Pancreatic Cancer Patients.” Clinical Cancer Research 7(11 SUPPL.). 
Biankin, Andrew V et al. 2012. “Pancreatic Cancer Genomes Reveal Aberrations in 
Axon Guidance Pathway Genes.” Nature 491(7424):399–405. 
Bingle, L., N. J. Brown, and C. E. Lewis. 2002. “The Role of Tumour-Associated 
Macrophages in Tumour Progression: Implications for New Anticancer 
Therapies.” Journal of Pathology 196(3):254–65. 
Biswas, Subhra K. and Alberto Mantovani. 2010. “Macrophage Plasticity and 
Interaction with Lymphocyte Subsets : Cancer as a Paradigm.” Nature 
Immunology 11(10):889–96. 
Bonde, Anne-Katrine, Verena Tischler, Sushil Kumar, Alex Soltermann, and Reto a 
Schwendener. 2012. “Intratumoral Macrophages Contribute to Epithelial-
Mesenchymal Transition in Solid Tumors.” BMC Cancer 12(1):35. 
Borghaei, Hossein et al. 2015. “Nivolumab versus Docetaxel in Advanced 
Nonsquamous Non–Small-Cell Lung Cancer.” New England Journal of Medicine 
373(17):1627–39. 
Bowman, Tammy, Roy Garcia, James Turkson, and Richard Jove. 2000. “STATs in 
Oncogenesis.” Oncogene 19(21):2474–88. 
Brabletz, T. et al. 2001. “Variable -Catenin Expression in Colorectal Cancers Indicates 
209 
 
Tumor Progression Driven by the Tumor Environment.” Proceedings of the 
National Academy of Sciences 98(18):10356–61. 
Brahmer, Julie R. et al. 2010. “Phase I Study of Single-Agent Anti-Programmed 
Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, 
Pharmacodynamics, and Immunologic Correlates.” Journal of Clinical Oncology 
28(19):3167–75. 
Brana, Irene et al. 2015. “Carlumab, an Anti-C-C Chemokine Ligand 2 Monoclonal 
Antibody, in Combination with Four Chemotherapy Regimens for the Treatment 
of Patients with Solid Tumors: An Open-Label, Multicenter Phase 1b Study.” 
Targeted Oncology 10(1):111–23. 
Bromberg, Jacqueline. 2002. “Stat Proteins and Oncogenesis.” Journal of Clinical 
Investigation 109(9):1139–42. 
Bromberg, Jacqueline F. et al. 1999. “Stat3 as an Oncogene.” Cell 98(3):295–303. 
Buettner, Ralf, Linda B. Mora, and Richard Jove. 2002. “Activated STAT Signaling in 
Human Tumors Provides Novel Molecular Targets for Therapeutic Intervention.” 
Clinical Cancer Research 8(4). 
Bugno, M. et al. 1995. “Identification of the Interleukin-6/oncostatin M Response 
Element in the Rat Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) Promoter.” 
Nucleic Acids Research 23(24):5041–47. 
Burris 3rd, H. A. et al. 1997. “Improvements in Survival and Clinical Benefit with 
Gemcitabine as First-Line Therapy for Patients with Advanced Pancreas Cancer: 
A Randomized Trial.” J Clin Oncol 15(6):2403–13. 
Byrne, Katelyn T., Robert H. Vonderheide, Elizabeth M. Jaffee, and Todd D. 
Armstrong. 2015. “Special Conference on Tumor Immunology and 
Immunotherapy: A New Chapter.” Cancer Immunology Research 3(6):590–97. 
Cancer Research UK. 2017. “CANCER RESEARCH UK.” Retrieved 
(http://www.cancerresearchuk.org). 
Di Caro, Giuseppe et al. 2015. “Dual Prognostic Significance of Tumour-Associated 
Macrophages in Human Pancreatic Adenocarcinoma Treated or Untreated with 
Chemotherapy.” Gut (November 2016):gutjnl-2015-309193. 
Carpenter, Richard L. and Hui Wen Lo. 2014. “STAT3 Target Genes Relevant to 
Human Cancers.” Cancers 6(2):897–925. 
Carr, Ryan M. and Martin E. Fernandez-Zapico. 2016. “Pancreatic Cancer 




Cassier, Philippe A. et al. 2015. “CSF1R Inhibition with Emactuzumab in Locally 
Advanced Diffuse-Type Tenosynovial Giant Cell Tumours of the Soft Tissue: A 
Dose-Escalation and Dose-Expansion Phase 1 Study.” The Lancet Oncology 
16(8):949–56. 
Catanzaro, Joseph M. et al. 2014. “Oncogenic Ras Induces Inflammatory Cytokine 
Production by Upregulating the Squamous Cell Carcinoma Antigens 
SerpinB3/B4.” Nature Communications 5:3729. 
Catlett-Falcone, R. et al. 1999. “Constitutive Activation of Stat3 Signaling Confers 
Resistance to Apoptosis in Human U266 Myeloma Cells.” Immunity 10(1):105–
15. 
Chen, Jingqi et al. 2011. “CCL18 from Tumor-Associated Macrophages Promotes 
Breast Cancer Metastasis via PITPNM3.” Cancer Cell 19(4):541–55. 
Chen, Limo et al. 2014. “Metastasis Is Regulated via microRNA-200/ZEB1 Axis 
Control of Tumour Cell PD-L1 Expression and Intratumoral 
Immunosuppression.” Nature Communications 5:5241. 
Chen, Xue-song et al. 2007. “Diverse Effects of Stat1 on the Regulation of hsp90alpha 
Gene under Heat Shock.” Journal of Cellular Biochemistry 102(4):1059–66. 
Cheng, Fengdong et al. 2003. “A Critical Role for Stat3 Signaling in Immune 
Tolerance.” Immunity 19:425–36. 
Chin, Y. E. et al. 1996. “Cell Growth Arrest and Induction of Cyclin-Dependent 
Kinase Inhibitor p21 WAF1/CIP1 Mediated by STAT1.” Science (New York, 
N.Y.) 272(5262):719–22. 
Choi, Hye-Jin and Joong-Soo Han. 2012. “Overexpression of Phospholipase D 
Enhances Bcl-2 Expression by Activating STAT3 through Independent 
Activation of ERK and p38MAPK in HeLa Cells.” Biochimica et Biophysica 
Acta (BBA) - Molecular Cell Research 1823(6):1082–91. 
Choy, Ernest H. et al. 2013. “Safety, Tolerability, Pharmacokinetics and 
Pharmacodynamics of an Anti- Oncostatin M Monoclonal Antibody in 
Rheumatoid Arthritis: Results from Phase II Randomized, Placebo-Controlled 
Trials.” Arthritis Research & Therapy 15(5):R132. 
Cioffi, Michele et al. 2015. “The miR-17-92 Cluster Counteracts Quiescence and 




Cioffi, Michele et al. 2017. “The miR-25-93-106b Cluster Regulates Tumor 
Metastasis and Immune Evasion via Modulation of CXCL12 and PD-L1.” 
Oncotarget 8(13):21609–25. 
Ciscato, Francesco et al. 2014. “SERPINB3 Protects from Oxidative Damage by 
Chemotherapeutics through Inhibition of Mitochondrial Respiratory Complex I.” 
Oncotarget 5(9):2418–27. 
Clark, C. E. et al. 2007. “Dynamics of the Immune Reaction to Pancreatic Cancer 
from Inception to Invasion.” Cancer Research 67(19):9518–27. 
Clarke, Michael F. et al. 2006. “Cancer Stem Cells - Perspectives on Current Status 
and Future Directions: AACR Workshop on Cancer Stem Cells.” Pp. 9339–44 in 
Cancer Research, vol. 66. 
Collisson, Eric A. et al. 2011. “Subtypes of Pancreatic Ductal Adenocarcinoma and 
Their Differing Responses to Therapy.” Nature Medicine 17(4):500–503. 
Colotta, Francesco, Paola Allavena, Antonio Sica, Cecilia Garlanda, and Alberto 
Mantovani. 2009. “Cancer-Related Inflammation, the Seventh Hallmark of 
Cancer: Links to Genetic Instability.” Carcinogenesis 30(7):1073–81. 
Conroy, T. et al. 2011. “FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic 
Cancer.” N Engl J Med 364(19):1817–25. 
Corcoran, Ryan B. et al. 2011. “STAT3 Plays a Critical Role in KRAS-Induced 
Pancreatic Tumorigenesis.” Cancer Research 71(14):5020–29. 
Coward, J. et al. 2011. “Interleukin-6 as a Therapeutic Target in Human Ovarian 
Cancer.” Clinical Cancer Research 17(18):6083–96. 
Craene, Bram De and Geert Berx. 2013. “Regulatory Networks Defining EMT during 
Cancer Initiation and Progression.” Nature Reviews Cancer 13(2):97–110. 
Creighton, Chad et al. 2003. “Profiling of Pathway-Specific Changes in Gene 
Expression Following Growth of Human Cancer Cell Lines Transplanted into 
Mice.” Genome Biology 4(7):R46. 
Dejeans, Nicolas, Kim Barroso, Martin E. Fernandez-Zapico, Afshin Samali, and Eric 
Chevet. 2015. “Novel Roles of the Unfolded Protein Response in the Control of 
Tumor Development and Aggressiveness.” Seminars in Cancer Biology 33:67–
73. 
Demetri, George D. et al. 2016. “Efficacy and Safety of Trabectedin or Dacarbazine 
for Metastatic Liposarcoma or Leiomyosarcoma after Failure of Conventional 
Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.” 
212 
 
Journal of Clinical Oncology 34(8):786–93. 
Derouet, Damien et al. 2004. “Neuropoietin, a New IL-6-Related Cytokine Signaling 
through the Ciliary Neurotrophic Factor Receptor.” Proceedings of the National 
Academy of Sciences of the United States of America 101(14):4827–32. 
Dorff, T. B. et al. 2010. “Clinical and Correlative Results of SWOG S0354: A Phase II 
Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in 
Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer.” 
Clinical Cancer Research 16(11):3028–34. 
Drysdale, B. E., C. M. Zacharchuk, and H. S. Shin. 1983. “Mechanism of 
Macrophage-Mediated Cytotoxicity: Production of a Soluble Cytotoxic Factor.” 
The Journal of Immunology 131(5). 
Ducreux, M. et al. 2015. “Cancer of the Pancreas: ESMO Clinical Practice Guidelines 
for Diagnosis, Treatment and Follow-Up.” Annals of Oncology 26(5):56–68. 
Dyck, Helen G. et al. 1996. “Autonomy of the Epithelial Phenotype in Human Ovarian 
Surface Epithelium: Changes with Neoplastic Progression and with a Family 
History of Ovarian Cancer.” International Journal of Cancer 69(6):429–36. 
Eggermont, Alexander M. M. et al. 2015. “Adjuvant Ipilimumab versus Placebo after 
Complete Resection of High-Risk Stage III Melanoma (EORTC 18071): A 
Randomised, Double-Blind, Phase 3 Trial.” The Lancet Oncology 16(5):522–30. 
Elson, G. C. et al. 2000. “CLF Associates with CLC to Form a Functional Heteromeric 
Ligand for the CNTF Receptor Complex.” Nature Neuroscience 3:867–72. 
Epelman, Slava, Kory J. Lavine, and Gwendalyn J. Randolph. 2014. “Origin and 
Functions of Tissue Macrophages.” Immunity 41(1):21–35. 
Epling-Burnette, P. K. et al. 2001. “Inhibition of STAT3 Signaling Leads to Apoptosis 
of Leukemic Large Granular Lymphocytes and Decreased Mcl-1 Expression.” 
Journal of Clinical Investigation 107(3):351–61. 
Evans, R. and P; Alexander. 1970. “Cooperation of Immune Lymphoid Cells with 
Macrophages in Tumour Immunity.” Nature 228(24):361–62. 
Faris, Jason E. et al. 2013. “FOLFIRINOX in Locally Advanced Pancreatic Cancer: 
The Massachusetts General Hospital Cancer Center Experience.” The Oncologist 
18(5):543–48. 
Fehrenbacher, Louis et al. 2016. “Atezolizumab versus Docetaxel for Patients with 
Previously Treated Non-Small-Cell Lung Cancer (POPLAR): A Multicentre, 




Feng, Xi et al. 2015. “Loss of CX3CR1 Increases Accumulation of Inflammatory 
Monocytes and Promotes Gliomagenesis.” Oncotarget 6(17):15077–94. 
Ferlay, J. et al. 2014. “GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality 
Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International 
Agency for Research on Cancer;” Retrieved (http://globocan.iarc.fr). 
Fesinmeyer, Megan Dann, Melissa A. Austin, Christopher I. Li, Anneclaire J. De 
Roos, and Deborah J. Bowen. 2005. “Differences in Survival by Histologic Type 
of Pancreatic Cancer.” Cancer Epidemiology and Prevention Biomarkers 14(7). 
Fischer, Richard et al. 2012. “Early Recurrence of Pancreatic Cancer after Resection 
and during Adjuvant Chemotherapy.” Saudi Journal of Gastroenterology : 
Official Journal of the Saudi Gastroenterology Association 18(2):118–21. 
Frank, David A. 2007. “STAT3 as a Central Mediator of Neoplastic Cellular 
Transformation.” Cancer Letters 251(2):199–210. 
Fu, Xiu-Tao et al. 2014. “Macrophage-Secreted IL-8 Induces Epithelial-Mesenchymal 
Transition in Hepatocellular Carcinoma Cells by Activating the 
JAK2/STAT3/Snail Pathway.” International Journal of Oncology. 
Gaemers, Ingrid C., Hans L. Vos, Haukeline H. Volders, Sylvia W. Van der Valk, and 
John Hilkens. 2001. “A STAT-Responsive Element in the Promoter of the 
Episialin/MUC1 Gene Is Involved in Its Overexpression in Carcinoma Cells.” 
Journal of Biological Chemistry 276(9):6191–99. 
Gal, A. et al. 2008. “Sustained TGFβ Exposure Suppresses Smad and Non-Smad 
Signalling in Mammary Epithelial Cells, Leading to EMT and Inhibition of 
Growth Arrest and Apoptosis.” Oncogene 27(9):1218–30. 
Ganesh, Kasturi et al. 2012. “Prostaglandin E2 Induces Oncostatin M Expression in 
Human Chronic Wound Macrophages through Axl Receptor Tyrosine Kinase 
Pathway.” The Journal of Immunology 189(5). 
Garon, Edward B. et al. 2015. “Pembrolizumab for the Treatment of Non–Small-Cell 
Lung Cancer.” New England Journal of Medicine 372(21):2018–28. 
Gearing, D. P. et al. 1992. “The IL-6 Signal Transducer, gp130: An Oncostatin M 
Receptor and Affinity Converter for the LIF Receptor.” Science (New York, N.Y.) 
255(5050):1434–37. 
Germano, Giovanni et al. 2010. “Antitumor and Anti-Inflammatory Effects of 




Ghebeh, Hazem et al. 2006. “The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule 
Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: 
Correlation with Important High-Risk Prognostic Factors.” Neoplasia 8(3):190–
98. 
Gillen, Sonja, Tibor Schuster, Christian Meyer zum Büschenfelde, Helmut Friess, and 
Jörg Kleeff. 2010. “Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A 
Systematic Review and Meta-Analysis of Response and Resection Percentages” 
edited by C. Seiler. PLoS Medicine 7(4):e1000267. 
Gillet, J. P. et al. 2011. “Redefining the Relevance of Established Cancer Cell Lines to 
the Study of Mechanisms of Clinical Anti-Cancer Drug Resistance.” Proceedings 
of the National Academy of Sciences 108(46):18708–13. 
Giraud, Sandrine et al. 2002. “Functional Interaction of STAT3 Transcription Factor 
with the Coactivator NcoA/SRC1a.” Journal of Biological Chemistry 
277(10):8004–11. 
Glass, George, Jason A. Papin, and James W. Mandell. 2009. “SIMPLE: A Sequential 
Immunoperoxidase Labeling and Erasing Method.” The Journal of 
Histochemistry and Cytochemistry : Official Journal of the Histochemistry 
Society 57(10):899–905. 
Godinho, Susana A. et al. 2014. “Oncogene-like Induction of Cellular Invasion from 
Centrosome Amplification.” Nature 510(7503):167–71. 
Gordon, Siamon and Fernando O. Martinez. 2010. “Alternative Activation of 
Macrophages: Mechanism and Functions.” Immunity 32(5):593–604. 
Gordon, Siamon and Philip R. Taylor. 2005. “Monocyte and Macrophage 
Heterogeneity.” Nature Reviews. Immunology 5(12):953–64. 
Greaves, Paul et al. 2013. “Expression of FOXP3, CD68, and CD20 at Diagnosis in 
the Microenvironment of Classical Hodgkin Lymphoma Is Predictive of 
Outcome.” Journal of Clinical Oncology : Official Journal of the American 
Society of Clinical Oncology 31(2):256–62. 
Gritsko, Tanya et al. 2006. “Persistent Activation of Stat3 Signaling Induces Survivin 
Gene Expression and Confers Resistance to Apoptosis in Human Breast Cancer 
Cells.” Clinical Cancer Research 12(1):11–19. 
Guerra, Carmen et al. 2007. “Chronic Pancreatitis Is Essential for Induction of 




Guo, L. et al. 2013. “Stat3-Coordinated Lin-28–let-7–HMGA2 and miR-200–ZEB1 
Circuits Initiate and Maintain Oncostatin M-Driven Epithelial–mesenchymal 
Transition.” Oncogene 32(45):5272–82. 
Gupta, Piyush B. et al. 2009. “Identification of Selective Inhibitors of Cancer Stem 
Cells by High-Throughput Screening.” Cell 138(4):645–59. 
Halama, Niels et al. 2016. “Tumoral Immune Cell Exploitation in Colorectal Cancer 
Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer 
Patients.” Cancer Cell 29(4):587–601. 
Hamada, Tetsuhiro et al. 2007. “Oncostatin M Gene Therapy Attenuates Liver 
Damage Induced by Dimethylnitrosamine in Rats.” The American Journal of 
Pathology 171(3):872–81. 
Hamanishi, J. et al. 2007. “Programmed Cell Death 1 Ligand 1 and Tumor-Infiltrating 
CD8+ T Lymphocytes Are Prognostic Factors of Human Ovarian Cancer.” 
Proceedings of the National Academy of Sciences 104(9):3360–65. 
Hamid, Omid et al. 2013. “Safety and Tumor Responses with Lambrolizumab (Anti–
PD-1) in Melanoma.” New England Journal of Medicine 369(2):134–44. 
Hamilton, Kathryn E., James G. Simmons, Shengli Ding, Laurianne Van Landeghem, 
and P.Kay Lund. 2011. “Cytokine Induction of Tumor Necrosis Factor Receptor 
2 Is Mediated by STAT3 in Colon Cancer Cells.” Molecular Cancer Research : 
MCR 9(12):1718–31. 
Han, Woody, Richard L. Carpenter, Xinyu Cao, and Hui Wen Lo. 2013. “STAT1 
Gene Expression Is Enhanced by Nuclear EGFR and HER2 via Cooperation With 
STAT3.” Molecular Carcinogenesis 52(12):959–69. 
Hanahan, Douglas and Robert A. Weinberg. 2011. “Hallmarks of Cancer: The next 
Generation.” Cell 144(5):646–74. 
Harrison, C. N. et al. 2017. “Long-Term Findings from COMFORT-II, a Phase 3 
Study of Ruxolitinib vs Best Available Therapy for Myelofibrosis.” Leukemia 
31(3):775–775. 
Harrison, M. L. et al. 2007. “Tumor Necrosis Factor Alpha as a New Target for Renal 
Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and 
High Dose.” J Clin Oncol 25(29):4542–49. 
Heery, Christopher R. et al. 2017. “Avelumab for Metastatic or Locally Advanced 
Previously Treated Solid Tumours (JAVELIN Solid Tumor): A Phase 1a, 
Multicohort, Dose-Escalation Trial.” The Lancet Oncology 18(5):587–98. 
216 
 
Heinrich, Peter C. et al. 2003. “Principles of Interleukin (IL)-6-Type Cytokine 
Signalling and Its Regulation.” The Biochemical Journal 374(Pt 1):1–20. 
Helm, Ole et al. 2014. “Tumor-Associated Macrophages Exhibit pro- and Anti-
Inflammatory Properties by Which They Impact on Pancreatic Tumorigenesis.” 
International Journal of Cancer 135(4):843–61. 
Herbst, Roy S. et al. 2014. “Predictive Correlates of Response to the Anti-PD-L1 
Antibody MPDL3280A in Cancer Patients.” Nature 515(7528):563–67. 
Hermann, Patrick C. et al. 2007. “Distinct Populations of Cancer Stem Cells 
Determine Tumor Growth and Metastatic Activity in Human Pancreatic Cancer.” 
Cell Stem Cell 1(3):313–23. 
Hidalgo, Manuel et al. 2014. “Patient-Derived Xenograft Models: An Emerging 
Platform for Translational Cancer Research.” Cancer Discovery. 
Hino, Ryosuke et al. 2010. “Tumor Cell Expression of Programmed Cell Death-1 
Ligand 1 Is a Prognostic Factor for Malignant Melanoma.” Cancer 116(7):1757–
66. 
Hirai, Mariko et al. 2017. “Regulation of PD-L1 Expression in a High-Grade Invasive 
Human Oral Squamous Cell Carcinoma Microenvironment.” International 
Journal of Oncology 50(1):41–48. 
Hirakawa, Hiroshi et al. 2004. “Regulation of Squamous Cell Carcinoma Antigen 
Production by E-Cadherin Mediated Cell-Cell Adhesion in Squamous Cell 
Carcinoma Cell Line.” Oncology Reports 11(2):415–19. 
Hodi, F.Stephen et al. 2010. “Improved Survival with Ipilimumab in Patients with 
Metastatic Melanoma.” New England Journal of Medicine 363(8):711–23. 
Von Hoff, Daniel D. et al. 2013. “Increased Survival in Pancreatic Cancer with Nab-
Paclitaxel plus Gemcitabine.” The New England Journal of Medicine 
369(18):1691–1703. 
Hong, David S. et al. 2014. “MABp1, a First-in-Class True Human Antibody 
Targeting Interleukin-1α in Refractory Cancers: An Open-Label, Phase 1 Dose-
Escalation and Expansion Study.” The Lancet. Oncology 15(6):656–66. 
Huang, Suyun. 2007. “Regulation of Metastases by Signal Transducer and Activator 
of Transcription 3 Signaling Pathway: Clinical Implications.” Clinical Cancer 
Research 13(5). 
Hudes, Gary et al. 2013. “A Phase 1 Study of a Chimeric Monoclonal Antibody 
against Interleukin-6, Siltuximab, Combined with Docetaxel in Patients with 
217 
 
Metastatic Castration-Resistant Prostate Cancer.” Investigational New Drugs 
31(3):669–76. 
Hung, W. and B. Elliott. 2001. “Co-Operative Effect of c-Src Tyrosine Kinase and 
Stat3 in Activation of Hepatocyte Growth Factor Expression in Mammary 
Carcinoma Cells.” The Journal of Biological Chemistry 276(15):12395–403. 
Hurwitz, Herbert I. et al. 2015. “Randomized, Double-Blind, Phase II Study of 
Ruxolitinib or Placebo in Combination With Capecitabine in Patients With 
Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.” 
Journal of Clinical Oncology 33(34):4039–47. 
Iacobuzio-Donahue, Christine A. et al. 2009. “DPC4 Gene Status of the Primary 
Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic 
Cancer.” Journal of Clinical Oncology 27(11):1806–13. 
Ino, Y. et al. 2013. “Immune Cell Infiltration as an Indicator of the Immune 
Microenvironment of Pancreatic Cancer.” British Journal of Cancer 108(4):914–
23. 
Ip, Nancy Y. et al. 1992. “CNTF and LIF Act on Neuronal Cells via Shared Signaling 
Pathways That Involve the IL-6 Signal Transducing Receptor Component 
gp130.” Cell 69(7):1121–32. 
Itoh, M. et al. 2006. “Requirement of STAT3 Activation for Maximal Collagenase-1 
(MMP-1) Induction by Epidermal Growth Factor and Malignant Characteristics 
in T24 Bladder Cancer Cells.” Oncogene 25(8):1195–1204. 
Iwasaki, Masahiro et al. 2004. “E1AF/PEA3 Reduces the Invasiveness of SiHa 
Cervical Cancer Cells by Activating Serine Proteinase Inhibitor Squamous Cell 
Carcinoma Antigen.” Experimental Cell Research 299(2):525–32. 
Jiang, Jian, Ya-ling Tang, and Xin-hua Liang. 2011. “EMT: A New Vision of Hypoxia 
Promoting Cancer Progression.” Cancer Biology & Therapy 11(8):714–23. 
Jones, Siân et al. 2008. “Core Signaling Pathways in Human Pancreatic Cancers 
Revealed by Global Genomic Analyses.” Science 321(5897). 
Jung, M. et al. 2012. “Interleukin-10-Induced Neutrophil Gelatinase-Associated 
Lipocalin Production in Macrophages with Consequences for Tumor Growth.” 
Molecular and Cellular Biology 32(19):3938–48. 
Kalluri, Raghu and Robert A. Weinberg. 2009. “The Basics of Epithelial-
Mesenchymal Transition.” The Journal of Clinical Investigation 119(6):1420–28. 
Katagiri, Chika, Jotaro Nakanishi, Kuniko Kadoya, and Toshihiko Hibino. 2006. 
218 
 
“Serpin Squamous Cell Carcinoma Antigen Inhibits UV-Induced Apoptosis via 
Suppression of c-JUN NH2-Terminal Kinase.” Journal of Cell Biology 
172(7):983–90. 
Kato, H. and T. Torigoe. 1977. “Radioimmunoassay for Tumor Antigen of Human 
Cervical Squamous Cell Carcinoma.” Cancer 40(4):1621–28. 
Kesanakurti, D., C. Chetty, D. Rajasekhar Maddirela, M. Gujrati, and J. S. Rao. 2013. 
“Essential Role of Cooperative NF-κB and Stat3 Recruitment to ICAM-1 Intronic 
Consensus Elements in the Regulation of Radiation-Induced Invasion and 
Migration in Glioma.” Oncogene 32(43):5144–55. 
Kiuchi, N. et al. 1999. “STAT3 Is Required for the gp130-Mediated Full Activation of 
the c-Myc Gene.” The Journal of Experimental Medicine 189(1):63–73. 
Klausen, Pia, Lone Pedersen, Jesper Jurlander, and Heinz Baumann. 2000. 
“Oncostatin M and Interleukin 6 Inhibit Cell Cycle Progression by Prevention of 
p27kip1 Degradation in HepG2 Cells.” Oncogene 19(32):3675–83. 
Kleeff, Jorg et al. 2016. “Pancreatic Cancer.” Nature Reviews Disease Primers 
2:16022. 
Kondo, A. et al. 2010. “Interferon- and Tumor Necrosis Factor- Induce an 
Immunoinhibitory Molecule, B7-H1, via Nuclear Factor- B Activation in Blasts 
in Myelodysplastic Syndromes.” Blood 116(7):1124–31. 
Krebs, Angela M. et al. 2017. “The EMT-Activator Zeb1 Is a Key Factor for Cell 
Plasticity and Promotes Metastasis in Pancreatic Cancer.” Nature Cell Biology 
19(5):518–29. 
Kreso, Antonija and John E. Dick. 2014. “Evolution of the Cancer Stem Cell Model.” 
Cell Stem Cell 14(3):275–91. 
Kryczek, I. et al. 2007. “Relationship between B7-H4, Regulatory T Cells, and Patient 
Outcome in Human Ovarian Carcinoma.” Cancer Research 67(18):8900–8905. 
Kryczek, Ilona et al. 2006. “B7-H4 Expression Identifies a Novel Suppressive 
Macrophage Population in Human Ovarian Carcinoma.” The Journal of 
Experimental Medicine 203(4):871–81. 
Kuang, Dong-Ming et al. 2009. “Activated Monocytes in Peritumoral Stroma of 
Hepatocellular Carcinoma Foster Immune Privilege and Disease Progression 
through PD-L1.” The Journal of Experimental Medicine 206(6):1327–37. 
Kucia-Tran, Justyna A. et al. 2016. “Overexpression of the Oncostatin-M Receptor in 
Cervical Squamous Cell Carcinoma Is Associated with Epithelial–mesenchymal 
219 
 
Transition and Poor Overall Survival.” British Journal of Cancer 115(2):212–22. 
Kurahara, Hiroshi et al. 2013. “M2-Polarized Tumor-Associated Macrophage 
Infiltration of Regional Lymph Nodes Is Associated with Nodal 
Lymphangiogenesis and Occult Nodal Involvement in pN0 Pancreatic Cancer.” 
Pancreas 42(1):155–59. 
Kurzrock, R. et al. 2013. “A Phase I, Open-Label Study of Siltuximab, an Anti-IL-6 
Monoclonal Antibody, in Patients with B-Cell Non-Hodgkin Lymphoma, 
Multiple Myeloma, or Castleman Disease.” Clinical Cancer Research 
19(13):3659–70. 
Kusaba, Hitoshi et al. 2005. “Interleukin-12-Induced Interferon-Gamma Production by 
Human Peripheral Blood T Cells Is Regulated by Mammalian Target of 
Rapamycin (mTOR).” The Journal of Biological Chemistry 280(2):1037–43. 
Lapeire, Lore et al. 2014. “Cancer-Associated Adipose Tissue Promotes Breast Cancer 
Progression by Paracrine Oncostatin M and Jak/STAT3 Signaling.” Cancer 
Research 74(23). 
Larkin, J. M. G. et al. 2010. “A Phase I/II Trial of Sorafenib and Infliximab in 
Advanced Renal Cell Carcinoma.” British Journal of Cancer 103(8):1149–53. 
Larkin, James et al. 2015. “Combined Nivolumab and Ipilimumab or Monotherapy in 
Untreated Melanoma.” New England Journal of Medicine 373(1):23–34. 
Lesina, Marina et al. 2011. “Stat3/Socs3 Activation by IL-6 Transsignaling Promotes 
Progression of Pancreatic Intraepithelial Neoplasia and Development of 
Pancreatic Cancer.” Cancer Cell 19(4):456–69. 
Leslie, Kenneth et al. 2006. “Cyclin D1 Is Transcriptionally Regulated by and 
Required for Transformation by Activated Signal Transducer and Activator of 
Transcription 3.” Cancer Research 66(5):2544–52. 
Li, D. H., K. P. Xie, R. Wolff, and J. L. Abbruzzese. 2004. “Pancreatic Cancer.” 
Lancet 363:1049–57. 
Liang, Chun-Chi, Ann Y. Park, and Jun-Lin Guan. 2007. “In Vitro Scratch Assay: A 
Convenient and Inexpensive Method for Analysis of Cell Migration in Vitro.” 
Nature Protocols 2(2):329–33. 
Lin, E. Y. et al. 2006. “Macrophages Regulate the Angiogenic Switch in a Mouse 
Model of Breast Cancer.” Cancer Research 66(23):11238–46. 
Lin, E. Y., A. V Nguyen, R. G. Russell, and J. W. Pollard. 2001. “Colony-Stimulating 
Factor 1 Promotes Progression of Mammary Tumors to Malignancy.” The 
220 
 
Journal of Experimental Medicine 193(6):727–40. 
Lin, Elaine Y. et al. 2007. “Vascular Endothelial Growth Factor Restores Delayed 
Tumor Progression in Tumors Depleted of Macrophages.” Molecular Oncology 
1(3):288–302. 
Liu, Bingyan et al. 2016. “Tumor-Associated Macrophage-Derived CCL20 Enhances 
the Growth and Metastasis of Pancreatic Cancer.” Acta Biochimica et Biophysica 
Sinica 48(12):1067–74. 
Liu, Chao-Ying et al. 2013. “M2-Polarized Tumor-Associated Macrophages Promoted 
Epithelial–mesenchymal Transition in Pancreatic Cancer Cells, Partially through 
TLR4/IL-10 Signaling Pathway.” Laboratory Investigation 93(7):844–54. 
Liu, Mingli, Nana O. Wilson, Jacqueline M. Hibbert, and Jonathan K. Stiles. 2013. 
“STAT3 Regulates MMP3 in Heme-Induced Endothelial Cell Apoptosis.” PLoS 
ONE 8(8). 
Lo, H. W. et al. 2007. “Epidermal Growth Factor Receptor Cooperates with Signal 
Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal 
Transition in Cancer Cells via up-Regulation of TWIST Gene Expression.” 
Cancer Research 67(19):9066–76. 
Lo, Hui-Wen, Xinyu Cao, Hu Zhu, and Francis Ali-Osman. 2010. “Cyclooxygenase-2 
Is a Novel Transcriptional Target of the Nuclear EGFR-STAT3 and EGFRvIII-
STAT3 Signaling Axes.” Molecular Cancer Research : MCR 8(2):232–45. 
Lo, Hui Wen et al. 2005. “Nuclear Interaction of EGFR and STAT3 in the Activation 
of the iNOS/NO Pathway.” Cancer Cell 7(6):575–89. 
Lu, Chunwan, Asif Talukder, Natasha M. Savage, Nagendra Singh, and Kebin Liu. 
2017. “JAK-STAT-Mediated Chronic Inflammation Impairs Cytotoxic T 
Lymphocyte Activation to Decrease Anti-PD-1 Immunotherapy Efficacy in 
Pancreatic Cancer.” OncoImmunology 6(3):e1291106. 
Lu, Haihui et al. 2014. “A Breast Cancer Stem Cell Niche Supported by Juxtacrine 
Signalling from Monocytes and Macrophages.” Nature Cell Biology 
16(11):1105–17. 
Lust, J. A. et al. 1992. “Isolation of an mRNA Encoding a Soluble Form of the Human 
Interleukin-6 Receptor.” Cytokine 4(2):96–100. 
Madamanchi, N. R., S. Li, C. Patterson, and M. S. Runge. 2001. “Thrombin Regulates 
Vascular Smooth Muscle Cell Growth and Heat Shock Proteins via the JAK-
STAT Pathway.” The Journal of Biological Chemistry 276(22):18915–24. 
221 
 
Madhusudan, Srinivasan et al. 2004. “A Phase II Study of Etanercept (Enbrel), a 
Tumor Necrosis Factor Alpha Inhibitor in Patients with Metastatic Breast 
Cancer.” Clinical Cancer Research : An Official Journal of the American 
Association for Cancer Research 10(19):6528–34. 
Madhusudan, Srinivasan et al. 2005. “Study of Etanercept, a Tumor Necrosis Factor-
Alpha Inhibitor, in Recurrent Ovarian Cancer.” Journal of Clinical Oncology : 
Official Journal of the American Society of Clinical Oncology 23(25):5950–59. 
Malka, D. et al. 2002. “Risk of Pancreatic Adenocarcinoma in Chronic Pancreatitis.” 
Gut 51(6):849–52. 
Mani, Sendurai A. et al. 2008. “The Epithelial-Mesenchymal Transition Generates 
Cells with Properties of Stem Cells.” Cell 133(4):704–15. 
Mantovani, Alberto et al. 1979. “Effects on in Vitro Tumor Growth of Macrophages 
Isolated from Human Ascitic Ovarian Tumors.” International Journal of Cancer 
23(2):157–64. 
Mantovani, Alberto et al. 2008. “Cancer-Related Inflammation.” Nature 
454(7203):436–44. 
Mantovani, Alberto, Federica Marchesi, Alberto Malesci, Luigi Laghi, and Paola 
Allavena. 2017. “Tumour-Associated Macrophages as Treatment Targets in 
Oncology.” Nature Reviews Clinical Oncology. 
Martinez, Fernando O. and Siamon Gordon. 2014. “The M1 and M2 Paradigm of 
Macrophage Activation: Time for Reassessment.” F1000Prime Reports 6. 
Marzec, M. et al. 2008. “Oncogenic Kinase NPM/ALK Induces through STAT3 
Expression of Immunosuppressive Protein CD274 (PD-L1, B7-H1).” 
Proceedings of the National Academy of Sciences 105(52):20852–57. 
Massagu, Joan. 2008. “TGFbeta in Cancer.” Cell 134(2):215–30. 
McWhorter, F. Y., T. Wang, P. Nguyen, T. Chung, and W. F. Liu. 2013. “Modulation 
of Macrophage Phenotype by Cell Shape.” Proceedings of the National Academy 
of Sciences 110(43):17253–58. 
Medema JP, Vermeulen L. 2011. “Microenvironmental Regulation of Stem Cells in 
Intestinal Homeostasis and Cancer.” Nature 474(7351):318–26. 
Meng, Fanbin et al. 2015. “CCL18 Promotes Epithelial-Mesenchymal Transition, 
Invasion and Migration of Pancreatic Cancer Cells in Pancreatic Ductal 
Adenocarcinoma.” International Journal of Oncology 46(3):1109–20. 
222 
 
Mesa, Ruben A. et al. 2013. “Effect of Ruxolitinib Therapy on Myelofibrosis-Related 
Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A 
Randomized, Double-Blind, Placebo-Controlled Trial.” Journal of Clinical 
Oncology 31(10):1285–92. 
Mikiko, Kawata et al. 2012. “TGF-β-Induced Epithelial-Mesenchymal Transition of 
A549 Lung Adenocarcinoma Cells Is Enhanced by pro-Inflammatory Cytokines 
Derived from RAW 264.7 Macrophage Cells.” Journal of Biochemistry. 
Mitchem, Jonathan B. et al. 2013. “Targeting Tumor-Infiltrating Macrophages 
Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves 
Chemotherapeutic Responses.” Cancer Research 73(3):1128–41. 
Moffitt, Richard A. et al. 2015. “Virtual Microdissection Identifies Distinct Tumor- 
and Stroma-Specific Subtypes of Pancreatic Ductal Adenocarcinoma.” Nature 
Genetics 47(10):1168–78. 
Morel, Anne-Pierre et al. 2008. “Generation of Breast Cancer Stem Cells through 
Epithelial-Mesenchymal Transition.” PloS One 3(8):e2888. Retrieved 
(http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2492808&tool=pmc
entrez&rendertype=abstract). 
Motzer, Robert J. et al. 2015. “Nivolumab versus Everolimus in Advanced Renal-Cell 
Carcinoma.” New England Journal of Medicine 373(19):1803–13. 
Mueller, Maria-Theresa et al. 2009. “Combined Targeted Treatment to Eliminate 
Tumorigenic Cancer Stem Cells in Human Pancreatic Cancer.” Gastroenterology 
137(3):1102–13. 
Mukherjee, Somnath et al. 2013. “Gemcitabine-Based or Capecitabine-Based 
Chemoradiotherapy for Locally Advanced Pancreatic Cancer (SCALOP): A 
Multicentre, Randomised, Phase 2 Trial.” The Lancet Oncology 14(4):317–26. 
Mülberg, Jürgen et al. 1993. “The Soluble Interleukin-6 Receptor Is Generated by 
Shedding.” European Journal of Immunology 23(2):473–80. 
Murakami, a et al. 2001. “Squamous Cell Carcinoma Antigen Suppresses Radiation-
Induced Cell Death.” British Journal of Cancer 84:851–58. 
Murray, Peter J. et al. 2014. “Macrophage Activation and Polarization: Nomenclature 
and Experimental Guidelines.” Immunity 41(1):14–20. 
Murray, Peter J. and Thomas A. Wynn. 2011. “Protective and Pathogenic Functions of 
Macrophage Subsets.” Nature Reviews Immunology 11(11):723–37. 
Naaldijk, Yahaira et al. 2015. “Migrational Changes of Mesenchymal Stem Cells in 
223 
 
Response to Cytokines, Growth Factors, Hypoxia, and Aging.” Experimental Cell 
Research 338(1):97–104. 
Nakashima, Torahiko et al. 2006. “Role of Squamous Cell Carcinoma Antigen 1 
Expression in the Invasive Potential of Head and Neck Squamous Cell 
Carcinoma.” Head & Neck 28(1):24–30. 
NCCN. 2015. “National Comprehensive Cancer Network. NCCN Guidelines: 
Pancreatic Adenocarcinoma.” Retrieved (http://www.nccn.org.). 
Neoptolemos, J. P. et al. 2001. “Adjuvant Chemoradiotherapy and Chemotherapy in 
Resectable Pancreatic Cancer: A Randomised Controlled Trial.” Lancet (London, 
England) 358(9293):1576–85. 
Neoptolemos, John P. et al. 2010. “Adjuvant Chemotherapy With Fluorouracil Plus 
Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection.” JAMA 
304(10):1073. 
Neoptolemos, John P. et al. 2017. “Comparison of Adjuvant Gemcitabine and 
Capecitabine with Gemcitabine Monotherapy in Patients with Resected 
Pancreatic Cancer (ESPAC-4): A Multicentre, Open-Label, Randomised, Phase 3 
Trial.” The Lancet 389(10073):1011–24. 
Nielsen, Sebastian R. and Michael C. Schmid. 2017. “Macrophages as Key Drivers of 
Cancer Progression and Metastasis.” Mediators of Inflammation 2017:1–11. 
Niu, Guilian et al. 1999. “Gene Therapy with Dominant-Negative Stat3 Suppresses 
Growth of the Murine Melanoma B16 Tumor in Vivo.” Cancer Research 59(20). 
Niu, Guilian et al. 2008. “Signal Transducer and Activator of Transcription 3 Is 
Required for Hypoxia-Inducible Factor-1alpha RNA Expression in Both Tumor 
Cells and Tumor-Associated Myeloid Cells.” Molecular Cancer Research : MCR 
6(7):1099–1105. 
Nomi, T. et al. 2007. “Clinical Significance and Therapeutic Potential of the 
Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human 
Pancreatic Cancer.” Clinical Cancer Research 13(7):2151–57. 
Noy, Roy and Jeffrey W. Pollard. 2014. “Tumor-Associated Macrophages: From 
Mechanisms to Therapy.” Immunity 41(1):49–61. 
Numa, F. et al. 1996. “Tumor Necrosis Factor-Alpha Stimulates the Production of 
Squamous Cell Carcinoma Antigen in Normal Squamous Cells.” Tumour 
Biology : The Journal of the International Society for Oncodevelopmental 
Biology and Medicine 17(2):97–101. 
224 
 
Nywening, Timothy M. et al. 2016. “Targeting Tumour-Associated Macrophages with 
CCR2 Inhibition in Combination with FOLFIRINOX in Patients with Borderline 
Resectable and Locally Advanced Pancreatic Cancer: A Single-Centre, Open-
Label, Dose-Finding, Non-Randomised, Phase 1b Trial.” The Lancet Oncology 
17(5):651–62. 
Oettle, H. et al. 2007. “Adjuvantchemo- Therapy with Gemcitabine vs Observation 
Inpatients Undergoing Curative-Intent Resection of Pancreatic Cancer: A 
Randomized Controlled Trial.” JAMA 297:267–77. 
Oettle, Helmut et al. 2013. “Adjuvant Chemotherapy with Gemcitabine and Long-
Term Outcomes among Patients with Resected Pancreatic Cancer: The CONKO-
001 Randomized Trial.” JAMA : The Journal of the American Medical 
Association 310(14):1473–81. 
Ohigashi, Y. et al. 2005. “Clinical Significance of Programmed Death-1 Ligand-1 and 
Programmed Death-1 Ligand-2 Expression in Human Esophageal Cancer.” 
Clinical Cancer Research 11(8):2947–53. 
Ojalvo, Laureen S., William King, Dianne Cox, and Jeffrey W. Pollard. 2009. “High-
Density Gene Expression Analysis of Tumor-Associated Macrophages from 
Mouse Mammary Tumors.” The American Journal of Pathology 174(3):1048–64. 
Paget, S. 1989. “The Distribution of Secondary Growths in Cancer of the Breast. 
1889.” Cancer Metastasis Reviews 8(2):98–101. 
De Palma, Michele et al. 2005. “Tie2 Identifies a Hematopoietic Lineage of 
Proangiogenic Monocytes Required for Tumor Vessel Formation and a 
Mesenchymal Population of Pericyte Progenitors.” Cancer Cell 8(3):211–26. 
Phillips, Robert A.Kastelein et al. 2004. “WSX-1 and Glycoprotein 130 Constitute a 
Signal-Transducing Receptor for IL-27.” J. Immunol 172:2225–31. 
Pienta, Kenneth J. et al. 2013. “Phase 2 Study of Carlumab (CNTO 888), a Human 
Monoclonal Antibody against CC-Chemokine Ligand 2 (CCL2), in Metastatic 
Castration-Resistant Prostate Cancer.” Investigational New Drugs 31(3):760–68. 
Plimack, Elizabeth R. et al. 2017. “Safety and Activity of Pembrolizumab in Patients 
with Locally Advanced or Metastatic Urothelial Cancer (KEYNOTE-012): A 
Non-Randomised, Open-Label, Phase 1b Study.” The Lancet. Oncology 
18(2):212–20. 
Postow, Michael A. et al. 2015. “Nivolumab and Ipilimumab versus Ipilimumab in 
Untreated Melanoma.” New England Journal of Medicine 372(21):2006–17. 
Powles, Thomas et al. 2014. “MPDL3280A (Anti-PD-L1) Treatment Leads to Clinical 
225 
 
Activity in Metastatic Bladder Cancer.” Nature 515(7528):558–62. 
Quarta, S. et al. 2010. “SERPINB3 Induces Epithelial-Mesenchymal Transition.” The 
Journal of Pathology 221(3):343–56. 
Rahib, Lola et al. 2014. “Projecting Cancer Incidence and Deaths to 2030: The 
Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United 
States.” Cancer Research 74(11):2913–21. 
Ranjbar, Benyamin et al. 2016. “Anti-Apoptotic Effects of Lentiviral Vector 
Transduction Promote Increased Rituximab Tolerance in Cancerous B-Cells.” 
PloS One 11(4):e0153069. 
Reid J, Zamuner S, Edwards K, Rumley S, Sully K, Feeney M, Kumar S, Fernando D, 
Wisniacki N. T. 2016. “Targeting Oncostatin M in the Target Tissue: Assessment 
of in-Vivo Affinity and Target Engagement of an Anti-OSM Monoclonal 
Antibody By Combining Blood and Skin Blister Fluid Data [Abstract].” Arthritis 
Rheumatol. 68 (suppl. 
Rhim, Andrew D. et al. 2012. “EMT and Dissemination Precede Pancreatic Tumor 
Formation.” Cell 148(1–2):349–61. 
Riaz, Nadeem et al. 2016. “Recurrent SERPINB3 and SERPINB4 Mutations in 
Patients Who Respond to Anti-CTLA4 Immunotherapy.” Nature Genetics 
48(11):1327–29. 
Richards, Carl D. and Carl D. 2013. “The Enigmatic Cytokine Oncostatin M and 
Roles in Disease.” ISRN Inflammation 2013:512103. 
Ries, Carola H. et al. 2014. “Targeting Tumor-Associated Macrophages with Anti-
CSF-1R Antibody Reveals a Strategy for Cancer Therapy.” Cancer Cell 
25(6):846–59. 
Rishi, Arvind, Michael Goggins, Laura D. Wood, and Ralph H. Hruban. 2015. 
“Pathological and Molecular Evaluation of Pancreatic Neoplasms.” Seminars in 
Oncology 42(1):28–39. 
Robert, Caroline et al. 2011. “Ipilimumab plus Dacarbazine for Previously Untreated 
Metastatic Melanoma.” New England Journal of Medicine 364(26):2517–26. 
Robert, Caroline et al. 2014. “Anti-Programmed-Death-Receptor-1 Treatment with 
Pembrolizumab in Ipilimumab-Refractory Advanced Melanoma: A Randomised 
Dose-Comparison Cohort of a Phase 1 Trial.” The Lancet 384(9948):1109–17. 
Robert, Caroline et al. 2015. “Pembrolizumab versus Ipilimumab in Advanced 
Melanoma.” New England Journal of Medicine 372(26):2521–32. 
226 
 
Rodriguez, P. C. et al. 2004. “Arginase I Production in the Tumor Microenvironment 
by Mature Myeloid Cells Inhibits T-Cell Receptor Expression and Antigen-
Specific T-Cell Responses.” Cancer Research 64(16):5839–49. 
Rossi, J. F. et al. 2010. “A Phase I/II Study of Siltuximab (CNTO 328), an Anti-
Interleukin-6 Monoclonal Antibody, in Metastatic Renal Cell Cancer.” British 
Journal of Cancer 103(8):1154–62. 
Royal, Richard E. et al. 2010. “Phase 2 Trial of Single Agent Ipilimumab (Anti-
CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma.” 
Journal of Immunotherapy 33(8):828–33. 
Ruffell, Brian and Lisa M. Coussens. 2015. “Macrophages and Therapeutic Resistance 
in Cancer.” Cancer Cell 27(4):462–72. 
Sainz, B. et al. 2015. “Microenvironmental hCAP-18/LL-37 Promotes Pancreatic 
Ductal Adenocarcinoma by Activating Its Cancer Stem Cell Compartment.” Gut 
0:1–15. 
Sainz, Bruno, Beatriz Martín, Marianthi Tatari, Christopher Heeschen, and Susana 
Guerra. 2014. “ISG15 Is a Critical Microenvironmental Factor for Pancreatic 
Cancer Stem Cells.” Cancer Research 74(24):7309–20. 
Sakaguchi, S. et al. 2001. “Immunologic Tolerance Maintained by CD25+ CD4+ 
Regulatory T Cells: Their Common Role in Controlling Autoimmunity, Tumor 
Immunity, and Transplantation Tolerance.” Immunol Rev 182(8):18–32. 
Salgado, M. et al. 2017. “Management of Unresectable, Locally Advanced Pancreatic 
Adenocarcinoma.” Clinical and Translational Oncology 1–6. 
Sandhu, Shahneen K. et al. 2013. “A First-in-Human, First-in-Class, Phase I Study of 
Carlumab (CNTO 888), a Human Monoclonal Antibody against CC-Chemokine 
Ligand 2 in Patients with Solid Tumors.” Cancer Chemotherapy and 
Pharmacology 71(4):1041–50. 
Sansone, Pasquale and Jacqueline Bromberg. 2012. “Targeting the Interleukin-
6/Jak/stat Pathway in Human Malignancies.” Journal of Clinical Oncology : 
Official Journal of the American Society of Clinical Oncology 30(9):1005–14. 
Schaefer, Annette et al. 2009. “Mechanism of Interferon-Gamma Mediated down-
Regulation of Interleukin-10 Gene Expression.” Molecular Immunology 
46(7):1351–59. 
Schick, Charles et al. 1998. “Cross-Class Inhibition of the Cysteine Proteinases 
Cathepsins K, L, and S by the Serpin Squamous Cell Carcinoma Antigen 1: A 
Kinetic Analysis †.” Biochemistry 37(15):5258–66. 
227 
 
Scholz, Arne et al. 2003. “Activated Signal Transducer and Activator of Transcription 
3 (STAT3) Supports the Malignant Phenotype of Human Pancreatic Cancer.” 
Gastroenterology 125(3):891–905. 
Schuringa, J. J., H. Timmer, D. Luttickhuizen, E. Vellenga, and W. Kruijer. 2001. “C-
Jun and c-Fos Cooperate with STAT3 in IL-6-Induced Transactivation of the IL-
6 Respone Element (IRE).” Cytokine 14(2):78–87. 
SEER. 2017. “SEER DATABASE: Pancreatic Cancer Statistics.” Retrieved 
(https://seer.cancer.gov/statfacts/html/pancreas.html). 
Seidel, H. M. et al. 1995. “Spacing of Palindromic Half Sites as a Determinant of 
Selective STAT (Signal Transducers and Activators of Transcription) DNA 
Binding and Transcriptional Activity.” Proceedings of the National Academy of 
Sciences of the United States of America 92(7):3041–45. 
Shen, Zhanlong et al. 2013. “Macrophage Coculture Enhanced Invasion of Gastric 
Cancer Cells via TGF-β and BMP Pathways.” Scandinavian Journal of 
Gastroenterology 48(4):466–72. 
Sheshadri, Namratha et al. 2014. “SCCA1/SERPINB3 Promotes Oncogenesis and 
Epithelial-Mesenchymal Transition via the Unfolded Protein Response and IL6 
Signaling.” Cancer Research 74(21):6318–29. 
Shien, Kazuhiko et al. 2017. “JAK1/STAT3 Activation through a Proinflammatory 
Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-
Small Cell Lung Cancer.” 
Sinibaldi, D. et al. 2000. “Induction of p21WAF1/CIP1 and Cyclin D1 Expression by 
the Src Oncoprotein in Mouse Fibroblasts: Role of Activated STAT3 Signaling.” 
Oncogene 19(48):5419–27. 
Smigiel, Jacob M., Neetha Parameswaran, and Mark W. Jackson. 2017. “Potent EMT 
and CSC Phenotypes Are Induced by Oncostatin-M in Pancreatic Cancer.” 
Molecular Cancer Research. 
Snyder, M., X. Y. Huang, and J. J. Zhang. 2011. “Signal Transducers and Activators 
of Transcription 3 (STAT3) Directly Regulates Cytokine-Induced Fascin 
Expression and Is Required for Breast Cancer Cell Migration.” The Journal of 
Biological Chemistry 286(45):38886–93. 
Song, Yuhua et al. 2008. “Fra-1 and Stat3 Synergistically Regulate Activation of 
Human MMP-9 Gene.” Molecular Immunology 45(1):137–43. 




Stein, M., S. Keshav, N. Harris, and S. Gordon. 1992. “Interleukin 4 Potently 
Enhances Murine Macrophage Mannose Receptor Activity: A Marker of 
Alternative Immunologic Macrophage Activation.” The Journal of Experimental 
Medicine 176(1):287–92. 
Su, S. et al. 2014. “A Positive Feedback Loop between Mesenchymal-like Cancer 
Cells and Macrophages Is Essential to Breast Cancer Metastasis.” Cancer Cell 
25(5):605–20. 
Sueoka, Kotaro et al. 2005. “Tumor-Associated Serpin, Squamous Cell Carcinoma 
Antigen Stimulates Matrix Metalloproteinase-9 Production in Cervical Squamous 
Cell Carcinoma Cell Lines.” International Journal of Oncology 27(5):1345–53. 
Suminami, Y. et al. 2000. “Inhibition of Apoptosis in Human Tumour Cells by the 
Tumour-Associated Serpin, SCC Antigen-1.” British Journal of Cancer 
82(4):981–89. 
Taga, T. et al. 1989. “Interleukin-6 Receptor and a Unique Mechanism of Its Signal 
Transduction.” Pp. 713–22 in Cold Spring Harbor Symposia on Quantitative 
Biology, vol. 54. 
Techasen, Anchalee et al. 2012. “Cytokines Released from Activated Human 
Macrophages Induce Epithelial Mesenchymal Transition Markers of 
Cholangiocarcinoma Cells.” Asian Pacific Journal of Cancer Prevention 
13(SUPPL.1):115–18. 
Thiery, Jean Paul. 2002. “Epithelial-Mesenchymal Transitions in Tumour 
Progression.” Nature Reviews. Cancer 2(6):442–54. 
Thiery, Jean Paul, Hervé Acloque, Ruby Y. J. Huang, and M.Angela Nieto. 2009. 
“Epithelial-Mesenchymal Transitions in Development and Disease.” Cell 
139(5):871–90. 
Torres, Carolina et al. 2014. “Serum Cytokine Profile in Patients With Pancreatic 
Cancer.” Pancreas 43(7):1042–49. 
Torroella-Kouri, M. et al. 2009. “Identification of a Subpopulation of Macrophages in 
Mammary Tumor-Bearing Mice That Are Neither M1 nor M2 and Are Less 
Differentiated.” Cancer Research 69(11):4800–4809. 
Tsai, Jeff H., Joana L. Donaher, Danielle A. Murphy, Sandra Chau, and Jing Yang. 
2012. “Spatiotemporal Regulation of Epithelial-Mesenchymal Transition Is 
Essential for Squamous Cell Carcinoma Metastasis. TL - 22.” Cancer Cell 22 
VN-r(6):725–36. 
Tse, Joyce C. and Raghu Kalluri. 2007. “Mechanisms of Metastasis: Epithelial-to-
229 
 
Mesenchymal Transition and Contribution of Tumor Microenvironment.” 
Journal of Cellular Biochemistry 101(4):816–29. 
Tsuyama, S. et al. 1991. “Different Behaviors in the Production and Release of SCC 
Antigen in Squamous-Cell Carcinoma.” Tumour Biology : The Journal of the 
International Society for Oncodevelopmental Biology and Medicine 12(1):28–34. 
Turato, Cristian et al. 2015. “SerpinB3 and Yap Interplay Increases Myc Oncogenic 
Activity.” Scientific Reports 5:17701. 
Uemura, Y. et al. 2000. “Circulating Serpin Tumor Markers SCCA1 and SCCA2 Are 
Not Actively Secreted but Reside in the Cytosol of Squamous Carcinoma Cells.” 
International Journal of Cancer 89(4):368–77. 
Ullman, E., J. A. Pan, and W. X. Zong. 2011. “Squamous Cell Carcinoma Antigen 1 
Promotes Caspase-8-Mediated Apoptosis in Response to Endoplasmic Reticulum 
Stress While Inhibiting Necrosis Induced by Lysosomal Injury.” Molecular and 
Cellular Biology 31(14):2902–19. 
Vidalino, Laura et al. 2009. “SERPINB3, Apoptosis and Autoimmunity.” 
Autoimmunity Reviews 9(2):108–12. 
Villano, Gianmarco et al. 2014. “Hepatic Progenitor Cells Express SerpinB3.” BMC 
Cell Biology 15(1):5. 
Vincent, A., J. Herman, R. Schulick, R. H. Hruban, and M. Goggins. 2011. 
“Pancreatic Cancer.” Lancet 378(9791):607–20. 
Wachsmann, M. B., L. M. Pop, and E. S. Vitetta. 2012. “Pancreatic Ductal 
Adenocarcinoma: A Review of Immunologic Aspects.” Journal of Investigative 
Medicine 60(4):643–63. 
Waddell, Nicola et al. 2015. “Whole Genomes Redefine the Mutational Landscape of 
Pancreatic Cancer.” Nature 518(7540):495–501. 
Wang-Gillam, Andrea et al. 2016. “Nanoliposomal Irinotecan with Fluorouracil and 
Folinic Acid in Metastatic Pancreatic Cancer after Previous Gemcitabine-Based 
Therapy (NAPOLI-1): A Global, Randomised, Open-Label, Phase 3 Trial.” The 
Lancet 387(10018):545–57. 
Wang, Liancai et al. 2010. “Clinical Significance of B7-H1 and B7-1 Expressions in 
Pancreatic Carcinoma.” World Journal of Surgery 34(5):1059–65. 
Wang, T. et al. 2004. “Regulation of the Innate and Adaptive Immune Responses by 
Stat-3 Signaling in Tumor Cells.” Nat Med 10(1):48–54. 
230 
 
Wang, Xingyuan et al. 2017. “Bladder Cancer Cells Induce Immunosuppression of T 
Cells by Supporting PD-L1 Expression in Tumour Macrophages Partially through 
Interleukin 10.” Cell Biology International 41(2):177–86. 
Wang, Y. et al. 2000. “Receptor Subunit-Specific Action of Oncostatin M in Hepatic 
Cells and Its Modulation by Leukemia Inhibitory Factor.” Journal of Biological 
Chemistry 275(33):25273–85. 
Wang, Yuxin, Anette H. H. van Boxel-Dezaire, HyeonJoo Cheon, Jinbo Yang, and 
George R. Stark. 2013. “STAT3 Activation in Response to IL-6 Is Prolonged by 
the Binding of IL-6 Receptor to EGF Receptor.” Proceedings of the National 
Academy of Sciences of the United States of America 110(42):16975–80. 
Wang, Zhipeng et al. 2013. “STAT3 Is Involved in Esophageal Carcinogenesis 
through Regulation of Oct-1.” Carcinogenesis 34(3):678–88. 
Weber, Jeffrey S. et al. 2015. “Nivolumab versus Chemotherapy in Patients with 
Advanced Melanoma Who Progressed after Anti-CTLA-4 Treatment (CheckMate 
037): A Randomised, Controlled, Open-Label, Phase 3 Trial.” The Lancet 
Oncology 16(4):375–84. 
Weizman, N. et al. 2014. “Macrophages Mediate Gemcitabine Resistance of 
Pancreatic Adenocarcinoma by Upregulating Cytidine Deaminase.” Oncogene 
33(29):3812–19. 
West, N. R., J. I. Murray, and P. H. Watson. 2014. “Oncostatin-M Promotes 
Phenotypic Changes Associated with Mesenchymal and Stem Cell-like 
Differentiation in Breast Cancer.” Oncogene 33(12):1485–94. 
White, R. R. et al. 2001. “Neoadjuvant Chemoradiation for Localized 
Adenocarcinoma of the Pancreas.” Annals of Surgical Oncology 8(10):758–65. 
Winograd, R. et al. 2015. “Induction of T-Cell Immunity Overcomes Complete 
Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic 
Carcinoma.” Cancer Immunology Research 3(4):399–411. 
Wörmann, S. M., K. N. Diakopoulos, M. Lesina, and H. Algül. 2014. “The Immune 
Network in Pancreatic Cancer Development and Progression.” Oncogene 
33(23):2956–67. 
Wu, Christina et al. 2013. “Disrupting Cytokine Signaling in Pancreatic Cancer: A 
Phase I/II Study of Etanercept in Combination with Gemcitabine in Patients with 
Advanced Disease.” Pancreas 42(5):813–18. 
Wu, Yongzhong, Iman Diab, Xueping Zhang, Elena S. Izmailova, and Zendra E. 
Zehner. 2004. “Stat3 Enhances Vimentin Gene Expression by Binding to the 
231 
 
Antisilencer Element and Interacting with the Repressor Protein, ZBP-89.” 
Oncogene 23(1):168–78. 
Wyckoff, Jeffrey et al. 2004. “A Paracrine Loop between Tumor Cells and 
Macrophages Is Required for Tumor Cell Migration in Mammary Tumors.” 
Cancer Research 64(19):7022–29. 
Xiong, Hua et al. 2012. “Roles of STAT3 and ZEB1 Proteins in E-Cadherin Down-
Regulation and Human Colorectal Cancer Epithelial-Mesenchymal Transition.” 
Journal of Biological Chemistry 287(8):5819–32. 
Xu, Shili and Nouri Neamati. 2013. “gp130: A Promising Drug Target for Cancer 
Therapy.” Expert Opinion on Therapeutic Targets 17(11):1303–28. 
Yamashita, T. et al. 2010. “Oncostatin M Renders Epithelial Cell Adhesion Molecule-
Positive Liver Cancer Stem Cells Sensitive to 5-Fluorouracil by Inducing 
Hepatocytic Differentiation.” Cancer Research 70(11):4687–97. 
Yang, Edward, Lorena Lerner, Daniel Besser, and James E. Darnell. 2003. 
“Independent and Cooperative Activation of Chromosomal c-Fos Promoter by 
STAT3.” Journal of Biological Chemistry 278(18):15794–99. 
Yang, Jinbo et al. 2007. “Unphosphorylated STAT3 Accumulates in Response to IL-6 
and Activates Transcription by Binding to NF??B.” Genes and Development 
21(11):1396–1408. 
Yeo, Theresa Pluth. 2015. “Demographics, Epidemiology, and Inheritance of 
Pancreatic Ductal Adenocarcinoma.” Seminars in Oncology 42(1):8–18. 
Yin, T. et al. 1993. “Involvement of IL-6 Signal Transducer gp130 in IL-11-Mediated 
Signal Transduction.” Journal of Immunology (Baltimore, Md. : 1950) 
151(5):2555–61. 
Yu, H., H. Lee, A. Herrmann, R. Buettner, and R. Jove. 2014. “Revisiting STAT3 
Signalling in Cancer: New and Unexpected Biological Functions.” Nat Rev 
Cancer 14(11):736–46. 
Zavoral, Miroslav, Petra Minarikova, Filip Zavada, Cyril Salek, and Marek Minarik. 
2011. “Molecular Biology of Pancreatic Cancer.” World Journal of 
Gastroenterology 17(24):2897–2908. 
Zhang, D., M. Sun, D. Samols, and I. Kushner. 1996. “STAT3 Participates in 
Transcriptional Activation of the C-Reactive Protein Gene by Interleukin-6.” The 
Journal of Biological Chemistry 271(16):9503–9. 
Zhang, Jia et al. 2015. “Regulation of Epithelial-Mesenchymal Transition by Tumor-
232 
 
Associated Macrophages in Cancer.” American Journal of Translational 
Research 7(10):1699–1711. 
Zheng, Xiaofeng et al. 2015. “Epithelial-to-Mesenchymal Transition Is Dispensable 
for Metastasis but Induces Chemoresistance in Pancreatic Cancer.” Nature 
527(7579):525–30. 
Zhu, Y. et al. 2014. “CSF1/CSF1R Blockade Reprograms Tumor-Infiltrating 
Macrophages and Improves Response to T-Cell Checkpoint Immunotherapy in 
Pancreatic Cancer Models.” Cancer Research 74(18):5057–69. 
Zhu, Yu et al. 2017. “Tissue-Resident Macrophages in Pancreatic Ductal 
Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor 
Progression.” Immunity 47(2):323–338.e6. 
Zorn, Emmanuel et al. 2006. “IL-2 Regulates FOXP3 Expression in Human 
CD4+CD25+ Regulatory T Cells through a STAT-Dependent Mechanism and 

















Appendix 1. TCGA PDAC patient details 
Gender Grade  Stage T N M Status Follow Up (months) 
MALE G1 0 0 N0 MX 0 52.99726 
MALE G1 0 TX NX MX 0 47.21096 
FEMALE G2 0 T3 N1 MX 0 12.75616 
FEMALE G2 IA T1 N0 MX 0 28.73425 
MALE G1 IB T2 N0 MX 0 60.95342 
FEMALE G1 I T1 0 MX 0 84.09863 
FEMALE G2 IB T2 NX MX 0 68.51507 
FEMALE G1 IB T2 N0 MX 0 38.26849 
MALE G1 IB T2 N0 MX 0 30.6411 
FEMALE G1 IB T2 N0 MX 0 31.79178 
MALE G2 IA T1 N0 MX 0 29.62192 
MALE G3 IB T2 N0 M0 0 2.465753 
MALE G2 IA T1 N0 MX 1 8.021918 
MALE G2 IB T2 N0 MX 0 0 
MALE G3 IA T1 N0 MX 0 0.09863 
FEMALE GX IA T1 N0 MX 0 2.991781 
MALE G1 IB T2 N0 MX 0 0.230137 
MALE G3 IB T2 N0 M0 1 19.66027 
FEMALE G2 IB T2 N0 M0 1 7.2 
FEMALE G2 IB T2 N0 M0 1 4.734247 
FEMALE G1 IB T3 N1 MX 0 3.090411 
FEMALE G2 IB T2 N0 M0 0 0.29589 
MALE G2 IB T2 N0 M0 0 31.26575 
FEMALE G2 IB T2 N0 M0 0 23.67123 
MALE G3 IIB T3 N1 M0 1 2.169863 
MALE G2 IIB T2 N1 M0 0 23.96712 
MALE G2 IIA T3 N0 M0 1 9.632877 
MALE G3 IIB T3 N1 M0 0 2.630137 
FEMALE G1 IIB T3 N1 M0 1 20.6137 
MALE G2 IIB T3 N1 M0 1 19.95616 
MALE G2 IIA T3 N0 M0 0 21.79726 
MALE G3 IIB T3 N1 M0 1 22.71781 
MALE G3 IIA T3 N0 M0 0 22.06027 
FEMALE G3 IIA T3 N0 M0 0 10.84932 
MALE G2 IIB T3 N1 M0 0 15.91233 
MALE G2 IIB T3 N1 M0 0 11.34247 
FEMALE G4 IIB T3 N1 M0 0 11.67123 
FEMALE G3 IIA T3 N0 M0 0 10.75068 
FEMALE G2 IIB T3 N1 M0 0 10.48767 
MALE G3 IIB T3 N1 M0 1 9.106849 
MALE G4 IIB T3 N1 M0 1 21.43562 
MALE G2 IIB T3 N1 MX 1 4.70137 
MALE G2 IIB T3 N1 M0 1 22.48767 
MALE G3 IIB T3 N1 MX 1 3.386301 
MALE G3 IIB T3 N1 MX 1 9.6 
MALE G1 IIB T3 N1 MX 0 30.04932 
MALE G2 IIB T3 N1 MX 0 23.60548 
MALE G2 IIA T3 N0 MX 1 20.84384 
FEMALE G3 IIB T3 N1 MX 1 7.364384 
FEMALE G2 IIB T3 N1 MX 1 24.26301 
MALE G3 IIB T3 N1 MX 1 15.05753 
MALE G2 IIB T3 N1 MX 1 10.12603 
MALE G2 IIB T3 N1 MX 0 12.39452 
MALE G3 IIB T3 N1 MX 0 71.40822 
MALE G2 IIA T3 N0 MX 1 71.73699 
MALE G2 IIB T3 N1 M0 1 10.98082 
MALE G1 IIB T3 N1 M0 0 9.69863 
MALE G3 IIB T3 N1 M0 0 11.83562 
MALE G1 IIB T3 N1 M0 1 7.10137 
FEMALE G2 IIB T3 N1 M0 0 5.030137 
MALE G2 IIA T3 N0 M0 0 5.194521 
MALE G3 IIB T3 N1 M0 1 3.123288 
MALE G2 IIA T3 N0 M0 0 5.490411 
FEMALE G2 IIB T3 N1 MX 0 0.131507 
MALE G1 IIB T3 N1 MX 0 0.230137 
FEMALE G2 IIB T3 N1 M0 0 0.032877 
FEMALE G2 IIB T3 N1 M0 0 0.032877 
MALE G2 IIA T3 NX M0 0 5.457534 
MALE G3 IIB T3 N1 MX 1 15.94521 
MALE G2 IIB T3 N1 MX 1 37.15068 
FEMALE G2 IIB T2 N1 MX 0 7.49589 
FEMALE G2 IIA T3 N0 MX 1 12.52603 
MALE G2 IIB T2 N1 MX 1 34.81644 
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MALE G3 IIB T2 N1 MX 0 7.430137 
MALE G3 IIA T3 N0 MX 1 15.55068 
MALE G2 IIB T3 N1 MX 1 4.043836 
FEMALE G3 IIB T3 N1 MX 1 5.030137 
FEMALE G2 IIB T3 N1 MX 1 1.019178 
FEMALE G3 IIB T3 N1 M0 0 5.950685 
FEMALE G3 IIB T3 N1 MX 0 7.660274 
MALE G2 IIA T3 N0 MX 0 13.01918 
MALE G2 IIA T3 NX MX 1 4.208219 
FEMALE G2 IIA T3 N0 MX 0 7.627397 
FEMALE G2 IIB T3 N1 M0 0 9.50137 
FEMALE G1 IIB T3 N1b M0 0 64.20822 
MALE G2 IIA T3 N0 MX 0 8.284932 
MALE GX IIB T3 N1 M0 0 28.2411 
MALE G3 IIB T3 N1 MX 0 29.91781 
FEMALE G2 IIB T2 N1 MX 1 17.49041 
MALE G1 IIB T3 N1 MX 0 7.890411 
MALE G3 IIB T3 N1 M0 0 0.920548 
FEMALE G2 IIB T3 N1 M0 0 0.657534 
FEMALE G1 IIB T3 N1 MX 0 0.131507 
MALE G2 IIA T3 N0 MX 0 0.263014 
FEMALE G2 IIA T3 N0 MX 0 12.13151 
MALE G2 IIB T3 N1 MX 0 11.86849 
MALE G1 IIB T3 N1 MX 0 0.263014 
MALE G2 IIB T3 N1 MX 0 0.789041 
FEMALE G2 IIB T3 N1 MX 0 0.690411 
MALE G3 IIB T3 N1 MX 1 3.945205 
FEMALE G2 IIA T3 N0 MX 0 0.920548 
FEMALE G1 IIB T3 N1 MX 0 0.526027 
FEMALE G3 IIB T3 N1 MX 0 0 
FEMALE G2 IIB T2 N1 MX 0 0.756164 
FEMALE G2 IIB T3 N1 MX 0 0.953425 
MALE G2 IIB T3 N1 MX 0 0 
MALE G3 IIB T3 N1b MX 0 6.378082 
MALE G3 IIB T3 N1 MX 0 1.512329 
FEMALE G2 IIB T2 N1 MX 0 0.361644 
MALE G1 IIB T3 N1 MX 0 0.427397 
FEMALE G2 IIB T3 N1 MX 0 1.084932 
MALE G1 IIB T3 N1 MX 0 0 
FEMALE G1 IIB T3 N1 M0 1 49.38082 
MALE G2 IIB T3 N1 M0 1 4.767123 
FEMALE G2 IIB T3 N1 M0 1 15.35342 
FEMALE G2 IIB T3 N1 M0 1 19.82466 
FEMALE G2 IIB T3 N1 M0 0 15.64932 
MALE G2 IIB T2 N1 M0 1 15.64932 
FEMALE G2 IIB T3 N1 M0 0 27.97808 
MALE G3 IIB T3 N1 M0 1 4.043836 
FEMALE G2 IIB T3 N1 M0 1 3.616438 
FEMALE G2 IIA T3 N0 M0 1 43.79178 
FEMALE G1 IIB T3 N1 M0 1 15.8137 
FEMALE G1 IIB T3 N1 M0 0 16.04384 
MALE G3 IIA T3 N0 M0 1 3.846575 
FEMALE G2 IIB T3 N1 M0 1 15.97808 
MALE G2 IIB T3 N1 M0 0 6.378082 
MALE G2 IIB T3 N1 M0 0 10.81644 
MALE G2 IIA T3 N0 M0 0 9.863014 
FEMALE G3 IIB T3 N1 M0 1 15.12329 
FEMALE G2 IIB T3 N1 M0 0 0.263014 
MALE G2 IIB T3 N1 M0 0 8.153425 
MALE G3 IIB T3 N1 M0 1 1.347945 
MALE G2 IIB T3 N1 MX 1 8.219178 
MALE G3 IIB T3 N1 MX 0 5.950685 
MALE G3 IIB T2 N1 M0 0 0.263014 
FEMALE G3 IIB T3 N1 M0 1 7.857534 
MALE G2 IIB T3 N1 M0 0 9.534247 
MALE G2 IIB T3 N1 M0 1 6.016438 
MALE G1 IIB T3 N1 M0 0 4.208219 
FEMALE G2 IIB T3 N1 M0 0 5.884932 
MALE G1 IIB T2 N1 M0 0 6.180822 
MALE G3 IIB T3 N1 M0 0 5.030137 
MALE G2 IIB T3 N1 M0 0 7.528767 
FEMALE G3 IIB T3 N1 M0 0 5.884932 
FEMALE G3 IIB T3 N1 M0 0 5.391781 
FEMALE G2 IIB T3 N1 MX 0 4.175342 
FEMALE G1 IIA T3 N0 MX 0 1.150685 
FEMALE G3 IIB T3 N1 MX 0 5.09589 
FEMALE G2 IIA T3 N0 M0 0 19.2 
MALE G1 IIA T3 N0 M0 0 3.616438 
FEMALE G3 IIB T3 N1 MX 0 8.120548 
MALE G2 IIB T3 N1 MX 0 3.452055 
FEMALE G2 IIB T3 N1 MX 0 1.183562 
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MALE G3 IIB T1 N1 MX 0 1.380822 
MALE G3 IIB T3 N1 MX 0 13.05205 
FEMALE G2 IIB T3 N1 MX 0 6.476712 
FEMALE G3 IIB T3 N1 MX 1 23.07945 
FEMALE G3 IIB T3 N1 MX 1 22.84932 
MALE G2 IIA T3 N0 MX 0 27.74795 
FEMALE G1 IIB T3 N1b MX 1 16.8 
MALE G3 IIB T3 N1 MX 1 14.13699 
MALE G2 IIB T3 N1 MX 1 0.394521 
FEMALE G2 IIB T3 N1b MX 1 18.67397 
FEMALE G2 IIB T3 N1 M0 0 5.391781 
FEMALE G2 IIB T3 N1 MX 0 6.641096 
MALE G2 IIA T3 N0 MX 0 6.180822 
MALE G2 IIB T3 N1 MX 0 5.260274 
FEMALE G3 IIB T3 N1 MX 0 60.29589 
FEMALE G1 IIA T3 N0 M0 0 0.690411 
FEMALE G2 III T4 N0 MX 1 12.95342 
MALE G2 III T4 N0 MX 0 0.624658 
FEMALE G1 III T4 N1 M0 0 0.558904 
FEMALE G3 IV T3 N0 M1 0 0.164384 
MALE G2 IV T3 N0 M1 0 19.82466 
FEMALE G2 IV T3 N1 M1 0 11.40822 
FEMALE G2 IV T3 N1 M1 0 5.293151 
 
 
